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Osama Yousef Alshogran, PhD  
University of Pittsburgh, 2014 
Chronic kidney disease (CKD) affects the disposition of drugs by altering their renal excretion. 
Well-established evidence suggests that CKD also impacts the nonrenal clearance of drugs by 
modulating drug metabolism and transport. The overall objective of this dissertation was to 
investigate the effect of CKD on hepatic reduction, an important Phase I drug metabolism pathway. 
In order to achieve our goals, a novel analytical method was developed and validated to measure 
warfarin and its alcohol metabolites.   
In vitro studies utilizing rat hepatic cytosol and microsomes showed significant decreases 
in the formation of RS/SR-warfarin alcohol in the CKD group compared to control, suggesting 
decreased reductase activity. Significantly decreased mRNA and protein expression (>30%) of 
selective reductase enzymes was also observed in rats with CKD. In vitro studies of human liver 
cytosol and microsomes collected from patients with end stage renal disease (ESRD) revealed a 
trend toward decreased formation of RS/SR-warfarin alcohol. A significant decrease (65%) in 
protein expression of carbonyl reductase 1 was observed in livers from ESRD compared to control 
livers. Together, the in vitro findings implicate transcriptionally or translationally mediated 
changes in reductase enzyme function in CKD. 
In vivo studies assessing the effect of CKD on steady-state warfarin and warfarin alcohol 
disposition showed increased concentrations of RR/SS-warfarin alcohol along with decreased 
kidney function, indicating impaired renal elimination of the RR/SS-warfarin alcohol metabolite 
iv 
in kidney disease patients. Additionally, increased free and total S/R warfarin observed in ESRD 
patients potentially suggests reduced CYP2C9 activity.  
Collectively, our findings demonstrate that drug reduction is impacted by kidney function, 
and provide a mechanism for altered nonrenal clearance and disposition of drugs in CKD. The 
findings of these studies may be clinically relevant in improving the management of drug 
substrates of reductases, specifically warfarin, in patients with CKD. Given the high frequency 
with which these drugs are prescribed for CKD patients, dosing adjustments and frequent 
monitoring may be warranted.   
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1.0  INTRODUCTION AND LITERATURE REVIEW 
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1.1 CHRONIC KIDNEY DISEASE (CKD) 
1.1.1 Definition and Stages  
Chronic kidney disease (CKD) is a general term that describes the progressive and heterogeneous 
disorders that are associated with functional and structural abnormalities of the kidney, and occur 
for greater than a period of three months. Two fundamental factors are used for defining CKD 
including the degree of kidney function (i.e., estimated glomerular filtration rate; eGFR<60 
mL/min/1.73m2) and the presence of kidney damage (i.e., proteinuria) (James et al., 2010). The 
National Kidney Foundation, a leading CKD advocacy organization, classifies CKD into five 
stages according to the degree of disease severity as indicated primarily by GFR, with increased 
severity for lower GFR values. Table 1-1 presents the classification of CKD according to the 
eGFR values. The early stages of CKD are generally asymptomatic; however, the advanced stages 
are more aggressive and associated with uremia (Levey et al., 2003). The progressive decline in 
kidney function becomes ultimately irreversible leading to end-stage renal disease (ESRD) 
(eGFR<15 mL/min/1.73m2), which requires renal replacement therapy including dialysis or 
kidney transplantation (Coresh et al., 2007). 
 
Table 1-1 Classification of chronic kidney disease 
CKD Stage Description eGFR (mL/min/1.73m2) 
1 Kidney damage with normal or elevated GFR >90 
2 Kidney damage with mildly decreased GFR 60-89 
3 Moderate decrease of GFR 30-59 
4 Severe decrease of GFR 15-29 
5 Kidney failure <15 
      Adapted from (Naud et al., 2012) 
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1.1.2 Risk Factors and Epidemiology 
Kidney disease is the ninth leading cause of death in the United States. Several risk factors are 
associated with CKD and can be divided into non-modifiable and modifiable factors. The non-
modifiable factors include age, race, and genetic susceptibility. Obesity, diabetes, and 
hypertension are the primary modifiable factors (Levey et al., 2005). Chronic kidney disease is 
considered a major public health problem that affects approximately 26 million Americans with a 
prevalence estimated to be 13% of the US population (Levey and Coresh, 2012; Weiner, 2009). 
The prevalence of CKD markedly increases with age from approximately 4% at age 20-39 years 
to about 47% in people older than 70 years, due in part, to the known decrease in kidney function 
with aging (Coresh et al., 2007; Zhang and Rothenbacher, 2008). Additionally, prevalence of CKD 
is increasing rapidly due to the epidemics of diabetes and hypertension, the two most common 
causes of CKD worldwide (Coresh et al., 2007). Diabetes, the primary etiology of kidney disease, 
accounts for about 40% of all new cases (Levey and Coresh, 2012).  
1.1.3 Cardiovascular Complications and Comorbidities  
CKD places patients at high risk of cardiovascular comorbidities, which is the leading cause of 
death in ESRD patients (Schiffrin et al., 2007; Thomas et al., 2008). CKD is associated with 
hemostatic defects predisposing patients to a hypercoagulable state that increases the risk for 
venous thromboembolism and stroke (Wattanakit and Cushman, 2009). CKD is also associated 
with the incidence of arrhythmias that raise the risk of stroke, morbidity, and mortality (Wetmore 
et al., 2013; Winkelmayer et al., 2011b). Atrial fibrillation (AF), the most common cardiac 
arrhythmia, independently increases the risk of ischemic stroke by 5-10-fold in hemodialysis (HD) 
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patients (Vazquez et al., 2009; Vazquez et al., 2003). The prevalence of AF among long-term HD 
patients is reported to be 13-27%, which is 10 to 20-fold higher than that in the general population 
(Reinecke et al., 2009). Other studies have also reported similar AF prevalence in non–dialysis-
dependent CKD patients (Alonso et al., 2011; Ananthapanyasut et al., 2010; Hart et al., 2011). For 
example, the large population-based cohort study of Alonso et al. showed that the hazard ratio 
(HR) of AF is approximately 3-fold higher in patients with eGFR of 15-30 mL/min/1.73m2 
compared to individuals with normal kidney function (Alonso et al., 2011). The prevalence of AF 
in this observational study was 18%. Together, these data indicate that cardiovascular 
complications are common in patients with various stages of CKD. Because CKD is associated 
with thromboembolism, AF and stroke, anticoagulant use is essential for prevention and treatment 
of thromboembolic events in high-risk CKD patients. 
1.2 EFFECT OF CKD ON PHARMACOKINETICS  
Optimizing drug therapy is necessary in patients with kidney disease. Thus, it is important to assess 
how kidney disease may affect disposition of drugs used in this patient population. Kidney disease 
changes the exposure of drugs by altering their urinary excretion through the processes of filtration 
and active tubular secretion. Therefore, for drugs that are predominantly eliminated renally, it is 
intuitive that dosage adjustments are needed in patients with progressive deterioration of kidney 
function. However, a growing body of evidence demonstrates alterations in disposition of drugs 
that are eliminated by nonrenal clearance pathways (i.e., metabolism and hepatic transport), 
suggesting that these medications may require consideration when taken by patients with CKD. In 
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this section, we will provide an overview of the major pharmacokinetic concepts, and discuss how 
CKD may impact individual steps in drug absorption and disposition. 
1.2.1 Overview of Pharmacokinetics   
The pharmacokinetic properties of drugs are basically determined by absorption, distribution, 
metabolism, and excretion. Absorption is an important determinant of the bioavailability of drugs 
administered orally. Bioavailability reflects the rate and extent to which the parent drug appears in 
the systemic circulation. Hence, it determines how much drug will be available to bind to its target 
site in the desired tissue. After the drug reaches the blood, it circulates through the entire body. 
The volume of distribution is the term used to describe the degree to which the drug is distributed 
throughout the body. Metabolism accounts for the biochemical modification processes of drug that 
are principally mediated in the liver, the major drug detoxification organ in the body. The parent 
drug and/or its metabolite(s) are excreted from the body primarily through urine or bile. 
Metabolism and excretion are together known as drug elimination. Because drug metabolism is 
the major focus of this dissertation, it will be further discussed in this section. 
Phase I metabolism primarily involves oxidation, reduction, and hydrolysis. The most 
prevalent phase I metabolism pathway is oxidation, which is mainly mediated by the cytochrome 
P450 (CYP450) enzymes (Guengerich, 2008). CYP450 enzymes are separated into different 
subfamilies and isoforms based on the similarity in their structure and function. For example, 
isoforms that possess more than 55% sequence homology are assigned to the same subfamily, as 
in the case of CYP3A4 and CYP3A5 which belong to the CYP3A subfamily (Lamba et al., 2002). 
In the liver, the most abundant CYP450 enzymes are CYP3A4 and CYP2C, representing about 
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30% and 20% of total liver CYPs, respectively (Pinto and Dolan, 2011). In fact, CYP3A accounts 
for around 50% of all CYP450-mediated drug metabolism (Rendic, 2002). 
Phase I metabolism plays critical roles in the biosynthesis, transformation, and regulation 
of endogenous compounds such as sterols, fatty acids, prostaglandins and others, as well as 
numerous xenobiotics and drugs (Xu et al., 2005). This metabolic pathway usually converts parent 
compounds into more polar and biologically inactive metabolites that can be directly excreted from 
the body and/or further conjugated by phase II enzymes. However, it is not uncommon that drug-
metabolizing enzymes (DMEs) transform drug substrates into partially or totally reactive or toxic 
metabolites (Sheweita, 2000). One important pathway of phase I metabolism is reduction, which 
accounts for the metabolism of a significant number of endogenous and exogenous substrates. This 
pathway is the focus of our work and will be discussed separately later in this chapter. 
Parent drug and/or metabolites can be targeted by phase II metabolism through the 
processes of glucuronidation, sulfation, acetylation, methylation, and glutathione or amino acid 
conjugation. Glucuronidation is the most common phase II metabolic pathway. It is mediated by 
uridine diphoshate (UDP)-glucuronosyltransferase (UGTs). In most of the cases, phase II 
metabolism generates hydrophilic metabolites (except methylation and acetylation) that are readily 
excreted through urine or bile (Rowland et al., 2013; Tukey and Strassburg, 2000). 
Oxidative and conjugative DMEs exhibit wide tissue distribution with high levels being 
observed in the liver, kidney, gut, lung, and brain. While drug metabolizing CYP450 and UGT 
enzymes are located in the microsomal fraction of the cell (membrane of the endoplasmic 
reticulum), reductase, acetylase, and sulfatase isoforms are primarily found in the cytosol 
(Sheweita, 2000). 
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Finally, drug transport has become increasingly important in determining 
pharmacokinetics. Transporters are transmembrane proteins that are directed toward the apical or 
luminal site of the membrane where they control substrate influx (uptake) or efflux in or out of the 
cells. Recently, transport proteins have been described by the terms phase 0 and phase III for the 
uptake and efflux transporters, respectively (Doring and Petzinger, 2014). Drug transporters 
belong to two main families; the ATP binding cassette (ABC) and the solute carrier (SLC) 
transporters. The ABC carriers mediate primarily drug efflux from cells to the lumen using ATP 
as the source of energy. The major subgroups of the ATP family are multi-drug resistance protein 
(MDR; also called P-glycoprotein (P-gp)), multi-drug resistance associated protein (MRP), and 
breast cancer resistance protein (BCRP) (International Transporter et al., 2010). On the other hand, 
the primary function of the SLC transporters is intracellular uptake of chemicals. SLC transporters 
consist of organic anion transporters (OAT), organic anion transporter polypeptide (OATP), and 
organic cation transporters (OCT) (Roth et al., 2012). Besides the liver, transporters are also 
expressed in extra-hepatic tissues such as gut, kidney, brain, adrenal gland and lung, where they 
act together to govern drug absorption, distribution, or elimination (Doring and Petzinger, 2014). 
In the following sections, the effect of kidney disease on DMEs and transport proteins at 
the level of absorption and elimination (metabolism and excretion) will be discussed. Tables 1-2 
and 1-3 provide a comprehensive review of experimental studies that have demonstrated 
alterations of intestinal, hepatic, and renal metabolizing enzymes and transporters, respectively in 
the setting of kidney disease. 
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Table 1-2  Alterations of intestinal, hepatic, and renal metabolic enzymes in experimental kidney disease 
    Intestine 1   Liver 2-10   Kidney 10, 11 
    mRNA Protein Activity   mRNA Protein Activity   mRNA Protein Activity 
CYP1A1  Decreased 
(32%) 
Decreased 
(43%) 
Decreased 
(25%) 
 - Unchanged2 -  Decreased11 
(98%) 
Decreased11 
(48%) 
- 
CYP1A2  - - -  Unchanged4 
Decreased9 
Unchanged4 
Decreased9  
Increased2 
Unchanged3  - - - 
CYP2B1  - Unchanged  -  - Unchanged2 -  - - - 
CYP2B2  - -   -  - Unchanged2 -  - - - 
CYP2C6  - Unchanged  -  - Unchanged4 
Decreased2,5 
(38%) 
-  - - - 
CYP2C11  Unchanged  Unchanged  -  Decreased4,5,6 
(27-95%)  
Decreased2,3,4,5,6  
(40-68%)      
Decreased3,6 
(35-82%)     
 - - - 
CYP2D1  - - -  Unchanged5 Unchanged2,4,5 -  - - - 
CYP2E1  - - -  - Unchanged4 -  - - - 
CYP3A1  - - -  Decreased4 Decreased3,4,5  
(37-85%)  
Decreased8 
(50%) 
 Unchanged11 Unchanged11 - 
CYP3A2  Decreased 
(36%)  
Decreased 
(71%) 
Decreased 
(25%) 
 Decreased4,5,6 
(36-99%)  
Decreased2,3,4,5,6  
(45-91%) 
Decreased3,4,6 
(45-72%) 
 - - - 
NAT1  - - -  Decreased7         
(25%) 
Decreased7  
(33%) 
-  - - - 
NAT2  - - -  Decreased7 
(35%) 
Decreased7  
(50%) 
Decreased7 
(50%) 
 - - - 
UGT1A  - - -  - Unchanged10 Unchanged10   - Unchanged10  Unchanged10 
UGT2B   - - -   - Unchanged10  Unchanged10    - Unchanged10  Unchanged10  
CYP: cytochrome P450; NAT: N-acetyltransferase; UGT: uridine diphoshate glucuronosyltransferase; (-) data are not available  
Table references: 1: (Leblond et al., 2002); 2: (Uchida et al., 1995); 3: (Leblond et al., 2000); 4: (Leblond et al., 2001); 5: (Guevin et al., 2002); 6: (Velenosi et 
al., 2012); 7: (Simard et al., 2008); 8: (Rege et al., 2003); 9: (Michaud et al., 2005); 10: (Yu et al., 2006); 11: (Naud et al., 2011)   
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Table 1-3  Alterations of intestinal, hepatic, and renal transport proteins in experimental kidney disease 
    Intestine 1-3   Liver 3-5   Kidney 3, 5-7 
    mRNA Protein Activity   mRNA Protein Activity   mRNA Protein Activity 
MRP2  Unchanged2  Decreased2 
(60%) 
Decreased2 
(25%) 
 Increased4,5 
(40-90%)       
Increased5 
(70%) 
Unchanged3,4 
-  Increased5,7    
(40-200%) 
Increased5,7    
(82-124%) 
- 
MRP3  Unchanged2,3 Decreased2 
(35%) 
Unchanged3 
-  Increased3 Increased3 -  Unchanged3 
Increased7 
(92%) 
Unchanged3 
Increased7 
(292%) 
- 
MRP4  - - -  Unchanged3 - -  Increased7 
(72%) 
Unchanged3 
Increased7 
(178%) 
- 
NPT1  - - -  - - -  Decreased7 
(46%) 
Decreased7 
(38%) 
- 
OAT1  - - -  - - -  Decreased7 
(78%) 
Decreased7 
(48%) 
Unchanged6 
- 
OAT2  - - -  - - -  Decreased7 
(98%) 
Decreased7 
(40%) 
- 
OAT3  - - -  - - -  Decreased7 
(69%) 
Decreased7 
(77%) 
Unchanged6 
- 
OATK1/K2  - - -  - - -  Decreased7 
(90%) 
Decreased7 
(82%) 
- 
OATP1  - - -  - - -  Decreased7 
(97%) 
Decreased7 
(74%) 
- 
OATP2  - Unchanged2  -  Unchanged4 Decreased4 
(40%) 
-  Increased7 
(125%) 
Increased7 
(144%) 
- 
OATP3  Unchanged2  Unchanged2  -  - - -  Increased7 
(179%) 
Increased7 
(108%) 
- 
OATP4  - - -  - - -  Decreased7 
(92%) 
Decreased7 
(68%) 
- 
OATP5  - - -  - - -  Decreased7 
(95%) 
- - 
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OCT-1  - - -  - - -  - Unchanged6 - 
OCT-2  - - -  - - -  - Decreased6 
(67%) 
Decreased6 
(82%) 
P-gp  Unchanged1, 2  Decreased2 
(65%) 
Unchanged1 
Decreased1, 
2 (30-33%)  
 Increased4 
(50%)    
Unchanged5 
Increased4 
(25%)     
Unchanged5 
Increased4 
(63%) 
 Decreased7 
(48%) 
Unchanged5 
Decreased7 
(44%) 
Unchanged5 
Decreased7 
URAT1   - - -   - - -   Decreased7 
(75%) 
Decreased7 
(38%) 
- 
MRP: multi-drug resistance associated protein; NPT1: sodium-dependent phosphate transport protein 1; OAT: organic anion transporter; OATP: 
organic anion transporter polypeptide; OCT: organic cation transporter; P-gp: P-glycoprotein; URAT: urate transporter; (-) data are not available  
 
Data were obtained from the following references: 1: (Veau et al., 2001); 2: (Naud et al., 2007); 3: (Gai et al., 2014); 4: (Naud et al., 2008); 5: (Laouari 
et al., 2001); 6: (Ji et al., 2002); 7: (Naud et al., 2011).  
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1.2.2 Effect of CKD on Absorption  
The 5/6th nephrectomy model has been widely used to evaluate the impact of CKD on 
pharmacokinetics. The model represents a progressive impairment of kidney function. In this 2-
stage model, a two-third nephrectomy of the left kidney is followed by a complete right 
nephrectomy seven days later. The targeted organ (i.e., liver, kidney, intestine) is harvested 6-7 
weeks after the surgery to assess the effect of kidney disease on enzyme or transporter function 
and expression (Leblond et al., 2000; Naud et al., 2011). Alterations in the metabolic enzymes 
located in enterocytes and transporters lining the apical membrane and endothelial cells will impact 
the amount of drug reaching the systemic circulation (bioavailability), and thus its pharmacological 
action (Momper et al., 2010). Previous studies using the 5/6th nephrectomy model have shown 
reduced activity and expression of intestinal CYP3A (by up to 25% and 71%, respectively) and 
CYP1A (by up to 25% and 43%, respectively) in rats. However, protein levels of CYP2B1, 
CYP2C6, and CYP2C11, and mRNA level of CYP2C11 were not affected (Leblond et al., 2002). 
In addition to DMEs, intestinal transporters were also shown to be differentially affected 
by CKD. One study showed a decrease in the activity of P-gp, but not intestinal mRNA expression 
in rats with CKD induced by 5/6th nephrectomy (Veau et al., 2001). Decreased P-gp activity has 
been recently confirmed by Naud and colleagues who showed that the activity of the efflux 
transporters P-gp and MRP2 as well as their intestinal protein expression were reduced in rats with 
kidney disease (Naud et al., 2007). However, this decrease in protein expression of P-gp and MRP 
is not parallel with their mRNA levels as they remained unaffected in nephrectomized rats (Naud 
et al., 2007). Together, this suggests the contribution of translational modifications and/or 
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degradation to reduced protein levels and therefore the activity of transporters in CKD rats (Naud 
et al., 2007). 
Decreased activity of DMEs and drug efflux by P-gp in the intestine may together explain 
increased bioavailability of tacrolimus in rats with CKD (Okabe et al., 2000) and increased 
maximum plasma concentration of fexofenadine observed in CKD patients (Nolin et al., 2009). 
However, these findings contradict other observations documented in clinical pharmacokinetic 
studies of drugs in ESRD. For instance, the pharmacokinetics of oral midazolam and the intestinal 
bioavailability of erythromycin were not affected by ESRD, suggesting that intestinal CYP3A is 
not significantly altered in kidney disease (Nolin et al., 2009; Sun et al., 2010). Together, these 
conflicting results, especially for erythromycin, indicate the complex interplay between DMEs and 
transporters. Additionally, this may also suggest that other factors such as changes in drug first-
pass metabolism could contribute to altering drug bioavailability in CKD. 
1.2.3 Effect of CKD on Distribution  
One important factor that influences drug distribution is the extent to which the drug binds to 
plasma or tissue proteins. Changes in plasma protein binding of high clearance drugs may affect 
the unbound fraction of in plasma, which could alter drug pharmacological action and clinical 
response. Thus, evaluation of the effect of disease state on drug plasma protein binding is 
important. Protein binding of many acidic drugs is reduced in CKD, which may result in increased 
volume of distribution. Decreased plasma protein binding has been correlated with plasma levels 
of urea and creatinine (Reidenberg, 1977; Sjoholm et al., 1976; Vanholder et al., 1988). For 
instance, binding of diazepam, salicylic acid, phenytoin, theophylline, and warfarin is considerably 
impaired in uremic serum (Reidenberg, 1977; Sjoholm et al., 1976; Vanholder et al., 1988). 
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Decreased plasma protein binding in uremia can be explained by reduced affinity of drugs to 
albumin, due to 1) conformational changes resulting in abnormal albumin or 2) the presence of 
chemical inhibitors in uremic serum (i.e., uremic toxins) that displace drugs from their binding 
sites (Sjoholm et al., 1976; Vanholder et al., 1993; Vanholder et al., 1988).  
1.2.4 Effect of CKD on Hepatic Elimination   
The liver is the major organ contributing to drug biotransformation in the body. Various 
experimental studies have investigated the effect of CKD on hepatic drug metabolism and 
transport. The metabolic activity of CYP2C11 and CYP3A2 measured using aminopyrine and 
erythromycin as probe substrates, respectively, was reduced up to 35% in rats with severe kidney 
disease (Leblond et al., 2000). This was also observed recently in rats with moderate CKD (induced 
by one-third removal of the left kidney and complete nephrectomy of the right kidney) suggesting 
that earlier stages of kidney impairment may also affect nonrenal drug clearance (Velenosi et al., 
2012). Besides activity, protein expression of CYP2C11 and CYP3A has been shown to be 
consistently reduced in moderate and severe experimental kidney disease (Leblond et al., 2001; 
Leblond et al., 2000; Rege et al., 2003; Velenosi et al., 2012). This decrease was secondary to 
reduced mRNA expression documented by downregulation of CYP2C11, CYP3A1, and CYP3A2 
genes. However, inconsistent results were obtained with respect to the expression of CYP1A2 and 
CYP2C6 (Leblond et al., 2001; Michaud et al., 2005; Rege et al., 2003; Uchida et al., 1995). 
Protein and mRNA levels of CYP2D and CYP2E1 remained unaffected (Leblond et al., 2001; 
Rege et al., 2003; Uchida et al., 1995). Generally, the experimental animal models of CKD 
demonstrate the presence of differential effect of kidney impairment on CYP450 functional 
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expression. However, the expression and activity of CYP2C11 and CYP3A2 were consistently 
decreased in rats with CKD.  
In order to test whether the alterations in the functional expression of CYP450 observed in 
animal models can be translated to humans, in vivo studies have been conducted using phenotypic 
probe substrates that are metabolized by specific CYP450 isoforms. Previous studies assessed the 
activity of CYP3A, the most abundant isoform in the liver, in patients with ESRD, utilizing the 
erythromycin breath test (Dowling et al., 2003). Patients with ESRD had 28% lower baseline 
erythromycin breath test demonstrating reduced CYP3A activity (Dowling et al., 2003). However, 
this finding may not be exclusively due to CYP3A activity since erythromycin is also a substrate 
for drug transporters that contribute to its elimination. A follow-up study aimed to identify whether 
the decrease in nonrenal clearance of erythromycin is as a result of reduced hepatic and/or gut 
metabolism (Sun et al., 2010), found that hepatic clearance of erythromycin is decreased in ESRD 
patients by 31% relative to controls receiving IV infusion of erythromycin. With oral 
administration, erythromycin bioavailability was increased by 36%, and that was attributed to 
change in liver, but not gut metabolism mediated by CYP3A (Sun et al., 2010). This is in contrast 
to the findings of Nolin et al., who showed that the pharmacokinetics of midazolam, a probe 
substrate for CYP3A, are not different between controls and ESRD patients receiving conventional 
HD therapy (Nolin et al., 2009). The contradictory observations may be explained by the effect of 
CKD on transport proteins, given that erythromycin is a substrate for the uptake transporter OATP 
and efflux transporter P-gp (Frassetto et al., 2007). CYP2C9 is another critical isoform that 
accounts for about 20% of drug metabolism (Miners and Birkett, 1998). The activity of CYP2C9 
was investigated in ESRD patients using warfarin as a substrate. A 50% increase of warfarin S/R 
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ratio has been observed in ESRD patients compared with control subjects, suggesting reduced 
CYP2C9 activity in patients with kidney disease (Dreisbach et al., 2003).  
Phase II conjugation is a crucial pathway for detoxification and excretion of several drugs 
from the body. The conjugation pathways have not been widely investigated in kidney disease, 
despite the fact that, a number of studies have shown decreases in liver metabolism of drugs that 
are metabolized by phase II pathways in kidney disease. Drugs that are primarily metabolized by 
acetylation such as procainamide and isoniazid were found to be accumulated in CKD (du Souich 
and Erill, 1978; Kim et al., 1993). Indeed, the effect of CKD on acetylation was clearly supported 
by around 30% decrease in protein and mRNA expression of N-acetyltransferase (NAT) enzymes, 
and a 50% reduction in NAT2 activity in rat with CKD relative to controls (Simard et al., 2008). 
Moreover, the down-regulation in protein (33%) and mRNA (23%) expression of NAT2 has been 
also shown in a murine model of CKD (Dani et al., 2009). Additionally, clinical studies have 
shown that the metabolic clearance of drugs that are extensively eliminated by glucuronidation 
such as metoclopromide, zidovudine, and morphine is significantly reduced in CKD patients 
(Lehmann et al., 1985; Osborne et al., 1993; Singlas et al., 1989). However, Yu and coworkers 
have shown negligible effect of CKD on the function and expression of liver UGTs in 
nephrectomized rats (Yu et al., 2006). These findings further demonstrate the disparity of the effect 
of CKD on drug metabolism.  
Hepatic drug transport is also important in drug disposition since many drugs are substrates 
for both CYP450 enzymes and transport proteins. As discussed with intestinal transporters, those 
located in the liver are also differentially affected by kidney disease. Hepatic P-gp activity was 
shown to be increased in rats with CKD secondary to increased protein and mRNA expression 
(Naud et al., 2008). This in contrast to what is already known about intestinal P-gp (Naud et al., 
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2007). On the other hand, protein level of OATP2 was decreased, and MRP2 remained unaffected 
(Naud et al., 2008). This effect on protein was not associated with the change in gene expression 
since mRNA levels of OATP2 and MRP2 were either unaffected or increased, respectively (Naud 
et al., 2008). A recent study also demonstrated that protein and mRNA expression of MRP3 and 
OST-α was up-regulated in rats with CKD (Gai et al., 2014). Together, these data may suggest that 
CKD decreases the functional expression of uptake transporters involved in drug absorption, and 
increases the functional expression of efflux transporters contributing to drug elimination. This 
may eventually impact drug disposition by altering its bioavailability through the intestine and the 
extent to which it is transported and be available to metabolizing enzymes located in the liver. For 
example, decreased efflux activity of P-gp in the intestine, and decrease uptake activity of OATP 
in the liver would increase drug bioavailability and exposure.  
Fexofenadine is a non-specific probe substrate of drug transporters that has been used to 
assess the effect of kidney disease on drug transporters in humans. Fexofenadine oral clearance is 
decreased in ESRD, suggesting either down-regulation of P-gp efflux transport in the intestine 
and/or decreased hepatic uptake by OATPs (Nolin et al., 2009). This observation has been recently 
confirmed by the results of a study that evaluated transporter activity in patients with 
glomerulonephritis using fexofenadine as a substrate, and documented a 40% reduction in 
fexofenadine oral clearance, which could be translated to decreased transporter activity (Joy et al., 
2014). 
1.2.5 Effect of CKD on Renal Excretion 
Urinary excretion of drugs and/or their metabolites is primarily mediated through the processes of 
filtration and active tubular secretion. These routes are highly affected by kidney impairment, 
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resulting in alterations in pharmacokinetics. Thus, dosing adjustments are applied to patients with 
CKD for drugs that are principally eliminated unchanged in the urine. DMEs and transporters are 
also expressed in the kidney and can contribute to elimination of drugs and their intracellular 
accumulation within the kidney. Therefore, several studies have been conducted to investigate 
whether CKD impacts DMEs and transporters located in the kidney (Lalande et al., 2014; Naud et 
al., 2012). The results demonstrate a differential impact of kidney disease on transporters. For 
example, while expression of OATs, OATP1, OCT2, and P-gp was reduced, levels of MRPs, 
OATP2, and OATP3 were up-regulated in nephrectomized rats (Ji et al., 2002; Laouari et al., 2001; 
Naud et al., 2011). These alterations in kidney transporters have resulted in increased intra-renal 
accumulation of [14C]benzylpenicillin (substrate for OATs and MRPs) and [3H]digoxin (substrate 
for P-gp) in the kidney of uremic rats (Naud et al., 2011). The latter study also showed decreased 
expression of CYP1A in CKD rats (Naud et al., 2011). Together, these data demonstrate that 
decreased expression of transporters in CKD may reduce renal excretion mediated by active 
tubular secretion, and thereby increase drug plasma exposure. Because renal elimination through 
filtration and protein binding of drugs (fraction unbound) are also affected by kidney disease, the 
ultimate effect of impaired kidney function on renal elimination may be drug dependent.  
Phase II renal UGT enzymes were also assessed in rats with kidney disease. The protein 
levels and activity of UGT2B and UGT1A were decreased in nephrectomized rats; however, this 
reduction was similar to that observed in the control pair-fed group, suggesting that food restriction 
but not kidney impairment contributed to decreased UGT expression and activity (Yu et al., 2006).  
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1.2.6 Mechanisms Contributing to Altered Drug Metabolism and Transport in CKD 
Impairment of drug metabolism and transport in CKD may be explained by two major mechanisms 
attributed to the accumulated uremic toxins and inflammatory cytokines. These toxins may 1) 
directly inhibit or 2) modulate protein and mRNA expression of DMEs and transport proteins. 
Multiple studies have shown that the activity of DMEs is impacted by uremic serum, indicating 
the direct inhibition of drug metabolism by uremic toxins (Michaud et al., 2005; Simard et al., 
2008). This was established by exploring N-demethylation of erythromycin, O-deethylation of 7-
ethoxyresorufin, and N-acetylation of p-aminobenzoic acid as indictors of CYP3A, CYP1A, and 
NAT activity, respectively (Michaud et al., 2005; Simard et al., 2008). Studies have also reported 
that protein and mRNA expression of several DMEs is modulated when normal rat hepatocytes 
were incubated with serum collected from rats or patients with CKD (Guevin et al., 2002; Michaud 
et al., 2005; Tsujimoto et al., 2012). For instance, levels of CYP1A, CYP2C, and CYP3A were 
reduced at mRNA and protein levels. Whether this decrease in expression is as a result of impaired 
transcription and translation or changes in mRNA and protein stability is unclear, and needs further 
investigation. The decline in the activity of selected DMEs (i.e., CYP3A, CYP2C, NAT) can be 
temporarily reversed after hemodialysis, but completely resolved after renal transplantation (Kim 
et al., 1993; Michaud et al., 2008; Nolin et al., 2006).   
Similarly, the function and expression of transport proteins located in intestine, liver, and 
kidney were also impacted by uremic serum (Naud et al., 2011; Naud et al., 2007; Naud et al., 
2008; Sun et al., 2004; Tsujimoto et al., 2012). For example, the observation of increased 
rhodamine-123 permeability from apical to basolateral side of Caco-2 or HK-2 cells treated with 
uremic serum versus control, indicates decreased P-gp activity (Naud et al., 2011; Naud et al., 
2007). Moreover, increased P-gp and decreased OATP2 protein expression was observed in 
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hepatocytes after treatment with CKD rat serum (Naud et al., 2008). Of note, the most common 
toxins implicated in alterations of DMEs and transporters in CKD include indole-3-acetic acid, 3-
indoxyl sulfate, p-cresol, hippuric acid, 3- carboxy-4-methyl-5-propy-2-furanpropanoic acid 
(CMPF), para-thyroid hormone (PTH), and cytokines (Barnes et al., 2014; Tsujimoto et al., 2013; 
Volpe et al., 2014).   
1.2.7 Does CKD Affect Drug Reduction? 
As we previously mentioned, reduction is an important pathway for elimination of an array of 
drugs commonly used in clinical practice. Unlike phase I oxidation and phase II conjugation, 
reduction has been studied very little in CKD. In fact, the disposition of several drugs that are 
extensively eliminated by reduction has been significantly impacted by the presence of kidney 
disease. For example, naltrexone exposure is dramatically increased in ESRD patients on 
hemodialysis, which could be explained in part by decreased elimination (Kambia et al., 2004). 
Moreover, a 30% decrease in the metabolic clearance of idarubicin was reported in patients with 
creatinine clearance (CLCr) of <60 mL/min (Camaggi et al., 1992). Given the high contribution 
of reductases to elimination of these drugs (Dayton and Inturrisi, 1976; Kang and Weiss, 2003), 
these findings demonstrate that, besides oxidation, phase I reduction of drugs may also be impaired 
in kidney disease. Table 1.4 summarizes the effect of kidney disease on the clinical 
pharmacokinetics of several reductase drug substrates. 
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Table 1-4  Clinical pharmacokinetics of selected drug substrates of reductases in CKD patients 
Drug 
Kidney Function      
(# of Pts) 
fe (%) CLt t1/2 Cmax AUC Comments 
Boceprevir1 Normal (6) 3 178 (L/h) 1.73 (h) 1730 (ng/mL) 5760 (ng*h/mL) No dose adjustment necessary in patients 
with ESRD, including those receiving 
dialysis 
 ESRD/ HD (8)  193 (L/h) 2.2 (h) 1340 (ng/mL) 5150 (ng*h/mL) 
       
        
Bupropion2 Normal (17) 0.5 414 (L/h) 8.1 (h) 66.1 (ng/mL) 490 (ng*h/mL) The authors state that despite the increases 
in the exposure observed in CKD patients, 
dosage recommendations cannot be given 
eGFR 15-59 (mL/min) Moderate-severe (10)   155 (L/h)$ 19.4 (h) $ 123 (ng/mL) $ 1100 (ng*h/mL) $ 
       
        
Dolasetron3 Normal (24) <1 114.9 (mL/min/kg) 8.6 (min) - 286.5 (ng*h/mL) Despite increased exposure, the authors 
state that there is no need for dosage 
adjustment due to high variability 
observed between patients 
CLCr 41-80 (mL/min) Mild-moderate (12)    55.7 (mL/min/kg) 22 (min) $ - 685.9 (ng*h/mL) $ 
CLCr 11-40 (mL/min) Moderate-severe (12)   117.5 (mL/min/kg) 30.1 (min) $ - 426.0 (ng*h/mL) 
CLCr <= 10 (mL/min)  ESRD/HD (12)   66.1 (mL/min/kg) 11.1 (min) - 594.4 (ng*h/mL) $ 
        
Doxorubicin4  Non-HD (8) 5-12 0.894 (L/h/kg) - - 21 (ng* h/mL*kg) The authors suggest to carefully monitor 
HD patients receiving doxorubicin therapy  ESRD/HD (5)  0.52 (L/h/kg) $ - - 36 (ng* h/mL*kg) $ 
       
Idarubicin5  Normal (6) <3 122.8 (L/h) 15.24 (h) - 186.5 (ng*h/mL) - 
CLCr <60 (mL/min) Moderate-severe (6)   83.4 (L/h) $ 19.03 (h) - 258.2 (ng*h/mL) $  
        
Ketanserin6 Normal (10) <3 6.4 (L/h) 18 (h) 198 (ng/mL) 625 (ng*h/mL) No dose adjustment necessary in spite of 
increased free fraction due to reduced 
plasma binding in kidney failure 
CLCr <30 (mL/min) Severe-ESRD (6)   6.33 (L/h) 29 (h) 127 (ng/mL) 632 (ng*h/mL) 
 ESRD/ HD (6)  5.94 (L/h) 28 (h) 60.7 (ng/mL) 637 (ng*h/mL) 
       
Ketoprofen7 Normal (7) 4 0.0766 (L/h/kg) 2.03 (h) 3.29 (mg/L) 11.2 (mg*h/L) The authors suggest decrease the dose or 
the frequency in patients with severe CKD CLCr 15-60 (mL/min) Moderate-severe (5)   0.0443 (L/h/kg) $ 3.17 (h) $ 3.68 (mg/L) 16.7 (mg*h/L) 
        
Naltrexone8 Normal (6)  <2 278.4 (L/h) 8.8 (h) 9-44 (ng/mL) - The authors concluded that the clinician 
could determine whether dosage 
adjustments are necessary in HD patients 
after careful monitoring 
 ESRD/HD (7)  118 (L/h) $ 1.48 (h) 255 (ng/mL) $ 739.46 (ng*h/mL) 
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Oxcarbazepine9 Normal (6) <1 - - 1.23 (µmole/L) 4.2 (µmole*h/L) The authors suggest reducing the dose by 
50% in moderate CKD patients. However, 
dosage adjustments in severe CKD cannot 
be proposed from this study 
CLCr 30-80 (mL/min) Mild (6)  - - 1.67 (µmole/L) 8.3 (µmole*h/L) 
CLCr 10-29 (mL/min) Moderate (7)  - - 1.45 (µmole/L) 9.2 (µmole*h/L) $ 
CLCr <10 (mL/min) Severe (7)  - - 1.82 (µmole/L)  7.9 (µmole*h/L) 
        
Pentoxifylline10  Normal (9)  <1 - - 393 (ng/mL) 2008 (ng*hr/mL) The authors state that although 
pentoxifylline kinetics were not affected 
by CKD,  dosage adjustment and close 
monitoring are recommended due to active 
metabolites accumulation 
CLCr 30-80 (mL/min) Moderate (6)  - - 187 (ng/mL) 1020 (ng*hr/mL) 
CLCr <30 (mL/min) Severe (10)  - - 152 (ng/mL) 829 (ng*hr/mL) 
              
AUC: area under the plasma concentration–time curve; CKD: chronic kidney disease; CLCr: creatinine clearance; Clt: total drug clearance; Cmax: peak plasma concentration; eGFR: 
estimated glomerular filtration rate; ESRD: end-stage renal disease; fe: percentage of drugs excreted unchanged in the urine; HD: hemodialysis; t1/2: half-life; (-): not available 
$ indicates statistically significant difference from the control group 
Data were obtained from the following references: 1: (Treitel et al., 2012); 2: (Turpeinen et al., 2007); 3: (Dimmitt et al., 1998); 4: (Yoshida et al., 1994); 5: (Camaggi et al., 1992); 6: 
(Barendregt et al., 1990); 7: (Stafanger et al., 1981); 8: (Kambia et al., 2004); 9: (Rouan et al., 1994); 10: (Paap et al., 1996).  
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1.3 PHASE I HEPATIC REDUCTION 
Compounds bearing a carbonyl group such as aldehydes and ketones are susceptible to reduction 
generating products with a hydroxyl group. The metabolites are more hydrophilic and can be 
conjugated by phase II enzymes or excreted unchanged without any further modification 
(Oppermann, 2007). Metabolism by reduction is considered the major elimination pathway for a 
variety of endogenous compounds and xenobiotics such as drugs, as the carbonyl moiety is quite 
common in these substrates. Table 1-5 provides a list of drugs that are metabolized through 
reduction pathway. Reduction can be either a deactivation and detoxification process producing 
inactive metabolites that are eliminated from the body, or can sometime produce toxic metabolites 
as is case with doxorubicin (Hoffmann and Maser, 2007). Additionally, reduction can act as an 
activation method for pro-drugs such as nabumetone and tibolone, producing pharmacologically 
active metabolites (Malatkova and Wsol, 2014).   
Our understanding of drug reduction pathway is limited, in part, due to relatively little 
research that has been conducted in this area. In fact, reduction has been poorly investigated in the 
literature compared to that of CYP450-mediated oxidation, which usually receives much more 
attention. However, recent development and advances in molecular biology has improved the 
opportunity for the researchers to study reductase enzymes and their important roles in endogenous 
and exogenous biotransformation (Malatkova and Wsol, 2014).   
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Table 1-5  List of drugs that are substrates for reductase enzymes  
Drug 
  
Class 
  
Drug 
  
Class 
      
L-691,121*  Antiarrhythmic  Haloperidol*$  Antipsychotic 
Ketotifen*  Antiasthmatic  Timiperone*  Antipsychotic 
Benfluron*  Anticancer  Boceprevir*  Antiviral 
Daunorubicin  Anticancer  S-1360  Antiviral 
Dimefluron  Anticancer  Levobunolol  β-Blocker 
Doxorubicin  Anticancer  Metyrapone  Diagnostic 
Epirubicin  Anticancer  Ethacrynic Acid$  Diuretic 
Idarubicin*  Anticancer  Pentoxifylline$  Hemorheological 
Iododoxorubicin  Anticancer  Oxisuran  Immunosuppressive 
Mitomycin C  Anticancer  Eperisone  Muscle Relaxant 
Oracin*  Anticancer  HY-770  Muscle Relaxant 
Wortmannin*  Anticancer  Tolperisone  Muscle Relaxant 
Warfarin$  Anticoagulant  CS-670  NSAID 
Nafimidone  Anticonvulsant  Flobufen*  NSAID 
Bupropion$  Antideprassant  Ketoprofen  NSAID 
E/Z-10-oxonortriptyline  Antideprassant  Loxoprofen  NSAID 
Acetohexamide*  Antidiabetic  Nabumetone*  NSAID 
Dolasetron*  Antiemetic  Methylnaltrexone  Opiate antagonist 
Oxcarbazepine*  Antiepileptic  Naloxone  Opiate antagonist 
Fenofibrate  Antihyperlipidemia  Naltrexone*  Opiate antagonist 
Triadimefon  Antifungal  Glucocorticoids$  Steroid 
Befunolol*  Antihypertensive  Norethynodrel*  Steroid 
Ketanserin*  Antihypertensive  Tibolone*  Steroid 
TA-510  Anti-inflammatoy  Naftazone  Vasoprotectant 
Bromperidol*   Antipsychotic   Menadione   Vitamin (K3) 
NSAID: non-steroidal anti-inflammatory drug 
*Drugs have reduction as a major metabolic pathway 
$Drugs that are commonly used in kidney disease patients  
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 Several reductase enzymes have been implicated in the elimination of reactive carbonyl 
ligands. Similar to other DMEs, reductases are separated into different families, groups, and 
individual isoforms based on the homology in their structure and amino acid sequence (Figure 1-
1). In general, reductase enzymes are grouped into carbonyl reducing enzymes and quinone 
reductases. Carbonyl reducing enzymes belong to two fundamentally distinct enzyme families, 
namely the short-chain dehydrogenase/reductase (SDR) and the aldo-keto reductase (AKR) that 
are further separated into different subgroups. On the other hand, carbonyl reduction by quinone 
reductases is principally mediated by the NADPH-dependent quinone reductases (NQO) (Forrest 
and Gonzalez, 2000; Oppermann, 2007). In the following sections, a detailed description of 
reductase subgroups and specific isoforms will be presented. 
 
 
 
Figure 1-1 Major human reductase isoforms and their sub-cellular location 
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1.3.1 Carbonyl Reducing Enzymes 
1.3.1.1 Short-chain dehydrogenase/reductase (SDR) 
The SDR superfamily of reductase enzymes is mainly located in the cytosol and mediates 
reduction primarily by the carbonyl reductases (CBRs). Further, the 11β-hydroxysteroid 
dehydrogenases (11β-HSDs), which are the main microsomal reductases, belong to the SDR 
superfamily (Hoffmann and Maser, 2007). Other enzymes of the SDR family that may contribute 
to carbonyl reduction are dicarbonyl/xylulose reductase (DCXR) and dehydrogenase/ reductase 
SDR family located in the cytosol (Matsunaga et al., 2006), and retinol dehydrogenase and 17β-
hydroxysteroid dehydrogenases located in the microsomes (Skarydova and Wsol, 2012).   
Carbonyl Reductases (CBRs)  
CBR isoforms: The major subgroup of the SDR superfamily that mediates cytosolic 
reduction of carbonyl-containing compounds is carbonyl reductase. CBRs are monomeric proteins 
that are mainly located in the cytosolic fraction of the cell and have a molecular weight of about 
30 KDa (Malatkova et al., 2010). CBRs are NADPH-dependent reductases, indicating that they 
prefer nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor in the carbonyl 
reduction of xenobiotics. Three CBR isoforms have been identified in humans which are CBR1, 
CBR3, and CBR4 (Malatkova et al., 2010). While CBR1 and CBR3 are located in the cytosol 
(Persson et al., 2009), CBR4 is expressed in the mitochondria (Endo et al., 2008). CBR enzymes 
show wide tissue distribution. For instance, CBR1 is highly expressed in the liver and kidney with 
lower amounts found in the placenta and the nervous system, however, CBR3 shows high levels 
in the pancreas, prostate, and ovary (Malatkova et al., 2010). The liver expression of CBR1 is 
about 10-fold higher than CBR3 (Bains et al., 2010). The mitochondrial CBR4 is almost 
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exclusively expressed in the liver, but at levels lower than CBR1. It is worth mentioning that 
another isoform of CBR called CBR2 is identified in rodents and does not have any homolog in 
humans. CBR1 and CBR3 are the two best studied isoforms and are also called SDR21C1 and 
SDR21C2, respectively, according to the SDR nomenclature classification system (Malatkova et 
al., 2010). In fact, these two isoforms share 70% in the identity, which could explain why they 
show overlapping substrate specificity (Miura et al., 2008).  
Endogenous substrates of CBR: CBRs play an important role in the metabolism and 
biotransformation of many biological compounds such as prostaglandins, steroids, lipids, and 
aldehydes. For example, the reduction of the 9-keto group of prostaglandins E1 and E2 (PGE1 and 
PGE2) to PGF2α is mediated by CBR1 (Schieber et al., 1992). Moreover, isatin, an indole 
derivative that is involved in regulation of blood pressure, stress, and sedation is found to be a 
substrate for both CBR1 and CBR3 (Usami et al., 2001). These data suggest that CBRs regulate 
the biological activity and biotransformation of many endogenous ligands.  
Exogenous substrates of CBR: Several xenobiotic compounds act as substrates for CBRs. 
These could be aldehydes, ketones or quinones in origin. Phenanthrenequinone, the product of 
poly aromatic hydrocarbons, can be toxic to the body through DNA alkylation or generation of 
reactive oxygen species. Reduction of this quinone to the hydroquinone form by CBRs is a 
detoxification process, because the resulting metabolite is readily conjugated and eliminated from 
the body, thus, this process protects the body from the harmful effect of quinones (Jarabak and 
Harvey, 1993). The carcinogenic tobacco product, 4-methylnitrosamino-1-(3-pyridyl)-1-butanone 
(NNK), is primarily eliminated through reduction. It is a common substrate for various reductase 
enzymes, of which, CBRs play a fundamental role and showed the highest catalytic efficiency in 
its metabolism (Atalla et al., 2000; Skarydova et al., 2012).   
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CBRs are also implicated in the metabolism of different group of drugs. The list of 
substrates includes mainly anticancers (i.e., benfluron, daunorubicin, doxorubicin, idarubicin, 
oracin), non-steroidal anti-inflammatory drugs (NSAIDS) (loxoprofen and nabumetone), 
antipsychotics (brompepridol, haloperidol, trimiperone), and others such as bupropion, dolasetron, 
metyrapone and pentoxifylline (Barski et al., 2008; Malatkova and Wsol, 2014). Daunorubicin and 
doxorubicin are the major CBR substrates that have been extensively studied (Lal et al., 2010; 
Skarka et al., 2011). Metabolism of these anti-cancer agents at C13 position generates the alcoholic 
forms that have much lower cytotoxic activity compared to the parent drug. However, these 
alcohol metabolites are believed to be responsible for cardiotoxicity, the major dose limiting 
toxicity of anthracyclines (Ax et al., 2000; Forrest et al., 2000). While CBR1 shows 10-fold higher 
activity toward daunorubicin reduction; CBR3 prefers doxorubicin as a substrate (Bains et al., 
2010; Kassner et al., 2008). Generally speaking, CBR3 endogenous and exogenous substrates are 
very limited, and it usually shows lower affinity (high Km) and maximum enzyme capacity (low 
Vmax) compared with CBR1. Collectively, the findings of several studies imply that CBR1 is the 
major carbonyl reductase of the SDR family involved in drug reduction (Pilka et al., 2009). 
 
11β-Hydroxysteroid Dehydrogenases (11β-HSDs) 
11β-hydroxysteroid dehydrogenases are the major SDR members that catalyze carbonyl reduction 
in the microsomes. Two microsomal HSD isoforms have been described to date, 11β-HSD1 
(SDR26C1) and 11β-HSD2 (SDR9C3), which vary in their biological activity and tissue 
distribution (Skarydova and Wsol, 2012). Of these, the NADPH-dependent 11β-HSD1 reductase 
is the most well-investigated and characterized isoform involved in the metabolism of xenobiotics. 
While 11β-HSD1 is predominantly expressed in the liver and adipose tissues, 11β-HSD2, the 
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NAD-dependent dehydrogenase, is abundant in the mineralocorticoid target tissues like kidney, 
colon, and to a lower extent in placenta (Masuzaki and Flier, 2003; Odermatt and Kratschmar, 
2012).  
11β-HSDs substrates: Glucocorticoides are important in the regulation of various 
biological processes. Besides their metabolic function, they are also critical modulators of 
inflammation and immune response. The inter-conversion between endogenous cortisone and 
cortisol is mediated through 11β-HSDs. Cortisone is the inactive form that has a carbonyl moiety 
at C11 position. Reduction at this position is mediated by 11β-HSD1 producing the biologically 
active alcohol form (i.e., cortisol). Conversely, the reverse reaction of cortisol deactivation to 
cortisone is catalyzed by 11β-HSD2 (Draper and Stewart, 2005). Thus, regulation of the 
availability and physiological functions of corticosteroids is governed by the 11β-HSDs activity. 
In addition, recent studies suggested that treatment with synthetic therapeutic corticosteroids might 
be impacted by the functional expression of 11β-HSDs (Diederich et al., 2002; Gathercole et al., 
2013).  
The 11β-HSD1 plays a crucial role in the metabolism of xenobiotics. The contribution of 
11β-HSD2 to drug detoxification is poorly studied so far, and it is suggested that it mainly 
contributes to endogenous glucocorticoids biotransformation (Skarydova and Wsol, 2012). 
Several drugs are substrates for the 11β-HSD1 including acetohexamide, benfluron, bupropion, 
daunorubicin, eperisone, ketoprofen, metyrapone, oracin, and prednisone (Malatkova and Wsol, 
2014). Of these, bupropion and eperisone are primarily metabolized by 11β-HSD1 (Meyer et al., 
2013; Yoo et al., 2011). Metabolism by 11β-HSD1 can eliminate the biological activity of drugs 
as in case of benfluron, or producing toxic metabolites as with daunorubicin (Barski et al., 2008; 
Malatkova and Wsol, 2014). Additionally, active metabolites can be generated by the metabolic 
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reduction of drugs. For instance, bupropion is metabolized by oxidation mediated by CYP2B6 
which generates hydroxybupropion, as well as by reduction mediated by reductases, with the latter 
being the major pathway and occurs in the cytosol and microsomes (Skarydova et al., 2014). 
Metabolism by reduction produces the diastereoisomers erythro- and threohydrobupropion that 
possess about 20% activity of the parent drug bupropion (Molnari and Myers, 2012). A recent 
study reported that bupropion metabolism is catalyzed primarily in the microsomes, producing 
threohydrobupropion as a predominant metabolite followed by hydroxybupropion and 
erythrobupropion (Meyer et al., 2013). Moreover, pro-drugs can also be activated by reduction. 
For example, prednisone is a pro-drug that is metabolized by 11β-HSD1 to prednisolone, which is 
the biologically active form (Diederich et al., 2002). Taken together, 11β-HSD1 is the major 
microsomal reductase enzyme located in the liver and implicated in phase I drug reduction. In 
addition to drugs, 11β-HSD1 also contributes to the detoxification of other xenobiotics such as the 
tobacco toxin (NNK) and quinones, and thus protecting the body from harm (Maser et al., 2006).  
1.3.1.2 Aldo-keto reductase (AKR) 
The second superfamily of the carbonyl reducing enzymes is the AKR. This group of reductases 
is further separated into multiple subfamilies including AKR1, AKR6, and AKR7 (Barski et al., 
2008). AKR1 is the largest subfamily and is divided into AKR1A, 1B, and 1C. AKR1A is called 
aldehyde reductase because it mainly reduces aldehyde-containing substrates into their respective 
alcohols, though it is not aldehyde specific. In fact, a broad spectrum of endogenous and xenobiotic 
carbonyls are reduced by AKR1A including succinic semialdehyde, 4-carboxybenzaldehyde, 4-
hydroxynonenal, haloperidol, metyrapone, loxoprofen, and daunorubicin (Oppermann, 2007). 
AKR1A1 is abundantly expressed in kidney, liver, central nervous system (CNS), and intestine 
(O'Connor et al., 1999).   
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Two major isoforms of aldose reductase (AKR1B) have been identified, AKR1B1 and 
AKR1B10. AKR1B1 is well known for its activity toward glucose reduction to sorbitol (Gabbay, 
2004). This reaction is responsible for microvascular complications associated with diabetes. In 
fact, several AKR1B1 inhibitors are under development to prevent tissue injury associated with 
diabetes (Comer and Ciulla, 2005). AKR1B1 is ubiquitously expressed and contributes to 
biotransformation of several endogenous substrates such as corticosteroids and lipid peroxidase 
products; however, its role in drug reduction has not clear (Barski et al., 2008; Jin and Penning, 
2007). On the other hand, AKRB10 is mainly expressed in the liver, colon, and small intestine, 
and it contributes to the metabolism of dolasetrone, nabumetone, and oracin (Martin et al., 2006).  
The primary AKR group that mediates xenobiotic phase I reduction is AKR1C. In humans, 
four isoforms have been characterized, AKR1C1, AKR1C2, AKR1C3, and AKR1C4, that share 
about 85% homology (Jez et al., 1997). The isoform, AKR1C1, is highly expressed in the liver 
and other tissues. AKR1C2 and AKR1C3 are predominantly expressed in prostate and mammary 
gland, and to a lower extent in the liver. AKR1C4 is exclusively found in the liver (Jin and Penning, 
2007). The major endogenous substrates for AKR1C are steroids, bile acids, and prostaglandins. 
Because of their ability to transform the dihydrodiols of aromatic hydrocarbons, these reductases 
are also called dihydrodiol dehydrogenases (Barski et al., 2008).   
AKR1C is the most important reductase that contributes to drug reduction. It shows wide 
and overlapping drug substrate specificity. AKR1C metabolizes drugs from different 
pharmacological classes such as anticancers, NSAIDS, antipsychotics, opiate antagonists and 
others (Matsunaga et al., 2006). AKR1C1 and AKR1C4 seem to be the most important, due in part 
to their high expression in the liver, the major detoxification organ in the body (Oppermann, 2007). 
The degree of involvement of these reductases to individual drug reduction is variable. For 
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example, the NSAID drug nabumetone was shown to be metabolized by all four AKR1C isoforms; 
however, the catalytic activity was the highest for AKR1C4, and the lowest for AKR1C2 (intrinsic 
clearance = 1.94 vs. 0.28 mL/mg/min, respectively) (Skarydova et al., 2013).  
1.3.2 Quinone Reductases 
Several enzyme systems have been reported to metabolize quinone-containing compounds such as 
those of the SDR or AKR families and thioredoxin reductase, however, the NADPH-dependent 
quinone reductase type 1 (NQO1, DT diaphorase) is the most extensively investigated (Siegel et 
al., 2012). NQO1 is a cytosolic reductase that protects cells from oxidative stress, and catalyzes 
the two-electron reduction of quinones to hydroquinones forms (Dinkova-Kostova and Talalay, 
2000). NQO1 is expressed at high levels in the epithelial tissues and adipocytes, nevertheless, low 
levels are found in the liver (Siegel and Ross, 2000). The anticancer quinone, mitomycin C, has 
been shown to be activated by NQO1. Mitomycin C is commonly used in solid tumors including 
pancreas, lung, and breast cancer. Reduction of mitomycin C by NQO1 results in production of 
the pharmacologically active leucomitomycin C (MMC hydroquinone) that cross-linked to the 
DNA and initiates cancer cell death (Danson et al., 2004; Siegel et al., 1990). Besides quinones, 
NQO1 also catalyzes the metabolism of azo and nitroaromatic compounds. Of note, NQO2 is 
another quinone reductase that has been reported to mediate quinone reduction, without utilizing 
NAPDH as a cofactor. Its role in drug reduction is unknown (Oppermann, 2007).  
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1.4 WARFARIN 
1.4.1 Warfarin Pharmacotherapy 
Warfarin is an oral vitamin K antagonist that has been the gold standard anticoagulant for the 
treatment and prevention of thromboembolic disorders since its introduction more than 50 years 
ago. It acts by inhibiting vitamin K epoxide reductase (VKOR), the enzyme that is involved in 
hepatic activation of vitamin k-dependent clotting factors II, VII, IX, and X and proteins C and S 
(Hirsh et al., 2001). Warfarin is administered clinically as a racemic mixture consisting of both R- 
and S- enantiomers, with the latter being 3-5 times more potent in inhibiting VKOR enzyme 
(Breckenridge et al., 1974).   
Warfarin is a very widely used drug in the clinical practice. It is prescribed to 
approximately 2 million Americans each year, and currently there are around 50 million people in 
the US under warfarin therapy (Kim et al., 2009). The widespread use of warfarin might be 
attributed, in part, to its established efficacy for stroke prevention in the general medical 
population, and the rapid reversal of its action by vitamin K in case of over-anticoagulation. The 
effectiveness of warfarin is supported by a previous meta-analysis, which showed that warfarin 
use in AF patients is associated with 65% reduction in the relative risk of stroke compared to 
placebo or untreated patients (Hart et al., 2007). The analyses also showed that warfarin is about 
40% more effective than antiplatelet therapy for stroke prevention (Hart et al., 2007). Despite its 
extensive use, treatment with warfarin is challenging and complicated due to its narrow therapeutic 
window, high likelihood for food and drug interactions, and large inter-individual variability 
(Hirsh et al., 2003). The bleeding rate in AF patients who are under long-term warfarin therapy 
varies from 0.4 to 17% per year (Fang et al., 2011). Additionally, most patients under warfarin 
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treatment spend about one-third of the time outside the INR target range (Baker et al., 2009; Jones 
et al., 2005). This demonstrates the challenge of optimizing warfarin therapy. Thus, frequent 
monitoring of the international normalized ratio (INR) and individualized warfarin dosing are 
necessary to achieve safe and effective clinical outcomes.   
Individualizing warfarin therapy requires consideration of patient demographic factors, 
comorbid conditions such as liver disease, and variations in the genes encoding VKOR and 
CYP2C9 (White, 2010). Various dosing algorithms have been developed for estimation of 
therapeutic warfarin dose based on integration of patient’s clinical and pharmacogenetic data 
(Gage et al., 2004; Klein et al., 2009; Lenzini et al., 2010). Kidney function has been shown to be 
an important determinant of S-warfarin metabolic clearance (Gong et al., 2011), as well as a 
powerful and independent covariate for predicting warfarin-associated bleeding risk (Fang et al., 
2011; Gage et al., 2006; Pisters et al., 2010). Recently, a failure in pharmacogenetic-based 
algorithms for estimation of warfarin dosing has been observed (Schwartz et al., 2011). The 
combined genetic and clinical factors explained approximately 62% of warfarin dosing variability, 
however, the model overestimated the dose for 15 out of 16 patients requiring <2 mg/day warfarin 
dose. Based on patients’ data, the authors suggested that kidney disease is a potential variable that 
may be associated with lower dosing requirements in elderly patients (Schwartz et al., 2011). 
1.4.2 Warfarin Use in CKD 
Warfarin is commonly used among CKD patients, similar to that observed in the general medical 
population (Reinecke et al., 2009). Approximately 25% of ESRD patients use warfarin, primarily 
to prevent vascular access thrombosis during dialysis (Elliott et al., 2007; Miller et al., 2006) and/or 
to prevent thromboembolic complications in patients with AF (Hart et al., 2011; Yang et al., 2010). 
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Warfarin use is also prevalent in patients with mild/moderate CKD (Hart et al., 2011). Kidney 
disease patients are treated with warfarin despite the sparse evidence about its anticoagulant safety 
and efficacy in the CKD population. In fact, warfarin management in CKD is derived from studies 
that have evaluated the effectiveness of warfarin in other medical patients. Patients with advanced 
CKD are usually excluded from the clinical trials of warfarin therapy (Bansal, 2014). Additionally, 
there has been no randomized controlled study that directly assessed the safety and efficacy of 
warfarin for stroke prevention in HD patients (Winkelmayer and Turakhia, 2014). The lack of 
evidence based use of warfarin, primarily in HD patients, likely contributes to the high incidence 
of poor response in patients with CKD.  
1.4.3 Warfarin Dosing Requirements in CKD  
As previously mentioned the variability in warfarin dosing is partially accounted for by the 
differences in the clinical and genetic background of patients, which could eventually influence 
warfarin pharmacokinetics and pharmacodynamics. Recent studies have shown that dosing 
requirements are also affected by the presence of kidney disease. In a prospective cohort study of 
578 patients who were followed for up to two years, Limdi and colleagues showed that patients 
with severe CKD (eGFR of <30 mL/min/1.73m2) required 20% lower warfarin dosages, had higher 
proportion of INRs outside the therapeutic range, and were at increased over-anticoagulation (HR 
= 1.49) and major bleeding risks (HR = 2.4) compared with patients who had mild or no CKD. 
The findings remained significant even after adjustment for patient’s clinical and genetic variables 
(Limdi et al., 2009). The same group further reported that patients with moderate CKD (eGFR of 
30-59 mL/min/1.73m2) require approximately 10% warfarin dose reduction compared to patients 
with mild or no CKD (Limdi et al., 2010). Recent retrospective studies have confirmed these 
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findings, demonstrating dose reductions in CKD/ ESRD of up to 24% compared to control 
(Kleinow et al., 2011; Sakaan et al., 2014). One of these investigations has also documented that 
CKD patients are at high risk of decreased anticoagulation stability, thus they are required to visit 
anticoagulation clinics more frequently for warfarin dose manipulation (Kleinow et al., 2011). As 
indicated, warfarin dosing requirements are varied between CKD patients and other patients with 
normal kidney function; therefore, better understanding of factors that affect warfarin dosing in 
CKD may identify the appropriate and optimum warfarin therapeutic dosage for kidney disease 
patients, which would improve its clinical safety and efficacy. The recent findings suggest that the 
current approaches for warfarin management in CKD patients, which are reflections of those 
applied for the general medical patients, may be not suitable and they should be modified so they 
can account for the level of kidney function. 
1.4.4 Warfarin Outcomes in CKD 
Because AF patients with CKD experience an increased risk of bleeding and stroke, researchers 
questioned whether treating CKD patients with warfarin will be beneficial in preventing 
thromboembolic complications and will minimize the risk. Thus, several observational studies 
have investigated the safety profile and effectiveness of warfarin in CKD patients, demonstrating 
an association between increased risk of poor outcomes, such as hemorrhage, stroke, and mortality, 
and impaired kidney function (Chan et al., 2009a). The bleeding rate associated with warfarin 
anticoagulation in HD patients is 2-fold higher than those receiving no warfarin treatment (Elliott 
et al., 2007). A retrospective study of 255 HD patients reported that the risk of major bleeding 
increases with warfarin and/or aspirin use up to four or five times (Holden et al., 2008). This 
finding has also been supported recently in a study of 1626 HD patients, which showed a 44% 
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increased risk of bleeding in warfarin-treated patients (Shah et al., 2014). In addition to bleeding 
complications, there is an evidence of increased risk of mortality in ESRD patients (Chan et al., 
2009a). The recent epidemiological retrospective study of 41,425 incident HD patients showed 
that warfarin, clopidogrel, and aspirin were commonly prescribed among long-term HD patients. 
However, their use was significantly associated with increased risk for mortality. Warfarin hazard 
ratio (1.27) was higher than that for clopidogrel (1.24) and aspirin (1.06) (Chan et al., 2009a). In a 
follow-up study of 1,671 incident HD patients with preexisting atrial fibrillation, the same group 
also documented increased risk for new stroke in warfarin users but not with either users of 
clopidogrel or aspirin (Chan et al., 2009b). These strokes were more likely to be hemorrhagic in 
nature (Winkelmayer et al., 2011a). In both studies, however, the authors suggested that the 
confounding by indication cannot be ruled out.  
The above findings are in conflict with other reports that showed improved outcomes for 
CKD patients treated with warfarin. The most modern observational, prospective, multi-center 
cohort study of 24,317 patients (5292 warfarin users) demonstrated a lower risk of the composite 
outcome of death and ischemic stroke, with no increase in bleeding risk with warfarin treatment 
across all kidney disease levels (Carrero et al., 2014). Other elegant well-matched observational 
studies have also elucidated that warfarin use in CKD patients is associated either with decreased 
or in-different risk of mortality, stroke and bleeding in CKD patients, primarily those under 
hemodialysis (Hart et al., 2011; Lai et al., 2009; Olesen et al., 2012; Winkelmayer et al., 2011a). 
It is therefore obvious that further investigations are warranted to explore the possible reasons 
behind the anticoagulant instability of warfarin in patients with CKD. 
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1.4.5 Warfarin versus the New Oral Anticoagulants 
Several new oral anticoagulants (NOACs) have been recently approved for prevention and 
treatment of thromboembolism and as stroke prophylaxis in patients with AF. While dabigatran 
works as a direct thrombin inhibitor, rivaroxaban and apixaban act by inhibiting clotting factor X 
activation (Shameem and Ansell, 2013). Unlike warfarin, the NOACs have limited drug and food 
interactions, shorter half-lives, and do not require frequent lab monitoring of INR. However, these 
drugs are more expensive, and lack a specific antidote that would be essential to reverse their 
anticoagulation effect in case of toxicity (Reinecke et al., 2013). Most importantly, the NOACs 
are excreted unchanged in the urine in considerable amounts (25-80%), which indicates that 
dosage adjustment is necessary in patients with varying degrees of kidney impairment, especially 
those with severe CKD (Harder, 2012). 
These novel oral anticoagulants have been investigated for their efficacy and safety as 
compared to warfarin; however, most often patients with CrCl < 30 mL/min were usually excluded 
from these clinical trials. Dabigatran at 150 mg twice daily was more effective than warfarin in 
stroke prevention in AF patients, however, similar efficacy was also observed with dabigatran 110 
mg twice daily. The risk of major bleeding was similar and lower at 150 mg and 110 mg dabigatran, 
respectively, as compared with warfarin (Connolly et al., 2009). These findings remained 
consistent even after categorizing patients according to their kidney function (Hijazi et al., 2014). 
The randomized double-blinded control trial (ROCKET AF) investigated effectiveness and safety 
of rivaroxaban versus warfarin in AF patients, demonstrated the non-inferiority of rivaroxaban to 
warfarin in stroke prevention. Also, the risk of major bleeding was not different between the two 
groups (Patel et al., 2011). In the ARISTOTLE clinical trial, apixaban showed higher efficacy than 
warfarin in stroke prevention and reducing mortality with lower rates of major bleeding, 
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irrespective of the degree of kidney disease (Granger et al., 2011; Hohnloser et al., 2012). A recent 
systematic review and meta-analysis compared the use of new oral anticoagulants and vitamin K 
antagonists in CKD patients and reported no significant difference between the two groups in terms 
of efficacy outcomes of stroke and embolism, as well as the risk of major bleeding (Harel et al., 
2014). 
 The aforementioned findings raise many concerns and challenges for the value of warfarin 
use in CKD, leading many people to doubt and question the risk versus benefit of using warfarin 
in CKD, particularly in dialysis patients (Bennett, 2006; Finazzi and Mingardi, 2009; Sood et al., 
2009; Yang et al., 2010). With this controversy, definitive conclusions can only be obtained after 
conducting large randomized controlled trials (Granger et al., 2011). Until more data are available, 
clear understanding of mechanisms that lead to altered warfarin dose-response in CKD would be 
helpful in generating new approaches that would have the potential to improve warfarin 
management and pharmacotherapy especially in the CKD population. Because the NOAC agents 
have not been investigated across all levels of kidney function, definitive conclusion about 
switching from warfarin to NOAC cannot be drawn at this time.  
1.4.6 Warfarin Metabolism 
1.4.6.1 Phase I warfarin oxidation 
Warfarin is a highly metabolized drug that undergoes phase I and phase II metabolism in the liver. 
Phase I metabolism of warfarin is separated into oxidation and reduction reactions (Figure 1-2). 
Warfarin oxidation, which is mediated by CYP450 enzymes, shows stereoselective and 
regioselective features (Kaminsky and Zhang, 1997). The more potent isomer, S-warfarin, is more 
rapidly cleared by hepatic oxidation reactions, almost exclusively by CYP2C9 (~90%) producing 
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S-7-OH as a major hydroxylated metabolite (Kaminsky and Zhang, 1997). On the other hand, 
several CYP enzymes (CYPs 1A2, 2C8, 2C19, and 3A4) are involved in the metabolism of R-
warfarin into its hydroxy-metabolites (Kaminsky and Zhang, 1997; Wadelius et al., 2007). 
CYP1A2 is the principal enzyme catalyzing R-6-hydroxylation (Zhang et al., 1995). CYP2C19 
has an affinity toward production of R-8-OH and R-6-OH, favoring the former metabolite 
(Kaminsky et al., 1993; Wienkers et al., 1996). CYP3A4 has a 5-fold higher affinity toward R-
warfarin compared with S-warfarin to generate exclusively R-10-OH metabolite (Ngui et al., 2001; 
Rettie et al., 1992). Because S-warfarin is almost exclusively metabolized by CYP2C9, the ratio 
between the two enantiomers (S/R warfarin) is currently used as phenotypic index of CYP2C9 
activity (Dreisbach et al., 2003). Warfarin oxidation results in loss of anticoagulant activity. As 
such, the inactive warfarin hydroxy-metabolites can be either excreted unchanged in the urine, or 
further metabolized by phase II conjugation. Warfarin oxidation has received more attention to 
date due to its significant contribution to warfarin metabolism and overall elimination. 
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Figure 1-2  Phase I warfarin oxidation and reduction pathways 
 
1.4.6.2 Phase I warfarin reduction 
Reduction is the second major pathway of phase I warfarin biotransformation that accounts for 
approximately 15-20% of total warfarin metabolism (Lewis et al., 1974). The acetonyl side chain 
reduction of warfarin by hepatic reductases generates warfarin alcohols. Warfarin reduction results 
in creation of another chiral center on warfarin structure, thus, four stereoisomers of warfarin 
alcohols are produced (RS, RR, SS, and SR). These alcohols are separated into two pairs (mirror 
images): Alcohol 1; the RS/SR diastereoisomer, and Alcohol 2; the RR/SS diastereoisomer (Chan 
et al., 1972).  
Previous reports have shown that the NADPH-dependent reductases contribute to warfarin 
reduction. It is also known that warfarin reduction is predominantly catalyzed in the cytosol 
(Moreland and Hewick, 1975). In vitro studies showed that, after incubation of liver cytosolic 
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fractions with either warfarin or individual warfarin enantiomers, R-warfarin was reduced into 
primarily RS alcohol (77%), and S-warfarin was reduced to primarily SS alcohol (57%) (Moreland 
and Hewick, 1975). This indicates that the alcohol products of warfarin reduction are mainly in S-
configuration. The findings also demonstrate that the rate of R-warfarin reduction is higher than 
S-warfarin, and human reductases show 4-fold more activity toward warfarin reduction than rats 
(Moreland and Hewick, 1975). In order to assess the ability of microsomal reductases to 
metabolize warfarin, a study was conducted in several species using cytosolic and microsomal 
fractions of liver tissue (Hermans and Thijssen, 1989). The authors reported that the cytosolic 
reductases play a predominant role in warfarin reduction. Nonetheless, the microsomal enzymes 
have undetectable (in rats) or generally low (in humans) activity toward warfarin reduction; human 
microsomes metabolized the R-enantiomer to primarily the alcohol 1 (RS) metabolite (Hermans 
and Thijssen, 1989). In an effort to understand the contribution of cytosolic reductases to warfarin 
metabolism, a study was performed utilizing two purified rabbit liver cytosolic fractions and 
various reductase enzymes inhibitors. Warfarin reduction was inhibited by menadione, 
furosemide, indomethacin, and prostaglandin E2 in both fractions, suggesting that warfarin 
reduction is more likely to be catalyzed by several isoforms of the carbonyl reductase enzymes 
(Hermans and Thijssen, 1992; Hermans and Thijssen, 1993). To summarize, warfarin reduction 
shows substrate and product stereoselectivity. While R-warfarin is preferred as a substrate, the 
favored product is the S-configuration. Additionally, warfarin reduction primarily occurs in the 
cytosol. Nevertheless, the specific reductase isoforms that are involved in warfarin metabolism 
have not been characterized to date.  
Unlike warfarin hydroxy-metabolites, warfarin alcohols are excreted unchanged in the 
urine (Lewis et al., 1974). Moreover, the steady-state plasma levels of warfarin alcohol in patients 
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with long term anticoagulation therapy are comparable to that of 7-OH-warfarin, the most 
abundant warfarin hydroxy-metabolite, or even to the parent warfarin enantiomers, with the RS 
isomer being the most common warfarin alcohol in plasma (Chan et al., 1994; McAleer et al., 
1992). Most importantly, compared to hydroxy-metabolites, warfarin alcohols exert anti-coagulant 
activity. The oral administration of individual warfarin alcohols to healthy volunteers resulted in 
decreased plasma levels of vitamin-k dependent clotting factors with subsequent prolongation in 
prothrombin time. The anticoagulant response was equivalent for all four alcohols; however, it 
was more sustained after administration of RS alcohol, which could be attributed partially to its 
long half-life (34 h for RS versus 13 h for RR, RS, and SS) (Chan et al., 1972; Lewis and Trager, 
1971; Lewis et al., 1973). In addition, the recent in vitro findings have demonstrated that warfarin 
alcohols are 6-fold less potent than warfarin in their ability to inhibit VKOR enzyme (IC50 12.5 
vs. 2.2 µM) (Gebauer, 2007). Since warfarin alcohols possess anticoagulant activity and achieve 
considerably higher plasma concentrations, alteration of their disposition may contribute to the 
variability in warfarin response and dosing requirements in CKD patients.  
1.4.6.3 Phase II warfarin conjugation 
The hydroxy products of warfarin phase I metabolism can be further stereo- and regioselectively 
conjugated primarily by UGT isoforms, producing glucuronidated hydroxy-metabolites that are 
excreted principally in the urine (Jones et al., 2010). Several UGTs are involved in warfarin 
glucuronidation. Using human liver microsomes and recombinant human UGTs, Zielinska and 
coworkers illustrated that five UGTs were shown to be active toward warfarin hydroxy-
metabolites conjugation, including UGTs 1A1, 1A3, 1A8, 1A9, and 1A10 (Zielinska et al., 2008). 
The role of the extrahepatic UGT1A8 and UGT1A10 was significant in clearance of warfarin 
metabolites. The 6-OH metabolite was primarily metabolized by the extrahepatic UGT1A10. 
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Different UGTs recognized 7-OH and 8-OH metabolites with the highest activities related to 
UGT1A1 and UGT1A10, respectively. Lastly, UGT1A10 showed a little activity toward 4’-OH, 
nevertheless, 10-OH as well as warfarin were not recognized by any of the screened enzymes 
(Zielinska et al., 2008). These data suggest that UGT1A1 and UGT1A10 are the two principal 
UGT isoforms that catalyze warfarin conjugation. Additionally, the combined functional 
expression of hepatic and extrahepatic (i.e., stomach and intestines) UGTs derives the capacity 
and efficacy of this pathway toward warfarin elimination. Recently, the study of Bratton and 
colleagues has demonstrated the stereoselective effect of UGTs in metabolizing warfarin hydroxy-
metabolites. For instance, UGT1A8 and UGT1A9 selectively recognized S-8-OH metabolite, with 
no activity toward R-8-OH enantiomer (Bratton et al., 2012). Collectively, the complementary role 
of conjugative enzymes toward warfarin metabolism may open new avenues to better understand 
their contribution to warfarin disposition and response. 
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1.5 SUMMARY, RESEARCH HYPOTHESIS AND OBJECTIVES 
CKD is among the major public health problems that affect people worldwide. The prevalence of 
CKD is increasing due to the growing global epidemics of diabetes and hypertension. Deterioration 
of kidney function alters pharmacokinetics as a result of impaired filtration and/or active secretion 
processes, and may place patients at high risk of drug toxicity. Thus, dosing adjustments are 
important for drugs that are cleared unchanged via the kidneys. In addition to the effect of kidney 
disease on renal clearance of drugs, elimination mediated by drug metabolizing enzymes and 
transport proteins is also impacted. This suggests that drugs that are eliminated nonrenally may 
need dosing adjustments when prescribed to CKD patients. As described earlier, numerous studies 
have demonstrated alterations of drug metabolism and transport in kidney disease. This was 
evaluated from in vitro studies utilizing sub-cellular fractions or cell culture, to in vivo studies 
using phenotypic probe substrates. However, these studies were limited to phase I drug oxidation, 
phase II conjugation, and transport.  
Reduction is another critical drug metabolism pathway that accounts for the metabolism of 
a significant number of drugs and endogenous compounds. Alterations of drug metabolism 
catalyzed by reductase enzymes may influence drug disposition and its pharmacological response. 
In fact, several clinical studies outlined earlier demonstrated changes in exposure and metabolic 
clearance of drugs metabolized primarily by reduction. However, to date, limited information 
exists about whether kidney disease alters the activity and expression of reductase enzymes. Thus, 
the major goal of this dissertation work was to systematically evaluate the effect of kidney disease 
on hepatic reductase functional expression. This body of work will improve our understanding of 
the effect of kidney disease on drug disposition, nonrenal clearance in particular. It may also help 
improve drug management in patients with impaired kidney function.   
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The primary hypothesis guiding this work is that kidney disease decreases the functional 
expression of reductase enzymes located in the liver, resulting in altered drug disposition. In order 
to perform these assessments, we employed warfarin as a pharmacological probe substrate. As 
discussed earlier, warfarin is metabolized by reduction to produce distinct warfarin alcohol 
metabolites, and their formation rate may be used as a surrogate of the activity of reductase 
enzymes. In addition, utilizing warfarin as a substrate could explain mechanisms of altered 
warfarin dose-response in the setting of kidney disease.   
To test the central research hypothesis, it was first necessary to develop a novel analytical 
assay capable of quantifying warfarin alcohol metabolites. This was achieved by utilizing 
advanced and modern techniques and instruments as presented in chapter 2. The second objective 
was to investigate the effect of experimental kidney disease on hepatic reductase function and 
expression. This was completed in vitro using subcellular fractions of livers collected from control 
rats and those subjected to nephrectomy as described in chapter 3. Next, we predicted that human 
reductase isoforms will be impacted by kidney disease. Thus, the third objective was to explore 
the effect of ESRD on the activity and expression of human hepatic reductases. This work was 
accomplished in vitro using liver tissue collected from patients with and without ESRD as detailed 
in chapter 4. The last objective was to evaluate the steady-state pharmacokinetics of warfarin in 
patients with impaired kidney function. This was achieved by collecting blood samples from 
patients with varying degrees of kidney function, and conducting analytical work, pharmacokinetic 
and data analyses as presented in chapter 5. The last study may allow a potential translation of pre-
clinical findings into humans. Finally, the conclusions, limitations, and the recommended future 
directions of this thesis work are discussed in chapter 6.   
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2.0  DETERMINATION OF WARFARIN ALCOHOL METABOLITES USING 
ULTRA HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS 
SPECTROMETRY: METHOD DEVELOPMENT AND VALIDATION   
 
 
 
 
 
 
 
 
 
 
 
 
[Alshogran OY, Ocque AJ, Zhao J, Day BW, Leblond FA, Pichette V, Nolin TD. Determination 
of warfarin alcohols by ultra-high performance liquid chromatography-tandem mass spectrometry: 
application to in vitro enzyme kinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 
944: 63-68, 2014].  
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2.1 ABSTRACT 
A sensitive, accurate, and reproducible ultra-high performance liquid chromatography–tandem 
mass spectrometry method was developed and validated for determination of warfarin and its 
alcohol metabolites (RS/SR- and RR/SS-warfarin alcohol) in 10 mM Tris-HCl incubation buffer 
(pH 7.4). Sample preparation involved acidification with 4% formic acid, followed by liquid-liquid 
extraction using methyl tert-butyl ether. Chromatographic separation was achieved using a 
Hypersil Gold C18 (2.1  100 mm, 1.9 µm) analytical column with gradient elution of solvent A 
(water containing 0.01% formic acid) and solvent B (acetonitrile containing 0.1% formic acid). 
The flow rate was 0.4 mL/min and the total run time was 5 min. Detection of analytes was 
performed using heated electrospray ionization (negative mode) and selected reaction monitoring. 
Excellent linearity was observed for all analytes over the standard curve concentration ranges of 
100-10,000 ng/mL for warfarin, and 0.5-250 ng/mL for warfarin alcohols. The intra- and inter-day 
accuracy and precision for analytes were within ±10.0%. Excellent recovery and negligible matrix 
effects were observed. The method is sensitive, accurate and reproducible, and was successfully 
applied to in vitro enzyme kinetic studies of warfarin in rat liver cytosol. 
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2.2 INTRODUCTION 
Warfarin is administered clinically as a racemic mixture of both R- and S-enantiomers, and is 
highly metabolized, exhibiting regioselective and stereoselective metabolism (Jones et al., 2010; 
Kaminsky and Zhang, 1997). It undergoes phase I oxidation mediated mainly by CYP450 
enzymes, CYP2C9 in particular, producing hydroxy metabolites that can be further metabolized 
by phase II conjugation (Jones et al., 2010; Kaminsky and Zhang, 1997). The effect of various 
factors (e.g., disease, inflammation, genetic polymorphisms) on CYP2C9 function (Zanger and 
Schwab, 2013) and their subsequent impact on warfarin dose requirements has been extensively 
studied (Cavallari et al., 2010; Jorgensen et al., 2009), and this information is now used to optimize 
warfarin therapy (Klein et al., 2009; Lenzini et al., 2010). 
As discussed previously in chapter 1, reduction is an important metabolic pathway for 
warfarin elimination. Warfarin undergoes reduction by hepatic reductases, which generate 
warfarin alcohols of two diastereoisomers (alcohol 1 and alcohol 2) (Chan et al., 1972; Lewis et 
al., 1974). Warfarin reduction is catalyzed predominantly in the cytosol, producing warfarin 
alcohol 1 as the major metabolite (Hermans and Thijssen, 1989; Moreland and Hewick, 1975). 
Although reduction accounts for up to 20% of warfarin metabolism (Lewis et al., 1974) and 
produces pharmacologically active alcohol metabolites (Lewis et al., 1973), the effect of altered 
reductase function on the disposition of warfarin and its alcohol metabolites has not been studied 
to date. In order to do so, a robust and validated analytical method for the quantitative 
determination of each analyte is required. 
Several analytical assays have been developed for measuring the enantiomers of 
hydroxywarfarin metabolites in biological samples including HPLC with UV (Miura et al., 2011), 
combination of UV/fluorescence and circular dichroism (Takahashi et al., 1997) or MS detection 
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(Jones et al., 2011; Uno et al., 2007; Zuo et al., 2010), capillary zone electrophoresis with UV 
detection (Zhou et al., 2003), and micellar electrokinetic chromatography with MS detection 
(Wang et al., 2013). However, few methods have been reported for the determination of warfarin 
alcohol metabolites. These include conventional HPLC methods with UV or fluorescence 
detection (Banfield and Rowland, 1984; Fasco et al., 1979; Fasco et al., 1977; Wong and Davis, 
1989), and gas chromatography with mass spectrometric (GC-MS) detection (Duffield et al., 
1979). In general, HPLC with UV or fluorescence detection methods are not as sensitive and 
selective as MS techniques and require larger sample volume to achieve high sensitivity. The 
reported GC-MS method is complex, and requires extensive sample preparation including a 
derivatization step (Duffield et al., 1979). In addition, each of the reported methods include 
minimal or no validation parameters for detection and quantitation of warfarin alcohols.  
Recently, LC-MS techniques are considered as the gold standard for quantification of 
pharmaceuticals in different biological matrices, in part, due to the inherent selectivity and 
sensitivity. To date, use of contemporary LC-MS for the measurement of warfarin alcohols has 
not been reported. Thus, the goal of this work was to develop and validate an efficient, simple, 
robust, and rapid high throughput ultra-high performance liquid chromatography–tandem mass 
spectrometry (UHPLC-MS/MS) assay for determination of warfarin and its alcohol metabolites.  
The method was validated according to the current U.S. Food and Drug Administration 
(FDA) guidelines for bioanalytical method validation 
[http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM368107.pdf]. The method was utilized to examine the effect of CKD on the activity of hepatic 
reductases using warfarin as a probe as we will discuss in the following chapters of this thesis.  
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2.3 METHODS 
2.3.1 Chemical and Reagents 
Warfarin (C19H16O4), d5-7-hydroxywarfarin (C19H11D5O5, used as internal standard for warfarin 
alcohols), formic acid, NADPH, magnesium chloride, and tris(hydroxymethyl)aminomethane 
(Trizma base) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Warfarin alcohols 
(C19H18O4) were synthesized as previously described with the assistance of Dr. Billy Day 
laboratory at the University of Pittsburgh (Chan et al., 1972; Trager et al., 1970). Racemic d5-
warfarin (C19H11D5O4, used as internal standard for warfarin) was purchased from Toronto 
Research Chemical (North York, Ontario, Canada). Hydrochloric acid, methyl tert-butyl ether 
(MTBE), methanol, OPTIMA LC-MS grade water, and acetonitrile were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). All chemicals were LC-MS grade or of the highest purity 
available. Nitrogen gas (ultra-pure, >99.9%) was produced by a Parker Balston nitrogen generator 
(Haverhill, MA, USA). Argon gas (ultra-pure, >99.9%) was provided by Valley (Wheeling, WV, 
USA). 
2.3.2 Equipment and LC-MS/MS Conditions  
Liquid chromatography was performed with an Accela series UHPLC system (Thermo Scientific, 
San Jose, CA, USA) including an autosampler and ultra-high performance binary pump. 
Chromatographic separation of the samples was achieved with a Thermo Hypersil Gold C18 (2.1 
 100 mm, 1.9 µm) analytical column, connected to 0.22 µm frit filter. The flow rate was 400 
µL/min and composed of solvent A (water containing 0.01% formic acid), and solvent B 
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(acetonitrile containing 0.1% formic acid). The gradient consisted of 60% solvent A and 40% B 
for 0-2.0 min, followed by 35% A and 65% B from 2.0-3.0 min. The column was then re-
equilibrated to initial conditions for 2 min. The total run time was 5 min. The autosampler was 
maintained at 10ºC and the column temperature was held at 40ºC.  
Mass spectrometric detection was performed on a TSQ Quantum Ultra triple quadrupole 
mass spectrometer (Thermo Scientific San Jose, CA, USA) equipped with a heated electrospray 
ionization source (HESI). Analytes were detected in negative ionization mode using selected 
reaction monitoring. The spray voltage was set to 3000V and the vaporizer temperature was set to 
360ºC. The sheath gas and auxiliary gas were set to 65 and 55 (arbitrary units), respectively. The 
ion transfer tube was set to 350ºC. Collision gas (argon) pressure was set at 1.5 mTorr. Scan width 
was set to 0.01 m/z, scan time was set to 0.5 seconds, and full width at half maximum was set to 
0.7 m/z for quadrupole one (Q1) and three (Q3). The ion transition and collision energy of the 
analytes are presented in Table 2.1. Signal output was captured and processed with Xcaliber 
software v2.2 (Thermo Scientific, San Jose, CA, USA).  
 
Table 2-1  MS conditions of the analytes and internal standards in the negative 
electrospray ionization mode 
Analyte   
PrecursorProduct 
(m/z) 
  
Collision Energy 
(V) 
Warfarin  307.1  161.1  17 
     
d5-warfarin  312.2  161.2  22 
     
Warfarin alcohols  309.1  250.3  26 
     
d5-7-hydroxywarfarin    328.1  177.1   22 
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2.3.3 Preparation of Calibration Standard and Quality Control Samples  
Each analyte (warfarin and warfarin alcohols) was dissolved in methanol to obtain a 1.0 mg/mL 
stock solution. These stock solutions were mixed with methanol to prepare intermediate working 
solutions that were spiked into blank 10 mM Tris-HCl incubation buffer (pH 7.4) to create 
calibration standards at concentrations of 100, 200, 1000, 2000, 5000, and 10000 ng/mL for 
warfarin, and 0.5, 5.0, 25, 50, 125, and 250 ng/mL for warfarin alcohols. Three quality control 
samples (LQC, MQC, and HQC) containing both analytes were made by spiking a separate 1.0 
mg/mL stock solution into blank Tris-HCl solution at concentrations of 300, 4000, and 8000 
ng/mL for warfarin, and 1.5, 100, and 200 ng/mL for warfarin alcohols. Preliminary experiments 
showed that recoveries of analytes were not affected by the presence of microsomal or cytosolic 
protein and cofactors. Therefore, standards and QCs were prepared in the incubation buffer alone. 
All stock solutions, standards and QC samples were stored at -80ºC to simulate the storage 
conditions of study samples.  
2.3.4 Sample Preparation  
An internal standard working solution containing 5.0 µg/mL d5-warfarin and 1.2 µg/mL d5-7-
hydroxywarfarin was prepared in methanol. A 100 µL aliquot of sample (incubation sample, 
calibration standards, or quality controls) was spiked with 20 µL internal standard solution, and 
then acidified by adding 250 µL 4% formic acid in water. Sample extraction was carried out using 
liquid-liquid extraction procedure by adding 2 mL MTBE and placing on a shaker with continuous 
mixing for 20 min at room temperature. The upper organic layer was removed and evaporated to 
dryness for 10 min under a stream of nitrogen at 37ºC. The dried residue was reconstituted with 
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150 µL of acetonitrile-water (25:75, v/v). Samples were loaded into autosampler vials and 20 µL 
was injected into the LC-MS/MS system.  
2.3.5 Assay Validation  
2.3.5.1  Calibration and linearity 
Calibration curves were constructed using six concentrations of warfarin and warfarin alcohols. 
Each calibration level was run in duplicate for three days, except for the lower limit of 
quantification (LLOQ), which was run in triplicate. For each curve, the absolute peak-area ratios 
of the analyte to the internal standard were calculated and plotted against the nominal analyte 
concentration. Calibration curves were generated by equal weighting quadratic log-log regression 
analysis. 
2.3.5.2  Accuracy and precision 
Accuracy and precision were determined by the analysis of QC samples spiked at three 
concentrations (LQC, MQC, and HQC). Six replicate QC samples at each concentration were 
analyzed daily for two days, followed by analysis of twelve replicate QC samples at each 
concentration on the third day, for a total of n = 24 QC samples at each QC level. Intra-day 
accuracy and precision were determined from the twelve replicates on day 3, and inter-day 
accuracy and precision were calculated from all 24 QC samples. The calculated mean 
concentration relative to the nominal concentration was used to express accuracy (% bias) as 
follows: %bias = (calculated concentration – nominal concentration)/ nominal concentration×100. 
The relative standard deviation (% RSD) was calculated from the QC values and used to estimate 
the precision as follows: %RSD = (standard deviation/mean) ×100. The results of each run were 
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accepted when the accuracy and precision are falling within ±15% deviation from the nominal 
concentrations.  
A dilution analysis was performed on samples spiked to twice the concentration of the 
highest standard, then diluted 1:4, 1:20, or 1:100 with blank Tris-HCl buffer before analysis. Each 
dilution level was processed in triplicate and back calculated against the standard curves. 
2.3.5.3  Recovery, process efficiency and matrix effect 
Extraction recovery of warfarin alcohols was determined by comparing the absolute response 
(peak areas) of the analytes spiked in blank Tris-HCl buffer before and after the extraction. Process 
efficiency was evaluated by comparing the response of analytes spiked in the buffer before 
extraction with that of neat solutions spiked in mobile phase, which was defined as 100% recovery. 
Matrix effect was assessed by comparing the response of the analytes spiked in the buffer after 
extraction with that of neat solutions spiked in mobile phase, representing 100% (no matrix effect). 
All experiments were conducted at three QC levels in four replicates. Samples were analyzed using 
standard curves generated from warfarin alcohol standards as described previously.  
2.3.5.4  Stability 
Stability was evaluated at low and high QC levels in triplicate. Bench-top stability was tested by 
analyzing samples that were left out on the bench top at room temperature for four hours before 
analysis. Autosampler stability was determined for processed samples stored at 10ºC, which were 
re-injected and analyzed against a new standard curve up to 24 hours post-processing. Freeze-thaw 
stability was assessed for samples that were subjected to three freeze-thaw cycles at 24 hour 
intervals from -80C to room temperature prior to analysis. The results of all tested samples were 
compared with the recovery from samples that were freshly prepared and defined as 100% control. 
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In all cases, solutions were considered to be stable as long as the measured concentration deviated 
from control by less than 15%. 
2.3.6 Application of the Method  
The analytical method was applied to the quantification of alcohol metabolites generated after in 
vitro warfarin reduction. Briefly, liver cytosol was isolated from rat liver tissue by a standard 
differential centrifugation procedure (van der Hoeven and Coon, 1974). Cytosolic protein (0.5 
mg/mL) was incubated with warfarin (20-2000 µM) and 5 mM MgCl2 in 10 mM Tris-HCl buffer 
(pH 7.4). Reactions were started by the addition of 1 mM NADPH and conducted for 30 min at 
37ºC. Incubation conditions were optimized with respect to time and protein concentration. 
Following incubation, warfarin alcohols were measured as described above. A Michaelis-Menten 
model was used to fit the formation of alcohol metabolites, and total reductase enzyme activity 
was estimated (GraphPad Software Inc., San Diego, CA). 
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2.4 RESULTS 
2.4.1 Chromatographic Separation  
Representative chromatograms of analytes at the LLOQ and in a cytosolic reaction mixture are 
shown in Figure 2.1. The analytes were identified based on retention time and mass spectra of the 
injections of individual analytical standards. The retention times were approximately 2.23, 2.61 
and 2.86 min for warfarin alcohol 2, warfarin alcohol 1 and warfarin, respectively. The peaks of 
interest were well separated and free from evidence of ion suppression or enhancement. 
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Figure 2-1  Representative chromatograms of incubation buffer at LLOQ and a cytosolic 
incubation sample  
(A) warfarin: 100 ng/mL; (B, F) internal standard d5-warfarin; (C) warfarin alcohols: 0.5 ng/mL; 
(D, H) internal standard d5-7-hydroxywarfarin; (E) warfarin: 7,941 ng/mL; (G) warfarin alcohol 
2 & alcohol 1: 0.85, 7.97 ng/mL, respectively. 
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2.4.2 Assay Validation  
2.4.2.1 Calibration and linearity 
Calibration curves were obtained over concentration ranges of 100-10,000 ng/mL for warfarin, 
and 0.5-250 ng/mL for warfarin alcohols, with a correlation coefficient (r2) greater than 0.996 for 
all curves. The LLOQ for each calibration curve demonstrated acceptable accuracy and precision 
(RSD and bias were within ±11% and ±5%, respectively, Table 2.2), and signal-to-noise was 
greater than 10:1. The intra- and inter-day accuracy and precision were within ±12% for all 
calibration standards (Table 2.2). 
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Table 2-2  Intra-and inter-day accuracy (%Bias) and precision (%RSD) 
for calibration standards 
  
Nominal 
Conc 
  Intra-daya  Inter-dayb 
Analyte (ng/mL)   % Bias % RSD  % Bias % RSD 
Warfarin         
 100 (LLOQ)  -2.4 4.7  -5.4 7.8 
 200  6.2 0.3  2.8 3.9 
 1000  -4.2 2.0  -3.2 3.4 
 2000  4.7 2.6  6.4 3.7 
 5,000  -5.8 1.8  -7.1 1.5 
 10,000  3.4 1.8  3.5 1.5 
Warfarin alcohol 1        
 0.5 (LLOQ)  1.1 10.7  1.2 6.5 
 5  -1.7 1.3  -3.6 4.9 
 25  -8.2 8.6  -1.3 6.9 
 50  11.7 2.3  5.9 7.4 
 125  3.6 4.1  1.8 4.2 
 250  -5.0 0.9  -3.1 3.9 
Warfarin alcohol 2        
 0.5 (LLOQ)  0.3 10.8  0.4 8.8 
 5  2.1 3.1  0.4 2.9 
 25  -7.3 6.3  -2.8 5.5 
 50  5.4 1.6  2.0 5.4 
 125  3.2 3.4  2.7 3.6 
  250   -2.5 2.1   -1.9 2.4 
a 
3 replicates for LLOQ, 2 replicates for other standards 
b 
9 replicates for LLOQ; 6 replicates for other standards  
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2.4.2.2 Accuracy and precision 
The intra-day and inter-day accuracy (% bias) and precision (% RSD) were determined at warfarin 
QC concentrations of 300, 4000, and 8000 ng/mL, and alcohols concentrations of 1.5, 100, and 
200 ng/mL over three validation runs. Assay bias ranged from -10.0 to 8.8%, while the RSD ranged 
from 4.0 to 8.2% (Table 2.3). In all cases, bias and RSD values were within ±10% for all analytes 
indicating an accurate and a reproducible assay. Acceptable accuracy and precision were also 
observed during the dilution analysis, as bias and RSD were within ±14.4%, and 4.8% in all 
samples, respectively. 
 
Table 2-3  Intra-and inter-day accuracy (%Bias) and precision (%RSD) for quality 
controls 
  Nominal 
Conc 
(ng/mL) 
 Intra-daya  Inter-dayb 
Analyte Level   % Bias % RSD   % Bias % RSD 
Warfarin         
 LQC 300  -10 6.9  -8.9 5.7 
 MQC 4,000  -4.4 5.6  -4.7 6.3 
 HQC 8,000  0.79 5.8  -1.1 6.5 
Warfarin alcohol 1        
 LQC 1.5  -4.4 7.0  -2.9 8.2 
 MQC 100  5.2 6.7  5.8 6.3 
 HQC 200  2.2 5.0  0.53 5.1 
Warfarin alcohol 2        
 LQC 1.5  5.7 5.7  3.9 6.6 
 MQC 100  8.8 4.8  7.7 5.0 
 HQC 200  7.2 4.0  3.5 5.7 
a 12 replicates for LQC, MQC, HQC 
b 24 replicates for LQC, MQC, HQC 
  
61 
2.4.2.3 Recovery, process efficiency and matrix effect 
The extraction recoveries and process efficiency of analytes, which were determined at three QC 
levels, ranged from 73.2% to 90.2%, and 76.3% to 93.6% respectively (Table 2.4). Overall, the 
recoveries and process efficiency of analytes were consistent and reproducible. The matrix effect 
was negligible, with measured concentrations deviating by -2.7% to 11% from neat samples 
(Table 2.4). 
 
Table 2-4  Extraction recovery, process efficiency and matrix effect of analytes in incubation 
buffer 
Analyte 
 
  
Nominal 
Conc 
(ng/mL) 
  
Extraction 
Recovery 
  
Process 
Efficiency 
  
Matrix 
Effect 
  (%, mean)   (%, mean)   (%, mean) 
Warfarin         
  300  79.2  78.3  98.8 
  4,000  88.4  92.0  104 
  8,000  90.2  93.6  104 
Warfarin alcohol 1       
  1.5  73.2  76.3  104 
  100  79.8  81.8  102 
  200  81.0  82.4  102 
Warfarin alcohol 2       
  1.5  77.5  92.0  111 
  100  80.5  79.3  98.5 
  200  80.7  78.5  97.3 
 n=4 for each QC level 
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2.4.2.4 Stability 
Bench-top, autosampler, and freeze-thaw stability were assessed for analytes in the buffer at LQC 
and HQC levels. Samples were found to be stable for 4 hours at room temperature (bench-top), 
and 24 hours post analysis at 10ºC in the refrigerated autosampler. Additionally, three freeze-thaw 
cycles had no effect on the stability of analytes in the buffer. The mean measured concentrations 
of analytes in the buffer ranged from 95% to 112% of freshly analyzed samples, indicating 
adequate stability under all conditions tested (Table 2.5). 
 
Table 2-5  Stability for quality controls (LQC & HQC) of warfarin and its alcohol metabolites 
Analyte 
  
Target 
(ng/mL) 
  Stability* 
  
Bench-top  
(4 hrs) 
  
Autosampler  
(24 hrs) 
  
Three Freeze/Thaw cycles 
(24 hrs) 
    
% of 
Target 
%RSD   
% of 
Target 
%RSD   
% of  
Target 
%RSD 
Warfarin            
  300  106 1.8  103 8.6  99.6 2.5 
  8,000  111 0.45  95.1 2.3  111 0.85 
Warfarin alcohol 1          
  1.5  112 3.5  103 5.9  111 7.4 
  200  103 3.6  101 0.82  95.9 1.1 
Warfarin alcohol 2          
  1.5  102 3.0  111 7.9  106 9.2 
    200   104 2.7   101 0.86   101 2.5 
*
Data are presented as means of n=3 for LQC and HQC levels 
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2.4.3 Assay Application  
The current method was successfully applied to the in vitro assessment of warfarin reduction. 
Michaelis-Menten plots of warfarin alcohols generated after incubation of rat cytosol with various 
concentrations of warfarin are shown in Figure 2.2. The metabolic activities (Vmax) for cytosolic 
reductases producing alcohol 1 and alcohol 2 were 33.2 and 9.9 pmol/mg protein/min, respectively. 
The affinity constant values (Km) were 434.8 and 1,583 µM for alcohol 1 and alcohol 2, 
respectively. These results imply that the current method is well suited and reliable for enzyme 
kinetic studies of warfarin requiring high-throughput quantitative determination of warfarin 
alcohol metabolites, as also shown in chapters 3 and 4 using subcellular fractions isolated from rat 
liver tissue and human liver tissue, respectively. 
 
 
Figure 2-2  Michaelis-Menten plots for formation of warfarin alcohols in rat liver cytosol 
Incubation was conducted using 0.5 mg/mL rat liver cytosolic protein in the presence of 1 mM 
NADPH, 5 mM MgCl2, and various concentrations of warfarin (20-2000 µM) for 30 min at 37ºC. 
The y-axis represents the formation rate of warfarin alcohol metabolites. Controls omitting 
warfarin or NADPH showed negligible formation of warfarin alcohol metabolites.  
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2.5 DISCUSSION 
In order to support studies exploring warfarin reduction, we aimed to develop and validate a simple 
UHPLC-MS/MS method for determination of warfarin and warfarin alcohol metabolites. In here, 
we present a robust method to measure warfarin and its alcohol metabolites in cellular fraction 
incubates. This is the first validated UHPLC-MS/MS method reporting quantification of warfarin 
alcohol metabolites. Furthermore, we have successfully applied the processing conditions and 
extraction procedure of the current method for the measurement of warfarin alcohols in incubates 
of rat cytosolic cellular fractions. Collectively, these results suggest that our assay is valid and 
reproducible, and can be used successfully to quantify warfarin alcohols after in vitro enzyme 
kinetic studies.  
The assay was developed in the negative ionization mode because of the enhanced 
sensitivity. The MS conditions were chosen to achieve optimum selectivity, specificity and 
sensitivity for the analytes. The liquid chromatography separation of the analytes was performed 
with gradient elution of the mobile phase. The selected percentages of formic acids in the mobile 
phase provided the optimum clear separation of the analytes with sharp peaks and short run time. 
In this assay, we used deuterated warfarin as an internal standard for measuring warfarin. However, 
a deuterated warfarin alcohol is not commercially available. Thus, we used deuterated 7-hydroxy-
warfarin as internal standard for measuring warfarin alcohols. The selected internal standards were 
eluted close to the analytes (warfarin and warfarin alcohols) and facilitated a short run time of 5 
min.  
The assay has been validated according to the FDA guidelines. The intra and inter-day 
accuracy and precision of analytes were within ±10% suggesting the validity and reproducibility 
of our method. In addition, the assay shows excellent (more than 73%) and consistent extraction 
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recovery of the analytes from the incubation buffer. We have not noticed any matrix effect of the 
Tris-HCl incubation buffer on the recovery of the analytes as there was less than 11% difference 
in the anayltes response. This was also confirmed by the absence of any ion suppression or 
enhancement by post-column infusion experiment.   
To simulate the real life situations, the calibration standards and QCs were stored at -80C, 
and the QC samples were exposed to various conditions to test for their stability. Our samples were 
found to be stable under the three explored conditions that may be subjected to prior to analysis. 
These include bench-top, autosampler, and freeze-thaw stability.   
The presented method was successfully applied to the measurement of warfarin alcohol 
metabolites generated during in vitro enzyme kinetic studies with rat liver tissue (chapter 3) and 
human liver tissue (chapter 4).. In rat tissue, the metabolic formation of warfarin alcohol 1 after 
cytosolic incubation with warfarin was about three-fold higher than alcohol 2. Also, the affinity 
constant (Km) for alcohol 1 was 3.6 fold lower than that of alcohol 2 suggesting higher affinity 
toward alcohol 1 formation in the cytosol.  This is in agreement with previous reports, which 
showed that warfarin alcohol 1 is the major reduced warfarin metabolite that is produced in the 
cytosol (Hermans and Thijssen, 1989; Moreland and Hewick, 1975).   
The previous reported methods for quantification of warfarin alcohols in different matrices 
have some limitations. These include inadequate sensitivity (LLOQ 10-40 ng/mL), extensive pre-
analysis work, large sample volume (250-1500 µL), long run time (7-60 min), and complexity 
(Banfield and Rowland, 1984; Duffield et al., 1979; Fasco et al., 1979; Fasco et al., 1977; Wong 
and Davis, 1989). Our modern and unique method has several advantages over the previously 
published non-LC/MS assays including: 1) simple and rapid sample processing based on liquid-
liquid extraction with no derivatization step; 2) a small sample volume requirement of 100 µL; 3) 
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short run time of 5 min; 4) high sensitivity with 0.5 ng/mL lower limit of quantification; 5) 
validation according to the FDA guidelines.  
In conclusion, a simple, rapid, accurate, and precise UHPLC-MS/MS method for the 
determination of warfarin and warfarin alcohols has been developed and validated. The short run-
time and high sensitivity and specificity associated with LC-MS/MS renders this method valuable 
for studies relating to warfarin reduction. 
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3.0  EFFECT OF EXPERIMENTAL KIDNEY DISEASE ON THE FUNCTIONAL 
EXPRESSION OF HEPATIC REDUCTASES  
 
 
 
 
 
 
 
 
 
 
 
 
 
[Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD. Effect of experimental 
kidney disease on the functional expression of hepatic reductases. Drug Metab Dispos 43: 100-
106, 2015]. 
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3.1 ABSTRACT  
CKD can affect the nonrenal clearance of drugs by modulating the functional expression of drug 
metabolizing enzymes and transporters. The impact of CKD on phase I oxidative and phase II 
conjugative metabolism has been extensively studied. However, the impact of CKD on hepatic 
drug reduction, an important phase I drug metabolism pathway, has not been investigated. We 
aimed to assess the effect of experimental CKD on hepatic reduction, using warfarin as a probe 
substrate. Cytosolic and microsomal fractions were isolated from liver tissue harvested from 5/6th-
nephrectomized and control rats (n=10 per group). The enzyme kinetics for warfarin reduction 
were evaluated in both fractions, and formation of warfarin alcohols was used as an indicator of 
hepatic reductase activity. Selective inhibitors were employed to identify hepatic reductases 
involved in warfarin reduction. mRNA and protein expression of reductases were quantified using 
qRT-PCR and Western blotting, respectively. Formation of RS/SR-warfarin alcohol was decreased 
by 39% (P<0.001) and 43% (P<0.01) in cytosol and microsomes, respectively in livers from CKD 
rats compared to control rats. However, RR/SS-warfarin alcohol formation was unchanged in the 
cytosol and microsomes. mRNA expression of cytosolic CBR1 and AKR1C3, and microsomal 
11β-HSD1 was significantly reduced by 34%, 93% and 35% (P<0.05), respectively in livers from 
CKD compared with control rats. Additionally, protein expression of the corresponding reductases 
was significantly down-regulated by >40% (P<0.05) in CKD rats versus controls. Collectively, 
these results suggest that the functional expression of hepatic reductases is selectively decreased 
in kidney disease. These findings support the hypothesis of altered nonrenal clearance, exposure, 
and response of certain drugs in CKD patients.  
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3.2 INTRODUCTION 
Chronic kidney disease is a major public health problem that affects approximately 26 million 
Americans (Weiner, 2009). Kidney disease is described as the general term of the progressive and 
heterogeneous disorders that are associated with functional and structural abnormalities of the 
kidney (Levey and Coresh, 2012). Patients with CKD commonly exhibit unpredictable changes in 
drug disposition and response, largely due to decreased renal clearance of drugs excreted 
unchanged by the kidney, as well as altered nonrenal drug clearance (Nolin et al., 2008). As we 
previously detailed in chapter 1 numerous experimental and clinical studies have documented 
remarkable decreases in the functional expression of drug metabolizing enzymes in CKD (Lalande 
et al., 2014; Naud et al., 2012), including particularly phase I oxidation mediated by CYP450 
enzymes (Yeung et al., 2014), and phase II conjugation via acetylation (Simard et al., 2008), while 
phase II glucuronidation is not affected (Yu et al., 2006). The effect of CKD on other drug 
metabolic pathways is less clear.  
As described earlier, carbonyl reduction represents an important phase I drug metabolism 
pathway (Malatkova and Wsol, 2014). Carbonyl reductases can be classified into quinone 
reductases and carbonyl reducing enzymes (Oppermann, 2007). Reduction by quinone reductases 
is mediated primarily by NQO1 (Oppermann, 2007; Siegel et al., 2012). The carbonyl reducing 
enzymes are further separated into two major superfamilies; SDR that includes primarily cytosolic 
CBR and microsomal 11β-HSD isoforms (Gathercole et al., 2013; Skarydova and Wsol, 2012), 
and AKR that mainly comprises the AKR1C subgroup (Malatkova et al., 2010; Matsunaga et al., 
2006). Collectively, reductase enzymes play key roles in the biotransformation of diverse 
endogenous compounds such as bile acids, glucocorticoids, prostaglandins, and numerous drugs 
(e.g., bromperidol, bupropion, doxorubicin, haloperidol, ketoprofen, naltrexone, and warfarin) 
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(Malatkova and Wsol, 2014; Oppermann, 2007; Skarydova et al., 2014). Although the 
pharmacokinetics of several drugs that are reductase substrates, including idarubicin (Camaggi et 
al., 1992) and bupropion (Turpeinen et al., 2007) are altered in patients with CKD, the effect of 
impaired kidney function on hepatic reductase enzymes has not been assessed to date.  
This study aimed to investigate the effect of severe CKD on the expression and function of 
several hepatic reductases in rats. This was accomplished utilizing warfarin as a probe substrate 
based on the premise that it undergoes reduction with formation of distinct alcohol metabolites, 
namely RS/SR-warfarin alcohol (alcohol 1), and RR/SS-warfarin alcohol (alcohol 2) (Alshogran et 
al., 2014b; Chan et al., 1972; Lewis et al., 1974). Moreover, recent evidence indicates that warfarin 
dosing requirements and response are altered in patients with impaired kidney function (Chan et 
al., 2009b; Granger and Chertow, 2014; Limdi et al., 2009; Shah et al., 2014), suggesting that 
warfarin disposition may also be altered in CKD. Our approach includes conducting enzyme 
kinetic studies to determine the activity of hepatic reductases in rat liver cytosol and microsomes. 
The mRNA and protein expression of selective hepatic reductases that mediate warfarin 
metabolism was also assessed. 
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3.3 METHODS 
3.3.1 Chemical Reagents  
Warfarin, NADPH, magnesium chloride, tris(hydroxymethyl)aminomethane (Trizma base), 
quercetin, flufenamic acid, indomethacin, dicoumarol, and 18β-glycyrrhetinic acid were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Warfarin alcohols were synthesized as previously 
described (Chan et al., 1972; Trager et al., 1970). Organic solvents were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Primers used for PCR quantification were purchased from 
Eurofins MWG Operon (Huntsville, AL, USA). Unless otherwise specified, all other chemicals 
and reagents were purchased from Sigma-Aldrich. All chemicals were LC-MS grade or of the 
highest purity available. 
3.3.2 Experimental Model  
Male Sprague-Dawley rats (Charles River, Saint-Charles, PQ, Canada) that weighed 200-300 g 
were housed in the Research Center animal care facility and maintained on a standard rat chow 
and water ad libitum on a 12-h light/dark cycle. Rats were allowed to acclimatize for at least three 
days before conducting any experimental procedure. All experiments were conducted according 
to the Canadian Council on Animal Care guidelines for care and use of laboratory animals. 
Studies were performed in two experimental groups of rats: control (n=10) and CKD 
(n=10). Control rats were pair-fed the same amount of rat chow that was ingested by CKD rats on 
the previous day. Severe CKD was induced by a standard two-stage 5/6th nephrectomy model as 
previously described (Leblond et al., 2000). This model represents an extreme and progressive 
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stage of uremia. Briefly, rats in the CKD group underwent a two-third nephrectomy of the left 
kidney that was followed by a complete right nephrectomy seven days later. Rats in the control 
group were subjected to two sham laparotomies. At day 41 of the surgery urine was collected over 
a period of 24 hour to determine creatinine clearance. Forty two days after the initial surgery, rats 
were scarified by decapitation. Liver tissue was harvested and stored at -80oC. Blood was collected 
for the measurement of serum creatinine and urea concentrations to determine the extent of kidney 
disease.  
3.3.3 Isolation of Hepatic Cytosolic and Microsomal Fractions  
Liver cytosol and microsomes were isolated by a standard differential centrifugation as described 
previously with slight modifications (Hermans and Thijssen, 1989). In brief, frozen tissue was 
homogenized in ice-cold buffer (50 mM Tris-HCl buffer, 150 mM KCl, 1 mM EDTA, 0.1 mM 
dithiothreitol and 20% glycerol, pH 7.4) containing 0.1 mM phenylmethylsulfonyl fluoride as a 
protease inhibitor and 0.113 mM butylated hydroxytoluene as an anti-oxidant. The homogenate 
was centrifuged at 20,000g for 30 min at 4°C. The supernatant was then centrifuged at 140,000g 
for 60 min at 4°C. The resulting 140,000g soluble supernatant was collected as a cytosol, and the 
microsomal pellet was washed twice and resuspended in 0.02 M Tris-HCl (pH 7.4) containing 0.25 
M sucrose. Protein concentrations were determined using a Bio-Rad protein assay (Bio-Rad 
Laboratories, Hercules, CA), according to the manufacturer’s instructions. Cytosolic and 
microsomal proteins were stored at -80oC until analysis.  
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3.3.4 In Vitro Warfarin Reduction Using Cytosolic and Microsomal Fractions 
The metabolic activity of rat hepatic reductases that catalyze warfarin reduction was assessed using 
cytosolic and microsomal cellular fractions of control and CKD liver tissue. Incubations were 
conducted using 0.5 mg/mL of either cytosolic or microsomal protein in 10 mM Tris-HCl buffer 
(pH 7.4) containing 5 mM MgCl2 and various concentrations of warfarin (20, 50, 100, 250, 500, 
1000, 1500, and 2000 µM). Reactions were started by the addition of 1 mM NADPH and 
conducted for 30 min at 37ºC. The final reaction volume was 500 µL. Substrates were added in 
acetone with a final concentration consistently maintained at 1%. Controls omitting 
substrate/NADPH were included in each incubation. Conditions were optimized during 
preliminary experiments to achieve linear formation of warfarin alcohol metabolites with respect 
to incubation time and protein concentration. Incubations were quenched by adding 500 µL ice-
cold acetonitrile. Samples were briefly vortex-mixed, placed on ice for 15 min and centrifuged at 
14,000 rpm for 10 min to pellet the protein. Metabolites were extracted using methyl tert-butyl 
ether, evaporated to dryness under nitrogen gas, and reconstituted with acetonitrile-water (25:75, 
v/v) prior to the injection onto the LC-MS system. Warfarin alcohol metabolites were quantified 
by UPLC-MS/MS as we have described in chapter 2 (Alshogran et al., 2014b). The intra-day 
accuracy and precision of analytes ranged from 90 to 108.8% and from 4 to 11%, respectively. 
The inter-day accuracy and precision ranged from 91 to 107.7% and from 5 to 8.2%, respectively 
(Alshogran et al., 2014b). 
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3.3.5 Identification of Rat Enzymes Involved in Warfarin Reduction 
To identify rat hepatic reductases that are involved in the carbonyl reduction of warfarin, pooled 
liver cytosol or microsomes of control rats were incubated with warfarin (1 mM) and a chemical 
inhibitor under the optimized conditions described in the previous section. Figure 3-1 depicts the 
classes of reductase enzymes and the corresponding chemical inhibitors utilized in this study. The 
inhibitors and concentrations (10 and 100 µM) used, and their selectivity for reductase enzymes 
were based on the previous reports, as follows: quercetin for cytosolic CBRs (Hermans and 
Thijssen, 1992; Tong et al., 2010); flufenamic acid for cytosolic AKRs (Atalla et al., 2000; Molnari 
and Myers, 2012; Rosemond et al., 2004); indomethacin for both cytosolic CBRs and AKRs (Tong 
et al., 2010; Usami et al., 2001); dicoumarol for cytosolic NQO1 (Tong et al., 2010); and 18β-
glycyrrhetinic acid for microsomal 11β-HSD1 (Breyer-Pfaff et al., 2004; Molnari and Myers, 
2012). The concentrations of the inhibitors utilized were based on the IC50 or Ki values reported 
in citations following each inhibitor. The concentration of the substrate (warfarin = 1 mM) was 
based on the Km value estimated from the activity studies in the previous sections. All inhibitors 
were dissolved in a mixture of dimethylsulfoxide-methanol (50:50, v/v) except for dicoumarol, 
which was prepared in 1% sodium hydroxide in water. Organic solvents were consistently 
maintained at a final concentration of 0.5% in all incubations. Control reactions were performed 
with the vehicles in the absence of the chemical inhibitors. All experiments were conducted in 
triplicate.  
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Figure 3-1  Schematic representation of the hepatic reductase enzymes and inhibitors 
investigated in the current study  
Cytosolic reductases can be classified into quinone reductases (NQO) and carbonyl reducing 
enzymes. Carbonyl reducing enzymes comprises two major superfamilies; the short-chain 
dehydrogenase reductase (SDR) and the aldo-keto reductase (AKR) enzymes. The main groups of 
these super-families implicated in ketone reduction of drugs are cytosolic carbonyl reductases 
(CBRs) and cytosolic 3α-hydroxysteroid dehydrogenases (AKR1C), respectively. 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the principal SDR enzyme catalyzes drug 
reduction in the microsomes. The selective inhibitors utilized in this study are: dicoumarol for 
NQO1, quercetin and flufenamic acid for CBR and AKR1C respectively. Indomethacin is a non-
specific inhibitor for both CBR and AKR1C. 18β-glycyrrhetinic acid is selective for 11β-HSD1 in 
the microsomes. 
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3.3.6 RNA Isolation and Quantitative Real-Time PCR Analysis 
Total RNA was extracted from liver tissue using TRIzol reagent (Invitrogen, San Diego, CA). 
RNA concentration and purity were measured by spectrophotometry at 260 nm. One microgram 
of total RNA was used to prepare the cDNA by reverse transcription using SuperScript III reverse 
transcriptase (Invitrogen, San Diego, CA, USA) in a 20-µL reaction volume. Expression of rat 
CBR1, CBR3, AKR1C3, AKR1C14, NQO1, 11β-HSD1, CYP1A2, CYP2D1, CYP2E1 and 
GAPDH genes was quantified by qRT-PCR performed with the ABI Prism 7300 system (Applied 
Biosystems, Foster City, CA, USA) using the SYBR Green master mix (Roche, Indianapolis, IN, 
USA) and specific primers (Table 3-1). Hepatic reductase mRNA levels were normalized to 
GAPDH and expressed relative to the controls using the 2-ΔΔCT method (Livak and Schmittgen, 
2001).   
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Table 3-1  Nucleotide sequence for the primers used in qRT-PCR for rat enzymes 
mRNA    Left Primer (5'-3')   Right Primer (5'-3')   
Predicted Product 
Size (base pair) 
CBR1  TCCACATTCAAGCAGAGGTG  CACTCTGCCTTGGGGTTTTA  98 
       
CBR3  ACCACATGGTAGAGTGGTGA  AGTGTGTCACATCGGAACCT  99 
       
AKR1C3  CCTGTGTGCAACCAGGTAGA  CCATAGGCAACCAGAACGAT  95 
       
AKR1C14  TTCCTGTACTGGGGTTTGGA  CAGAGTCAAAATGGCGGAAT  108 
       
NQO1  GCTTGACACTACGATCCGC  CACAGCAGCCTCCTTCATG  117 
       
11β-HSD1  AGCATTGCCATCATCTCCTC  GTGGAAAAGAACCCATCCAG  98 
       
CYP1A2  GGCAGGTCAACCATGATGAG  CTTGTCGATGGCCGTGTT  92 
       
CYP2D1  CTGCAGGTGGACCTCAGTAA  ATGGGCTTCCAACCCTTC  95 
       
CYP2E1  GGGACATTCCTGTGTTCCAG  GTCTCGGAGAATGCTTAGGG  104 
       
GAPDH   TGCCACTCAGAAGACTGTGG   GGATGCAGGGATGATGTTCT   85 
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3.3.7 Western Blot Analysis 
The protein expression of cytosolic CBR1 and AKR1C18 [also known as 20 alpha-hydroxysteroid 
dehydrogenase (20α-HSD)], and microsomal 11β-HSD1 was determined using Western blotting. 
Samples (50 µg total protein) were separated by 10% SDS-polyacrylamide gel electrophoresis and 
transferred onto nitrocellulose membranes. Transferred membranes were blocked for 1 hr at room 
temperature using 5% (w/v) non-fat powdered milk dissolved in PBS. Membranes were then 
incubated overnight at 4°C with specific primary antibodies diluted in 0.5% non-fat powdered milk 
dissolved in PBS (1:1000 rabbit polyclonal anti-CBR1, Abcam (Cambridge, MA); 1:2000 rabbit 
polyclonal anti-20α-HSD, Kera Fast (Boston, MA); 1:200 rabbit anti-11β-HSD, CAYMAN 
chemicals (Ann Arbor, MI); or 1:1000 mouse monoclonal anti-β-actin, GeneTex (Irvine, CA). 
After washing four times with PBS-Tween (0.1% Tween-20 in PBS), membranes were incubated 
for 1 hr at room temperature with HRP-conjugated secondary antibodies diluted in 0.5% milk 
(1:4000 goat anti-rabbit, Sigma; or 1:1000 goat anti-mouse, Sigma. The membranes were then 
washed with PBS-Tween, and the immune complexes were revealed by chemiluminescence 
Lumilight (Roche, Indianapolis, IN) detection system on the Fujifilm intelligent dark box equipped 
with the LAS-4000 camera (Fujifilm, Piscataway, NJ). Band intensity was quantified by 
densitometry using Multi Gauge Software (Fujifilm) and normalized to β-actin (This work was 
conducted in collaboration with Dr. François Leblond and Dr. Vincent Pichette, at the University 
of Montreal, Canada).  
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3.3.8 Data and Statistical Analysis  
The formation rate of alcohol metabolites was calculated from their measured concentrations. A 
non-linear regression Michaelis-Menten kinetic model was used to fit the formation of alcohol 
metabolites, and the maximum velocity of enzymes (Vmax) and the affinity constant (Km) were 
estimated and compared between groups using GraphPad Prism (Version 5; GraphPad Software 
Inc., San Diego, CA). Formation rate of alcohol metabolites in the inhibition studies was expressed 
as percent of control incubations, and statistical differences in formation of alcohols in the presence 
or absence of inhibitors were determined using student’s t-test. Reductases mRNA and protein 
expression of CKD rats were expressed relative to that of controls, and statistical differences 
between the two groups were assessed using student’s t-test. P value of <0.05 was considered 
significant for all comparisons. The results are expressed as mean ± SEM.  
3.4 RESULTS 
3.4.1 Characteristics of Control and CKD Rats 
Table 3-2 presents biochemical parameters and weight of the two studied groups of rats. 
Successful induction of severe kidney disease was confirmed by measuring the serum 
concentrations of creatinine and urea, the markers of kidney function. The levels of serum 
creatinine were significantly elevated in CKD group compared to controls. Likewise, the serum 
levels of urea were significantly higher in CKD rats versus controls. Body weight was not different 
between the two groups of rats. 
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Table 3-2  Characteristics of control pair-fed and CKD rats 
  
Control Pair-Fed  CKD 
P-value 
(n=10) (n=10) 
Body Weight (g) 386.0 ± 38.4 333.9 ± 75.0 NS 
    
Serum creatinine (µM) 40.4 ± 8.7 203.4 ± 83.9 <0.001 
    
Creatinine clearance            
(µL/100 g of body weight/min) 
359.7 ± 79.3 68.8 ± 41.3 <0.001 
    
Serum urea (mM) 3.6 ± 1.1 38.3 ± 26.1 <0.001 
    NS: non-significant 
 
3.4.2 In Vitro Cytosolic and Microsomal Warfarin Reduction 
To determine the impact of experimental kidney disease on hepatic reductase activity, we assessed 
warfarin reduction in vitro using rat liver cytosol and microsomes. Both cellular fractions were 
shown to generate warfarin alcohol metabolites, and the enzyme kinetics for alcohols were 
determined in this study. 
In the cytosol, Vmax for formation of warfarin alcohol 1 was significantly decreased by 39% 
in livers from CKD compared with control rats (23.3 ± 1.29 versus 38.0 ± 1.97 pmol/mg 
protein/min, P<0.001; Figure 3-2A). Vmax for formation of warfarin alcohol 2 was not different 
between the two group of rats (8.74 ± 0.47 versus 8.43 ± 0.61 pmol/mg protein/min, P=NS), and 
virtually superimposable Michaelis-Menten curves were observed (Figure 3-2B). 
In microsomes, Vmax of microsomal reductases producing warfarin alcohol 1 was 
significantly decreased by 43% in livers from CKD rats compared to control rats (5.49 ± 0.45 
versus 9.57 ± 1.25 pmol/mg protein/min, P<0.01; Figure 3-2C). The results for the metabolic 
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production of warfarin alcohol 2 in CKD group were unable to fit the Michalis-Menten model. 
However, the formation of alcohol 2 at the maximum substrate concentration (2000 µM warfarin) 
was markedly reduced by 87% in livers from CKD rats compared with controls (Figure 3-2D). 
The estimated Mechalis-Menten kinetic parameters (Vmax & Km) of cytosolic and microsomal 
studies are presented in Table 3-3. 
 
 
 
Figure 3-2  Effect of CKD on kinetic formation of warfarin alcohols in cytosol and microsomes 
Michaelis-Menten plots for the formation of warfarin alcohol 1 (A) and alcohol 2 (B) in rat liver 
cytosol, and alcohol 1 (C) and alcohol 2 (D) in rat liver microsomes of both control and CKD rats. 
Each point presents the mean ± SEM of 10 rats in each group. 
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Table 3-3  Michaelis-Menten kinetic parameters for warfarin reduction in control and CKD rat liver cytosol and microsomes 
 Alcohol 1 (RS/SR)   Alcohol 2 (RR/SS)  
 Km           
(µM) 
Vmax               
(pmol/mg protein/min) 
Clint               
(µL/mg protein/min) 
Km            
(µM) 
Vmax                
(pmol/mg protein/min) 
Clint             
(µL/mg protein/min) 
Cytosol        
Control 352.0 ± 59.6 38.0 ± 1.97 0.117 ± 0.016  1091 ± 167.4 8.43 ± 0.609 0.008 ± 0.0008 
CKD 359.3 ± 64.1 23.3 ± 1.29*** 0.065 ± 0.007**  1149 ± 127.1 8.74 ± 0.466 0.008 ± 0.0004  
Microsomes        
Control 446.9±174.7 9.57 ± 1.25 0.021 ± 0.005  158.0 ± 105.6 37.7 ± 6.17 0.243 ± 0.08 
CKD 365.6 ± 95.8 5.49 ± 0.45** 0.014 ± 0.002  No fit No fit No fit 
Data are presented as mean ± SEM of 10 rats in each group. Clint represents the intrinsic clearance (the enzymatic efficiency: Vmax/Km) 
** P < 0.01 compared with control. 
*** P < 0.001 compared with control. 
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3.4.3 Identification of Reductase Enzymes Catalyzing Warfarin Reduction  
Selective inhibitors were employed to identify reductase enzymes involved in warfarin reduction. 
The relative formation of warfarin alcohol 1 and alcohol 2 in the presence of inhibitors as 
normalized to control incubations is depicted in Figures 3-3A and 3-3B, respectively. Cytosolic 
reduction of warfarin to its alcohols was inhibited by quercetin (inhibitor of CBR), flufenamic acid 
(inhibitor of AKR1C), indomethacin (inhibitor of CBR and AKR1C), and dicoumarol (inhibitor 
of NQO1) in a concentration-dependent manner. The magnitude of inhibition to alcohol 1 and 
alcohol 2 at 10 µM inhibitor concentration ranged from 7-26% and 9-28%, respectively. The extent 
of inhibition at 100 µM was markedly increased and ranged from 33-81% and 32-70% for 
formation of alcohol 1 and alcohol 2, respectively. All inhibitions in the cytosol were statistically 
significant except for the formation of alcohol 1 in presence of 10 µM indomethacin, and alcohol 
2 in presence of 10 µM of both flufenamic acid and dicoumarol. Quercetin, an inhibitor of CBR, 
exhibited the most potent inhibition. Microsomal reduction of warfarin to alcohol 1 and alcohol 2 
was significantly inhibited by 15% and 44% respectively at 100 µM 18β-glycyrrhetinic acid 
(inhibitor of 11β-HSD1). 
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Figure 3-3  The effect of reductase inhibitors on warfarin reduction in rats 
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Formation of warfarin alcohol 1 (A) and alcohol 2 (B) was investigated in the presence of carbonyl 
reducing enzyme inhibitors in pooled rat liver cytosol (quercetin, flufenamic acid, dicoumarol, and 
indomethacin) and microsomes (18β-glycyrrhetinic acid). The corresponding reductase enzymes 
being targeted by the inhibitors are also included. Incubations were conducted at two different 
inhibitor concentrations (10 and 100 µM). Results are presented as mean ± SEM of triplicate 
incubations. Statistical differences are as follows: * (P<0.05); ** (P<0.01), and *** (P<0.001) 
compared with control incubations which were arbitrarily defined as 100%.  
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3.4.4 mRNA and Protein Expression of Hepatic Reductase Isoforms 
To determine whether the decrease in the metabolic activity of hepatic reductases in kidney disease 
was secondary to reduced mRNA expression, mRNA levels encoding cytosolic and microsomal 
reductase isoforms were measured by qRT-PCR (Figure 3-4). Although the results show that 
kidney disease has differential effects on the expression of hepatic reductases, many of the 
investigated reductases were down-regulated. The mRNA expression of cytosolic CBR1 was 
significantly decreased by 34% (P<0.001) in CKD rats compared with controls, but cytosolic 
CBR3 was not changed. While the mRNA expression of cytosolic AKR1C3 significantly 
decreased by 93% (P<0.001), the expression of AKR1C14 is significantly increased by 53% in 
CKD compared to control rats (P<0.05). Cytosolic NQO1 expression remained unchanged. Lastly, 
mRNA expression of the microsomal 11β-HSD1 isoform was significantly reduced by 35% 
(P<0.05) in CKD rats compared with controls. In order to further confirm the validity of our 
reductase mRNA expression findings in CKD rats, we measured the expression of selective 
CYP450 isoforms that are not known to be affected by kidney disease as additional controls. 
Consistent with previous findings (Leblond et al., 2001; Michaud et al., 2005; Rege et al., 2003), 
we found that mRNA levels of CYP1A2, CYP2D1, and CYP2E1 were not statistically different 
between CKD and control rats.  
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Figure 3-4  Effect of CKD on mRNA expression of rat hepatic reductases  
The mRNA expression of cytosolic (CBR1, CBR3, AKR1C3, AKR1C14, and NQO1) and 
microsomal (11β-HSD1) rat hepatic reductases, as well as CYP1A2, CYP2D1, and CYP2E1 in 
control and CKD rats. The mRNA expression of reductase isoforms was normalized to that of 
GAPDH. The results of CKD group were normalized to the control which was arbitrarily defined 
as 100%. Experiments were conducted in duplicates, and results are presented as mean ± SEM of 
10 rats in each group. * (P<0.05) and *** (P<0.001) compared with control. 
 
  
88 
Figure 3-5 depicts the results of the analysis of protein expression of hepatic reductases in 
CKD and control rats. Consistent with the findings of mRNA expression, we also found that 
protein expression of CBR1, AKR1C18 (encoded by AKR1C3), and 11β-HSD1 was decreased by 
43%, 76%, and 70% respectively in CKD rats versus controls (P<0.05). 
 
 
Figure 3-5  Effect of CKD on protein expression of rat hepatic reductases  
Protein expression of cytosolic (CBR1 and AKR1C18) and microsomal (11β-HSD1) reductases in 
control and CKD rat livers. The densitometry units of reductases protein expression was 
normalized to that of β-actin. The standardized densitometry units of control rats were arbitrarily 
defined as 100%. The upper panels represent blots of two control and two CKD rats. Results are 
presented as mean ± SEM of 10 rats in each group. ** (P<0.01) and *** (P<0.001) compared with 
control. 
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3.5 DISCUSSION 
The present study investigated the impact of experimental kidney disease on hepatic reduction 
using warfarin as a probe substrate. The enzyme kinetics of warfarin in both cytosolic and 
microsomal fractions of rat liver tissue were assessed. In addition, the effect of kidney disease on 
mRNA and protein expression of selective hepatic reductases was evaluated. This study 
demonstrates that the metabolic activities of selective hepatic reductases catalyzing warfarin 
reduction are decreased in CKD secondary to down-regulation of mRNA and protein expression 
of the enzymes (cytosolic CBR1 and AKR1C3, and microsomal 11β-HSD1). These findings 
suggest that CKD can alter the nonrenal clearance of drugs mediated by hepatic reduction. 
Carbonyl reducing enzymes catalyze the reduction of a diverse range of endogenous and 
exogenous xenobiotics. This includes numerous drugs representing several classes including 
anticoagulants, antidiabetics, antihypertensives, anticancers, opiate antagonists, NSAIDs, 
antihistamines, diuretics, and many others (Malatkova and Wsol, 2014; Rosemond and Walsh, 
2004). Several pharmacokinetic studies have shown that the disposition of drugs that are primarily 
metabolized by reduction is altered in patients with kidney disease. For instance, bupropion 
exposure is dramatically increased by 126% in patients with impaired kidney function, suggesting 
reduced metabolic clearance (Turpeinen et al., 2007). Moreover, a 30% decrease in the metabolic 
clearance of idarubicin was reported in patients with creatinine clearance of <60 mL/min (Camaggi 
et al., 1992). This suggests that phase I reduction of drug may be affected by kidney disease. 
In the present study we evaluated the impact of experimental kidney disease on the 
metabolic activity of cytosolic and microsomal reductases. Our results indicate that warfarin 
reduction is stereo-selectively decreased in both cytosolic and microsomal liver fractions of CKD 
rats. The metabolic activity (represented by Vmax) of cytosolic reductases generating warfarin 
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alcohol 1 was decreased by 39%, and formation of alcohol 2 was not affected. This suggests that 
there are multiple reductase enzymes implicated in warfarin reduction in the cytosol that are 
differentially affected by kidney disease. Dramatic decreases in the metabolic activity of 
microsomal reductases generating alcohol 1 and alcohol 2 was also observed. However, a 
definitive conclusion regarding the total activity of microsomal reductases generating alcohol 2 
cannot be drawn due to unsuccessful fit of the model to the CKD data. This can be explained, in 
part, by the linear formation of alcohol 2 observed in the microsomes over the range of the substrate 
concentrations used. On the other hand, no change on the Michaelis Menten constant (Km) of 
warfarin for formation of warfarin alcohols was observed in both fractions. Our results are in 
agreement with the previous findings showing that alcohol 1 is the major warfarin reductive 
metabolite in the cytosol (Hermans and Thijssen, 1989; Moreland and Hewick, 1975). Overall, our 
results suggest that kidney disease may impact hepatic reductases similar to other phase I and 
phase II metabolic pathways.  
In order to identify the carbonyl reductase enzymes that play a role in warfarin reduction, 
we utilized selective chemical inhibitors for cytosolic and microsomal reductases. Alcohol 
formation in the cytosol was inhibited up to 81% by quercetin, flufenamic acid, and dicoumarol 
suggesting the contribution of CBRs, AKRs, and NQO1 respectively, to warfarin reduction. In 
fact, the potent inhibition of warfarin reduction observed by quercetin, demonstrates the significant 
contribution of CBRs to warfarin reduction. We also showed that indomethacin, a non-selective 
inhibitor for both cytosolic CBRs and AKRs (Atalla et al., 2000; Rosemond and Walsh, 2004), 
significantly inhibited the formation of alcohols by up to 60%. This provides further evidence to 
the involvement of the two families in warfarin reduction. Our results are in agreement with the 
previous reports that showed that 4’-nitrowarfarin reduction in liver cytosol of human and rabbit 
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is strongly inhibited by quercetin and indomethacin (Hermans and Thijssen, 1992; Hermans and 
Thijssen, 1993). Our results also showed that microsomal warfarin reduction is inhibited by 18β-
glycyrrhetinic acid, which indicates that 11β-HSD1 is involved in the microsomal reduction of 
warfarin. Together, our findings suggest that the microsomal 11β-HSD1 and cytosolic isoforms of 
CBR, AKR and NQO are responsible for warfarin reduction in rats, with major contribution 
possibly by CBR isoforms. However, further investigations using recombinant enzyme 
preparations are required to confirm the specific reductase isoforms involved in warfarin reduction. 
Previous studies have demonstrated that the decrease in enzyme activity in CKD is partially 
due to the down-regulation of protein and mRNA expression of drug metabolizing enzymes 
(Leblond et al., 2001; Leblond et al., 2002; Simard et al., 2008; Velenosi et al., 2012). Based on 
the inhibition data, we measured the mRNA expression of cytosolic CBR1, CBR3, AKR1C3, 
AKR1C14, and NQO1, and microsomal 11β-HSD1 in livers of rats with CKD and control rats. 
Our study showed, for the first time, that the mRNA expression of hepatic reductases catalyzing 
warfarin reduction is decreased in the livers of CKD rats. In fact, we were able to detect decreased 
expression of several carbonyl reductases implicated in drug metabolism, in both cytosolic (CBR1 
and AKR1C3) as well as microsomal fractions (11β-HSD1) from the livers. The negligible effect 
of CKD observed on the expression of CBR3 and NQO1, and the up-regulation observed for 
AKR1C14 indicates an isoform-selective effect of kidney disease on reductase expression. Our 
results also showed that protein levels of CBR1, AKR1C18, and 11β-HSD1 are significantly 
reduced in CKD rats. These findings are similar to that observed for the corresponding genes, 
suggesting that reduced protein levels could be explained by the decrease in mRNA expression. 
Collectively, our results suggest that reduced metabolic activity of hepatic reductases in CKD 
could be, in part, secondary to decreased mRNA and protein expression. The decrease in reductase 
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activity (Vmax) and the negligible effect on warfarin affinity (Km) to reductase enzymes observed 
in kidney disease rats further support that the decrease in the activity is secondary to reduced 
mRNA and protein expression of the enzymes. It is well acknowledged that uremic toxins 
accumulated in uremia may be a reason for the diminished expression of certain CYP450 enzymes 
(Guevin et al., 2002; Michaud et al., 2005; Simard et al., 2008). However, further studies are 
warranted to elucidate this with regard to reductases.  
Our findings may have important clinical implications, as they may in part explain why the 
disposition of drugs that are metabolized through phase I reduction pathways (e.g., bupropion, 
idarubicin) is altered in patients with impaired kidney function. Moreover, our results may shed 
insight into warfarin treatment in patients with CKD, which is challenging because of the high 
inter-individual variability observed in the warfarin dose-response relationship (Kimmel et al., 
2013). Besides differences in the genetic and clinical background of patients, recent studies have 
shown that patients with severe CKD require lower warfarin maintenance dosages compared with 
those with mild or no CKD (Limdi et al., 2009). Moreover, multiple studies suggest that warfarin 
use in CKD patients is associated with increased risk of poor outcomes such as hemorrhage, stroke, 
and mortality (Chan et al., 2009a; Chan et al., 2009b; Shah et al., 2014). Although unproven, our 
findings of decreased warfarin reduction due to decreased metabolic activity of hepatic reductases 
may contribute to, and could provide a novel mechanistic explanation for, altered warfarin dose 
requirements and response in CKD patients.  
In conclusion, in this study we have demonstrated that CKD selectively decreases the 
metabolic activity of cytosolic and microsomal hepatic reductases, secondary to down-regulation 
in mRNA and protein expression of selective hepatic reductases. Figure 3-6 summarizes the effect 
of CKD on the activity and expression of reductase enzymes catalyzing warfarin reduction. 
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Collectively, our data suggest that kidney disease changes the nonrenal clearance of certain drugs 
mediated by hepatic reduction. The results of this investigation may provide a novel mechanistic 
explanation for reduced warfarin dose requirements and altered responses observed in CKD 
patients. 
 
 
Figure 3-6 Schematic presentation of the effect of experimental kidney disease on the activity 
and expression of reductases catalyzing warfarin reduction in cytosol and microsomes 
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4.0  EFFECT OF END STAGE RENAL DISEASE ON THE FUNCTIONAL EXPRESSION 
OF HUMAN HEPATIC REDUCTASE DRUG METABOLIZING ENZYMES  
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4.1 ABSTRACT 
The functional expression of hepatic drug metabolizing enzymes and transporters are altered in 
ESRD, leading to impaired nonrenal drug clearance. Reduction is a crucial pathway for the 
metabolism of an array of drugs and endogenous compounds. We aimed to assess the effect of 
ESRD on the functional expression of human hepatic reductases using warfarin as a probe 
substrate. Cytosolic and microsomal subcellular fractions were isolated from liver tissue collected 
from deceased ESRD (n=10) and deceased control patients (n=11). Metabolic activity, mRNA and 
protein expression of hepatic reductases were assessed by conducting enzyme kinetic studies, qRT-
PCR, and Western blotting, respectively. No significant difference in the formation of RS/SR-
warfarin alcohol was observed in cytosol or microsomes of ESRD livers relative to controls. 
Although not statistically significant, a decrease in mRNA expression of CBR1 and AKR1C1-4 
of up to 67% was observed in ESRD livers compared to controls (P=NS). A significant (65%) 
decrease in CBR1 protein expression was observed in ESRD livers versus controls (P<0.05). 
Together, these results demonstrate a trend toward decreased functional expression of selective 
hepatic reductases in livers of ESRD patients, which may partially explain altered nonrenal drug 
clearance of CBR1 drug substrates in ESRD. Given the large inter-individual variability observed, 
future studies with larger sample size are warranted to confirm these findings. 
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4.2 INTRODUCTION 
The previous chapter evaluated the effect of experimental CKD on the function and expression of 
rat hepatic reductases. We observed decreased activity of rat hepatic reductases generating 
warfarin alcohol 1 in cytosol and microsomes. A selective decrease in mRNA and protein 
expression of rat hepatic reductases was also observed. Together, this suggests that the nonrenal 
clearance of drugs mediated by reduction is impaired in the setting of CKD.  
As we previously discussed in the introduction chapter, CKD modifies bioavailability and 
disposition of drugs that are nonrenally eliminated, through its effect on the function and/or 
expression of DMEs and transport proteins (Naud et al., 2012; Nolin et al., 2008; Yeung et al., 
2014). These alterations have been demonstrated in clinical studies suggesting that human 
enzymes are also impacted by CKD. Based on the findings presented in the previous chapter, this 
study aimed to evaluate whether human hepatic reductases are also affected by kidney disease. To 
achieve our goals, we systematically explored the impact of ESRD on mRNA and protein 
expression of human hepatic reductases, as well as their metabolic activity using warfarin as a 
pharmacological probe substrate. This work was conducted in human liver tissue collected from 
recently deceased ESRD and control patients. This study is essential to further expand our findings 
of the effect of experimental kidney disease on drug reduction in humans. In addition, the findings 
of this investigation may help explain mechanisms behind altered clinical pharmacokinetics of 
drug substrates of hepatic reductase (e.g., doxorubicin (Yoshida et al., 1994), idarubicin (Camaggi 
et al., 1992), naltrexone (Kambia et al., 2004)) observed in CKD patients. 
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4.3 METHODS 
4.3.1 Chemicals and Human Liver Samples 
Warfarin, NADPH, magnesium chloride, tris(hydroxymethyl)aminomethane (Trizma base), 
quercetin, flufenamic acid, indomethacin, dicoumarol, and 18β-glycyrrhetinic acid were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Warfarin alcohols were synthesized as previously 
described (Chan et al., 1972; Trager et al., 1970). Organic solvents were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Primers used for PCR quantification were purchased from 
Eurofins MWG Operon (Huntsville, AL, USA). Unless otherwise specified, all other chemicals 
and reagents were purchased from Sigma-Aldrich. Cadaveric human liver specimens were 
procured by the National Disease Research Interchange (NDRI) from 10 ESRD patients who had 
previously been treated with standard hemodialysis and 11 control subjects who had no evidence 
of CKD. Samples were maintained at -80°C until conducting the experiments.  
4.3.2 Preparation of Human Liver Cytosol and Microsomes  
Cytosolic and microsomal subcellular fractions of human livers were isolated by standard 
differential centrifugation as described previously with slight modifications (Hermans and 
Thijssen, 1989). Briefly, frozen liver tissue was weighed and homogenized in 50 mM Tris-HCl 
ice-cold buffer (pH 7.4) containing 150 mM KCl, 1 mM EDTA, 0.1 mM dithiothreitol, 20% 
glycerol in the presence of the protease inhibitor phenylmethylsulfonyl fluoride (0.1 mM) and the 
anti-oxidant butylated hydroxytoluene (0.113 mM). The homogenate was centrifuged at 20,000g 
for 30 min at 4°C to yield the S9 fraction supernatant. The S9 fraction was centrifuged at 140,000g 
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for 60 min at 4°C. The resulting 140,000g soluble supernatant was collected as a cytosol, and the 
microsomal pellet was washed twice and resuspended in 0.02 M Tris-HCl (pH 7.4) containing 0.25 
M sucrose. Protein concentrations were determined with a Bio-Rad protein assay (Bio-Rad 
Laboratories, Hercules, CA) according to the manufacturer’s instructions, using bovine serum 
albumin as a standard protein. Aliquots of cytosolic and microsomal proteins were stored at -80oC 
until further analysis.  
4.3.3 Warfarin Reduction in Human Liver Cytosol and Microsomes 
The enzymatic activity of human reductases was investigated in cytosolic and microsomal 
fractions of control and ESRD liver tissue using warfarin as a substrate. Cytosolic or microsomal 
proteins (0.5 mg/mL) were incubated with various concentrations of warfarin (20, 50, 100, 250, 
500, 1000, 1500, and 2000 µM) in 10 mM Tris-HCl buffer (pH 7.4) containing 5 mM MgCl2 in a 
final reaction volume of 500 µL. Reactions were started by the addition of 1 mM NADPH and 
conducted for 30 min at 37ºC in a shaking water bath. Substrates were added in acetone with a 
final solvent concentration consistently maintained at 1%. Controls omitting substrate/NADPH 
were included in each incubation. Incubation time and protein concentration were optimized in 
preliminary experiments to achieve linear formation of alcohol metabolites. Metabolic reactions 
were terminated by the addition of 250 µL ice-cold acetonitrile. Then, samples were briefly vortex-
mixed, placed on ice for 15 min and centrifuged at 14,000 rpm for 10 min to pellet the protein. 
The generated warfarin alcohol metabolites in the supernatant were measured using UHPLC-
MS/MS as we previously described in chapter 2 (Alshogran et al., 2014b).  
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4.3.4 Inhibition of Warfarin Reduction in Human Liver Cytosol and Microsomes  
To identify the contribution of selective human reductases to carbonyl reduction of warfarin, 
pooled human liver cytosol or microsomes of the control group were incubated with warfarin (1 
mM) and a chemical inhibitor, under the conditions described in the previous section. We  have 
employed the same inhibitors and concentrations described in chapter 3 which include the 
following: quercetin for cytosolic CBRs (Hermans and Thijssen, 1992; Tong et al., 2010); 
flufenamic acid for cytosolic AKRs (Atalla et al., 2000; Molnari and Myers, 2012; Rosemond et 
al., 2004); indomethacin for both cytosolic CBRs and AKRs (Tong et al., 2010; Usami et al., 2001); 
dicoumarol for cytosolic NQO1 (Tong et al., 2010); and 18β-glycyrrhetinic acid for microsomal 
11β-HSD1 (Breyer-Pfaff and Nill, 2004; Molnari and Myers, 2012). Control reactions were 
performed with the vehicles in the absence of the chemical inhibitors.  
4.3.5 RNA Isolation, cDNA Synthesis, and Quantitative Real-Time PCR Analysis 
TRIzol reagent (Invitrogen, San Diego, CA) was used to extract total RNA from liver tissue. RNA 
concentration and purity were determined by spectrophotometry at 260 nm. One microgram of 
total RNA was reverse-transcribed into cDNA using SuperScript III reverse transcriptase 
(Invitrogen, San Diego, CA, USA). Each cDNA sample was diluted 4-fold and 2 µL of the dilution 
was used for qPCR analysis. The relative mRNA expression of human liver cytosolic CBR1, 
CBR3, AKR1C1-4, and NQO1, microsomal 11β-HSD1, and GAPDH was quantified by qRT-PCR 
performed using the ABI Prism 7300 system (Applied Biosystems, Foster City, CA, USA), SYBR 
Green master mix reagent (Roche, Indianapolis, IN, USA) and specific primers (Table 4-1). All 
samples were run in duplicate. Hepatic reductase mRNA levels were normalized to GAPDH and 
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expressed relative to the controls using the comparative quantitation (2-ΔΔCT) method (Livak and 
Schmittgen, 2001).    
 
 
Table 4-1  Nucleotide sequence for the primers used in qRT-PCR of human reductases 
           
mRNA     Primers (5'-3') 
  
Predicted Product 
Size (base pair) 
      
CBR1   Left  TTTGGTACCCGAGATGTGTG  98 
  Right TTAAGGGCTCTGACGCTCAT   
      
CBR3   Left  TCACCTTATGGGGTGTCCAAGTTGG  138 
  Right CCCATCCATGTCTGTCTTCACTGGT   
      
AKR1C1   Left  CTTGGCAAAAAAGCACAAGCGA  125 
  Right CAAACACCTGCACGTTCTGTCTGAT   
      
AKR1C2   Left  AACAAGCCAGGGCTCAAGTA  92 
  Right GACTTGCAGAAATCCAGCAG   
      
AKR1C3   Left  GCAGGCAGCTGGAGATGAT  91 
  Right CTCCGGTTGAAATACGGATG   
      
AKR1C4   Left  GATCCTCAACAAGCCAGGAC  95 
  Right TGCAGAAATCCAGCAGTTTG   
      
NQO1   Left  ACGAGCCCAGCCAATCAG  116 
  Right CAGCCTCCTTCATGGCATAG   
      
11β-HSD1   Left  AAGCAGAGCAATGGAAGCAT  108 
  Right GAAGAACCCATCCAAAGCAA   
      
GAPDH   Left  CTCAAGGGCATCCTGGGCTACA  110 
    Right TGGTCGTTGAGGGCAATGCC     
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4.3.6 Western Blotting  
Twenty-five microgram of total protein was loaded and electrophoresed on a 12% SDS-
polyacrylamide gel. The separated proteins were transferred to polyvinylidene difluoride (PVDF) 
membrane over 2 hr. Non-specific binding sites were blocked with 5% bovine serum albumin 
(BSA) in 1x Tris-buffered saline Tween (TBST) for 1 hr at room temperature. Membranes were 
then probed overnight at 4ºC with a specific primary antibody diluted in blocking buffer (1:1500 
mouse monoclonal anti-CBR1, Santa Cruz Biotechnology; 1:2000 goat polyclonal anti-AKR1C, 
Santa Cruz Biotechnology; or 1:1000 mouse monoclonal anti-β actin, Sigma-Aldrich). Blots were 
washed three times with TBST and then incubated with secondary antibody conjugated with HRP 
for 1 hr at room temperature (1:1000 sheep anti-mouse, GE healthcare Life Sciences; or 1:5000 
donkey anti-goat, Santa Cruz Biotechnology). Finally, blots were washed and bands were 
visualized using chemiluminescence ECL detection system. Band intensity was analyzed 
densitometrically using Image-J analysis software (National Institutes of Health, Bethesda, MD) 
and normalized to β-actin.        
4.3.7 Data and Statistical Analysis 
Enzyme kinetics for formation of warfarin alcohol metabolites were analyzed using a non-linear 
Michaelis-Menten regression model. The kinetic parameters including (Vmax) and (Km) were 
estimated and compared between groups using GraphPad Prism (Version 5; GraphPad Software 
Inc., San Diego, CA). In the inhibition studies, formation rate of alcohol metabolites was expressed 
as percent of control incubations, and statistical differences in alcohols formation in the presence 
or absence of inhibitors were determined using a student’s t-test. mRNA and protein expression of 
102 
reductases of livers of ESRD group were expressed relative to that of controls, and statistical 
differences between the two groups were assessed using student’s t-test. The threshold of 
significance was P value <0.05. All data are presented as mean ± SEM.   
4.4 RESULTS 
4.4.1 Human Samples and Patient Characteristics  
Table 4-2 presents clinical characteristics and demographic features of patients from whom liver 
samples were obtained right after their death. Patients were matched with respect to age, gender, 
body mass index (BMI), and race. The number of comorbid conditions was unsurprisingly higher 
in patients with ESRD compared to that in controls. The most commonly observed comorbid 
conditions in our sample were hypertension, congestive heart failure, and diabetes. Cardiovascular 
disease was the major cause of death in our patient sample. All medications taken by patients have 
not been shown to impact drug reduction, except for furosemide which was taken by one individual 
in each group, and previous data suggest that it may act as an inhibitor for hepatic reductases 
(Malatkova and Wsol, 2014). 
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Table 4-2  Demographics and patients characteristics 
Characteristic 
  Control 
(n=11) 
  ESRD 
(n=10) 
  
P  
      
Age (year; mean ± SD)  70.9 ± 9.7  74.8 ± 5.3  NS 
       
BMI (kg/m2; mean ± SD)  22.7 ± 4.8  25.8 ± 7.3  NS 
   Missing (n)  1  0   
       
Gender [n (%)]      
NS 
   Male  7 (63.6)  7 (70%)  
   Female  3 (27.3)  3 (30%)  
   Missing   1 (9.1)  0 (0)  
       
Race [n (%)]      
NS    Caucasian  11 (100)  8 (80)  
   African  0 (0)  2 (20)  
       
No. of Comorbid Conditions [n (%)]*      
0.016 
   Low (0 or 1)  5 (45.5)  0 (0)  
   Medium (2 to 4)  6 (54.5)  7 (70)  
   High (≥5)   0 (0)   3 (30)   
* The most commonly observed comorbid conditions in our sample were hypertension (10 patients), congestive heart 
failure (8), diabetes (6), chronic obstructive pulmonary disease (5), and coronary artery disease (4)  
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4.4.2 Effect of ESRD on Warfarin Reduction in Cytosol and Microsomes 
To determine the impact of ESRD on human hepatic reductase activity, we assessed in vitro steady-
state enzyme kinetics of warfarin reduction in a substrate concentration range of 20-2000 µM, 
using liver cytosol and microsomes of patients with and without ESRD. The estimated Michaelis-
Menten kinetic parameters (Vmax & Km) for the formation of alcohol metabolites in cytosolic and 
microsomal fractions are presented in Table 4-3.    
As depicted in Figure 4-1 and Table 4-3, the estimated steady-state kinetic parameters 
(Vmax & Km) as well as the intrinsic clearance (Clint) for formation of warfarin alcohol metabolites 
in cytosol and microsomes were not significantly different between ESRD and control livers. 
However, a trend of 22-27% decreased Vmax for formation of alcohol 1 and 29-41% increased 
warfarin Km value was observed in ESRD livers versus controls (P=NS).   
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Figure 4-1  Effect of kidney disease on the metabolic activity of human hepatic reductases that 
catalyze warfarin reduction 
Michaelis-Menten plots for the formation of warfarin (A) alcohol 1 and (B) alcohol 2 catalyzed by 
human liver cytosol, and (C) alcohol 1 and (D) alcohol 2 in human liver microsomes of both control 
and ESRD livers. Liver cytosolic or microsomal protein (0.5 mg/mL) was incubated with various 
concentrations of warfarin (20-2000 µM) for 30 min at 37ºC in the presence of cofactors. Each 
point represents the mean ± SEM of n=11 control and n=10 ESRD livers.   
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Table 4-3 Michaelis-Menten kinetic parameters for warfarin reduction in liver cytosol and microsomes of control and ESRD patients 
 Alcohol 1 (RS/SR)  Alcohol 2 (RR/SS) 
 Km              
(µM) 
Vmax                  
(pmol/mg protein/min) 
Clint                                         
(µL/mg protein/min) 
Km                      
(µM) 
Vmax                             
(pmol/mg protein/min) 
Clint                         
(µL/mg protein/min) 
Cytosol        
Control 677.3 ± 273.4 58.7 ± 9.28 0.088 ± 0.015  1119 ± 465.9 3.99 ± 0.78 0.0037 ± 0.00052 
ESRD 900.6 ± 486.0 45.8 ± 10.8 0.052 ± 0.012  1580 ± 1166 4.12 ± 1.65 0.0027 ± 0.00058 
Microsomes        
Control 594.7 ± 259.4 7.23 ± 1.18 0.0125 ± 0.0023  No fit No fit No fit 
ESRD 767.9 ± 300.1 5.30 ± 0.85 0.0071 ± 0.00098  No fit No fit No fit 
Data are presented as mean ± SEM of n=11controls and n=10 ESRD 
Clint represents the intrinsic clearance (the enzymatic efficiency: Vmax/Km) 
The differences in enzyme kinetic parameters between the two groups were not statistically significant.  
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4.4.3 Contribution of Human Hepatic Reductases to Warfarin Reduction 
The relative contribution of human reductases to warfarin reduction in pooled human liver cytosol 
or microsomes was identified by employing selective chemical inhibitors of reductase enzymes. 
The relative formation of warfarin alcohol 1 and alcohol 2 in the presence of inhibitors as 
normalized to control (vehicle) incubations is depicted in Figures 4-2A and 2B, respectively.    
Our results showed that quercetin, flufenamic acid and indomethacin (inhibitors of CBRs 
and AKR1Cs), and dicoumarol (inhibitor of NQO1) inhibited warfarin reduction in the cytosol in 
a concentration-dependent manner. The inhibition of alcohol 1 and alcohol 2 formation in the 
cytosol at 10 µM inhibitor concentration ranged from 31-39% and 16-40%, respectively. The 
extent of inhibition at 100 µM was markedly increased and ranged from 73-86% and 56-81% for 
formation of alcohol 1 and alcohol 2, respectively. All inhibitions were statistically significant at 
both inhibitor concentrations (10 at 100 µM) (P<0.05). Microsomal reduction of warfarin to 
alcohol 1 and alcohol 2 was not inhibited by 10 or 100 µM 18β-glycyrrhetinic acid. In fact, an 
inhibitor concentration of 250 µM was needed to inhibit warfarin reduction in the microsomes by 
43% (P<0.05).  
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Figure 4-2  Effect of reductase inhibitors on human warfarin reduction 
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Formation of warfarin (A) alcohol 1 and (B) alcohol 2 was assessed in the presence of selective 
carbonyl reducing enzyme inhibitors in pooled human liver cytosol (quercetin, flufenamic acid, 
dicoumarol, and indomethacin) and microsomes (18β-glycyrrhetinic acid). The corresponding 
reductase enzymes being targeted by the inhibitors are also included. Incubations were conducted 
at 10 and 100 µM inhibitor concentration in cytosol, and 10, 100, and 250 µM in microsomes. 
Data are presented as mean ± SEM of triplicate incubations. Statistical differences are as follows: 
*P<0.05; **P<0.01, and ***P<0.001, compared with control incubations which were arbitrarily 
defined as 100%. 
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4.4.4 Effect of Kidney Disease on mRNA and Protein Expression of Human Hepatic 
Reductases 
To determine whether the observed trend of decreased reductase metabolic activity in ESRD livers 
was secondary to reduced mRNA expression, we assessed mRNA levels encoding cytosolic 
(CBR1, CBR3, AKR1C1-4, and NQO1) and microsomal (11β-HSD1) human hepatic reductase 
isoforms by qRT-PCR. Figure 4-3 displays the relative mRNA expression of hepatic reductases 
in livers from patients with ESRD and control subjects. Our mRNA expression data showed a 
similar trend, with a decline in mRNA levels of cytosolic CBR1 and AKR1C1, AKR1C2, 
AKR1C3, and AKR1C4 of 56%, 63%, 67%, 50% and 28% respectively, in ESRD livers versus 
controls. However, the observed down-regulation was not statistically significant. Conversely, 
significant up-regulation in mRNA expression of cytosolic CBR3 was observed in ESRD livers 
relative to control livers (P<0.05). mRNA expression of cytosolic NQO1 and microsomal 11β-
HSD1 remained unaltered.   
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Figure 4-3  Effect of ESRD on mRNA expression of human hepatic reductases  
mRNA expression of cytosolic (CBR1, CBR3, AKR1C1-4, and NQO1) and microsomal (11β-
HSD1) human hepatic reductases in control and ESRD livers as determined by quantitative RT-
PCR. mRNA expression of reductase isoforms was normalized to that of GAPDH. The results of 
ESRD group were normalized to the control which was arbitrarily defined as 100%. Experiments 
were conducted in duplicates, and data are presented as mean ± SEM of n=11 control and n=10 
ESRD livers. * (P<0.05) compared with control. 
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To assess whether protein expression of CBR1 and AKR1C (AKR1C1, AKR1C2, 
AKR1C3, and AKR1C4 isoforms) in ESRD parallels mRNA expression, we examined CBR1 and 
total AKR1C protein expression using Western blotting (Figure 4-4). Our data showed that CBR1 
protein was significantly down-regulated by 65% in ESRD livers compared to controls (P<0.05), 
while total AKR1C protein expression was unaffected. 
 
 
Figure 4-4  Effect of ESRD on protein expression of human hepatic reductases  
Protein expression of cytosolic (CBR1 and AKR1C) human hepatic reductases in livers of patients 
with ESRD and control subjects examined by Western blotting. (A) Representative blots showing 
the expression of reductases and the internal control (β-actin) in both groups. (B) Densitometric 
analysis of protein expression as normalized to the β-actin. The densitometry units of ESRD group 
were normalized to that of control which was arbitrarily defined as 100%. Data are presented as 
mean ± SEM of n=11 control and n=10 ESRD livers. * (P<0.05) compared with control.  
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4.5 DISCUSSION 
This study evaluated the effect of ESRD on the metabolic activity and expression of reductase 
enzymes in the cytosolic and microsomal liver fractions from humans with ESRD and control 
subjects. A significant downregulation in CBR1 protein expression was observed in livers from 
ESRD patients. The findings of this study support the previous data observed in rat model of CKD 
as described earlier in chapter 3. Together, these results indicate that in patients with ESRD, 
hepatic reduction of drugs mediated by the CBR1 isoform may be compromised. 
Multiple clinical and experimental studies have established impaired drug metabolism and 
transport in the setting of kidney disease (Yeung et al., 2014) The results of the experimental 
studies also demonstrated that the change in mRNA and protein expression of drug metabolizing 
enzymes may mechanistically explain and at least partially contribute to the alterations in their 
function (Lalande et al., 2014). As reported in the previous chapter, the metabolic activity of 
hepatic reductases generating warfarin alcohols in cytosol and microsomes was selectively 
decreased in rats with experimental kidney disease, secondary to the differential downregulation 
of mRNA and protein expression of reductase isoforms (Alshogran et al., 2014a). The impact of 
kidney disease on the functional expression of human hepatic reductase is currently unknown.  
The appreciation of the importance of reduction pathways in drug metabolism has been 
growing. Notably, numerous recent reports have strongly recommended investigating carbonyl 
reduction of drugs during the processes of drug discovery and development (Malatkova and Wsol, 
2014). Reductases catalyze the reduction of a wide variety of drugs including anticoagulants, 
antidiabetics, antihypertensives, anticancers, opiate antagonists, NSAIDs, antihistamines, and 
diuretics (Rosemond and Walsh, 2004). As discussed in chapter 1, the disposition of many of these 
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drugs is shown to be altered in patients with CKD suggesting that phase I drug reduction could 
also be modulated by kidney disease. 
In this study we first assessed the metabolic activity of reductases in subcellular fractions 
of liver tissue from ESRD patients and control subjects. Although the difference in alcohol 1 
production did not reach statistical significance, a trend toward selectively decreased cytosolic (by 
22%) and microsomal (by 27%) hepatic reductase activity in ESRD livers was observed. Notably, 
large interindividual variability in formation rate ranging from 51-75% coefficient of variation 
(CV) with alcohol 1 to 65-126% CV with alcohol 2 was observed. The greatest variability was 
observed in ESRD livers, which may have contributed to the non-significant findings. Post-hoc 
power analysis revealed that our study was underpowered to determine a significant difference in 
reductase activity between the two groups. Using two-sided student’s t-test with alpha of 0.05, our 
study had only 13% power to detect approximately a 20% difference in formation of alcohol 1 in 
cytosol between ESRD and control livers (the calculated effect size was 0.4). Although the inter-
individual variability in human patients is expected to be higher than rats, the observed trend 
toward decreased alcohol 1 formation in humans with ESRD is consistent, in part, with our 
findings observed in the experimental model of kidney disease as reported in chapter 3.  
A preferential production of alcohol 1 was seen in the cytosol as indicated by its 8-fold 
higher metabolic formation in the cytosol compared to the microsomes. This is in agreement with 
previous studies that assessed R and S-warfarin reduction in the cytosolic and microsomal fractions 
of human liver tissue, and demonstrated a preference toward production of warfarin alcohol 1 in 
the cytosol (Hermans and Thijssen, 1993; Moreland and Hewick, 1975).  
We further investigated whether ESRD affects mRNA and protein expression of hepatic 
reductases. Selective chemical inhibitors of reductases were utilized to evaluate the contribution 
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of different group of reductase enzymes to warfarin reduction, because the specific human 
reductase isoforms that catalyze warfarin reduction have not been characterized to date. Overall, 
the inhibition studies suggest the involvement of cytosolic NQO1, CBRs, and AKR1C, as well as 
microsomal 11β-HSD1 isoforms in warfarin reduction. These results agree, in part, with the 
previous findings of Hermans and Thijssen who demonstrated that 4’-nitrowarfarin reduction in 
human liver cytosol is strongly inhibited by quercetin and indomethacin, inhibitors of CBR and 
AKR1C reductase isoforms, respectively (Hermans and Thijssen, 1993). The diverse levels of 
inhibition observed with these inhibitors revealed that the relative contribution of cytosolic 
reductases toward warfarin reduction is different. Perhaps, the highest degree of inhibition 
demonstrated by quercetin may indicate that CBRs are the predominant reductases involved in 
warfarin reduction. In addition, the inhibition pattern observed in human cytosol and microsomes 
is similar to that observed in rat livers as reported in the previous chapter. However, higher 
concentration of 18β-glycyrrhetinic acid was needed to inhibit 11β-HSD1 isoform in human liver 
fractions. This may be attributed to; first) low overall contribution of microsomal reductases to 
warfarin reduction, second) the low concentration of inhibitor used relative to substrate 
concentration (10 or 100 µM vs 1000 µM respectively). Together, these results may indicate 
similarity between human and rat reductase isoforms. 
We found that mRNA expression of hepatic reductases is differentially affected by ESRD. 
A non-significant decline of up to 67% in mRNA levels of CBR1 and AKR1C isoforms, and a 
significant upregulation of CBR3 mRNA expression was observed in ESRD livers versus controls. 
These findings may be partially attributed to accumulation of inflammatory cytokines that have 
been shown to differentially modulate the expression of several drug metabolizing enzymes and 
transporters as previously discussed in chapter 1 (Michaud et al., 2008; Reyes and Benet, 2011; 
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Tsujimoto et al., 2013; Volpe et al., 2014). In fact, the finding of increased CBR3 expression is 
consistent with the results of Malatkova and co-workers who elucidated that treatment of colon 
(HT-29) and liver (HepG2) cell lines with the inflammatory mediators TNF-α and IL-1β induced 
the expression of CBR3 up to 20-fold (Malatkova et al., 2012). Additionally, INF-γ has been 
shown to increase mRNA expression of CBR3 by 5.6-fold in human bronchial epithelial cells 
(Pawliczak et al., 2005).  
Because CBR3 is expressed in much lower levels in human liver compared to CBR1 and 
AKR1C (Malatkova et al., 2010), and contributes minimally to drug metabolism in vivo (Pilka et 
al., 2009), along with limited available resources to evaluate all enzymes, we chose to subsequently 
evaluate the corresponding protein expression of CBR1 and total AKR1C. Our data showed a 
significant down-regulation in CBR1 protein in ESRD livers; however, protein level of total 
AKR1C was unchanged. The disproportionate decrease in CBR1 protein versus mRNA expression 
observed may suggest the contribution of post-translational mechanisms to its downregulation in 
ESRD (Greenbaum et al., 2003; Vogel and Marcotte, 2012). The observation of decreased 
expression of CBR1 protein in ESRD may be clinically important, because this isoform is highly 
expressed in the liver and contributes significantly to the biotransformation of multiple 
endogenous compounds (e.g., prostaglandins, steroids, lipids) and metabolism of several drugs 
such as doxorubicin, dolasetron and nabumetone (Kassner et al., 2008; Malatkova et al., 2010). 
For instance, decreased doxorubicin clearance and the corresponding increase in its exposure 
observed in hemodialysis patients could be partially explained by decreased expression of CBR1 
protein (Yoshida et al., 1994). Taken together, these data suggest that kidney disease may 
selectively impair reductase protein expression. However, further well-powered investigations are 
required to confirm the results of the effect of ESRD on reductase mRNA expression.   
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In summary, CBR1 protein expression is significantly decreased in ESRD livers. Given the 
significant contribution of CBR1 to drug reduction, the findings could explain alterations of 
clinical pharmacokinetics of CBR1 drug substrates (i.e., idarubicin) in CKD patients. The findings 
also suggest that elimination of certain drugs that are metabolized by the CBR1 isoform could be 
impaired as a result of the alterations in its expression. However, due to the large inter-individual 
variability observed, future adequately powered studies with larger sample size are warranted to 
further confirm these findings. These results are consistent, in part, with our data reported in 
previous chapter where we established selective decrease in the expression of rat hepatic 
reductases due to kidney disease.  
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5.0  EFFECT OF CKD ON STEADY STATE WARFARIN DISPOSITION IN 
HUMANS: A PILOT STUDY 
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5.1 ABSTRACT 
Warfarin metabolism is decreased in CKD, suggesting its nonrenal clearance can be altered in 
CKD patients. However, little is known about warfarin pharmacokinetics in patients with different 
levels of kidney function. This work was conducted to explore the impact of impaired kidney 
function on steady-state pharmacokinetics of warfarin in humans. Blood samples were collected 
from patients (total n=25) with varying levels of kidney function (i.e., eGFR ranging from 3-80 
mL/min/1.73m2), who were on long-term warfarin therapy. Patients were separated into 5 groups 
according to the eGFR values. Total and free concentrations of warfarin, warfarin enantiomers, 
and alcohol metabolites were measured in serum and serum ultrafiltrate, respectively, using LC-
MS/MS. Warfarin clearance, S/R warfarin ratio, and exposure of warfarin alcohols were compared 
between groups using ANOVA. Regression analysis was performed to determine the impact of 
kidney function and other covariates on warfarin clearance. Also, the activity of warfarin alcohols 
against clotting factor XIa activity was assessed in vitro. Warfarin clearance was not different 
between patients with varying levels of kidney function. eGFR was a significant predictor of total 
S-warfarin clearance (P=0.045). The exposure of warfarin alcohol 2 was 6-fold higher in patients 
with ESRD compared to control/mild CKD patients (P<0.05). Further, warfarin S/R ratio was 2.5-
fold higher in ESRD patients versus control/mild CKD patients (P<0.05). No differences were 
observed in protein binding of warfarin between patients with varying levels of CKD. 
Additionally, in vitro studies showed negligible effect of warfarin alcohols against the activity of 
FXIa. Collectively, our data provide evidence for increased exposure of the warfarin alcohol 2 
metabolite as well as decreased CYP2C9-mediated warfarin metabolism in ESRD patients. These 
findings may partially explain decreased warfarin dosing requirements and increased risk of poor 
outcomes in CKD patients. 
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5.2 INTRODUCTION 
Patients on warfarin anticoagulant therapy exhibit high variability in dosing requirements and 
response. Several dosing algorithms incorporating clinical and genetic information that account 
for the inter-individual variability have been developed to improve warfarin dosing. However, 
these attempts have only accounted for approximately 60% of the variation in warfarin dosing, 
stressing the importance of additional factors that should be considered (Kimmel et al., 2013; Liao 
et al., 2014; Stergiopoulos and Brown, 2014). Recently, kidney function has been shown to be an 
important determinant of S-warfarin metabolic clearance in a pharmacokinetic model developed 
based on the measured plasma concentrations of S-warfarin in 167 patients (Gong et al., 2011). In 
addition, kidney function acts as a critical covariate in clinical schemes for predicting warfarin 
bleeding risk (Fang et al., 2011; Gage et al., 2006; Pisters et al., 2010). Warfarin is administered 
clinically as a racemic mixture of R and S enantiomers, which have different pharmacokinetic 
profiles and pharmacological potency (Fasco and Principe, 1982; Hewick and McEwen, 1973). 
Warfarin is nearly completely absorbed after oral administration, highly bound to plasma albumin 
(99%), and has a long half-life of about 40 hours (Holford, 1986). Warfarin is eliminated almost 
completely by metabolism, followed by urinary excretion of the metabolites, with only a very 
small percentage of the dose being recovered unchanged in the urine (Jones and Miller, 2011).  
Altered nonrenal clearance of drugs in kidney disease (Yeung et al., 2014) suggests that 
the disposition of the highly metabolized drugs, such as warfarin, may be impacted by impaired 
kidney function. This is supported by our work (presented in chapters 3 and 4) that demonstrates 
diminished warfarin reduction, along with the earlier findings of reduced activity of CYP2C9 
(Dreisbach et al., 2003) in kidney disease. Alterations in warfarin exposure may be detrimental, as 
it may result in severe clinical consequences in cases of enhanced and reduced anticoagulant 
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effects. In line with this, several recent observational studies have shown decreased warfarin dose 
requirements and increased bleeding risk and stroke in CKD patients receiving warfarin 
(Winkelmayer and Turakhia, 2014), suggesting that warfarin pharmacokinetics may be altered in 
patients with impaired kidney function. Together, these findings may indicate that kidney function 
is a significant factor to be considered when predicting warfarin dose besides other known clinical 
(age, diet, medications interactions, and liver disease) and genetic (CYP2C9 and VKORC1 
genotypes) parameters (Cavallari et al., 2010).  
Limited information is available on the elimination of warfarin in patients with CKD. To 
date, only one study has evaluated warfarin disposition in patients with kidney disease. This study 
included five subjects as controls and four patients with CKD (CLCr 11-48 mL/min/1.73m2) 
(Bachmann et al., 1977). After single dose warfarin administration, the results revealed shorter 
warfarin elimination half-life in CKD patients versus control group (mean ± SEM: 29.9 ± 5 h vs. 
44.8 ± 6 h, respectively) (Bachmann et al., 1977). This study has several limitations: 1) only two 
groups of participants were recruited with no evidence of inclusion of patients on hemodialysis; 2) 
evaluated only total concentration of warfarin without assessing the free concentration; and 3) did 
not assess differences in disposition of warfarin enantiomers in patients with impaired kidney 
function. To address these gaps, we explored the effect of varying degrees of kidney function on 
steady-state disposition of warfarin enantiomers. The disposition of warfarin alcohol active 
metabolites and their activity against vitamin-k independent clotting factor (FXIa) were also 
assessed. We hypothesized that warfarin clearance is decreased in patients with progressive kidney 
disease as a result of reduced non-renal clearance.  
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5.3 METHODS 
5.3.1 Clinical Study Design and Participants 
Patients on long-term anticoagulant warfarin therapy were eligible if they exhibited stable INR 
values for at least four previous clinic visits. Eligible patients were stratified into 5 groups based 
on eGFR calculated using the CKD-EPI equation (Levey et al., 2009) as follows: normal/mild 
kidney function (eGFR > 60 mL/min/1.73m2), moderate CKD (eGFR 30–60 mL/min/1.73m2), 
severe CKD (eGFR 15-30 mL/min/1.73m2), ESRD (eGFR < 15 mL/min/1.73m2 and not requiring 
renal replacement therapy), and ESRD/HD (eGFR < 15 mL/min/1.73m2 and on hemodialysis). 
Patients were excluded if they had a history of malabsorption or clinical/ laboratory evidence of 
liver disease, drink alcohol of exceeding 3 standard drinks daily, and receive concurrent treatment 
with drugs that strongly interact with warfarin such as amiodarone (enzyme inhibitor) and 
rifampicin (enzyme inducer). Patient characteristics including age, gender, BMI, race, serum 
albumin concentration, warfarin weekly dose, and indication for warfarin therapy were recorded. 
Patients were given warfarin at a time similar to that at which they usually self-administered this 
medication at home. After warfarin administration, a single blood sample (15 mL) was collected 
on the day of the clinic visit close to the mid-point of drug administration (i.e., approximately 12 
hours after the last dose). Because warfarin and its metabolites are highly bound to plasma proteins 
(>98%) (Chan et al., 1993; Lomonaco et al., 2013), we assume that their removal by hemodialysis 
will be very minimal, and collecting blood samples before or after hemodialysis will not have 
significant effect on the measured concentrations. Blood samples were allowed to clot, and then 
centrifuged to collect the serum, which was stored at -80oC until analysis. The study protocol was 
123 
approved by the Research and Ethics Committee of Maisonneuve-Rosemont Hospital. All subjects 
provided written informed consents prior to participation in the study.  
5.3.2 Determination of Total and Free Warfarin and Alcohol Metabolites  
Total serum concentrations of racemic warfarin and warfarin alcohol metabolites were determined 
using a validated LC-MS/MS analytical method as previously described in chapter 2 (Alshogran 
et al., 2014b). In brief, serum (100 µL) was combined with the internal standard mixture of d5-
warfarin and d5-7-hydroxywarfarin, and then extracted using TMBE. Warfarin and warfarin 
alcohols were separated using a Thermo Hypersil Gold C18 (2.1  100 mm, 1.9 µm) analytical 
column, connected to 0.22 µm frit filter. Chromatographic separation was achieved under gradient 
of solvent A (water containing 0.01% formic acid), and solvent B (acetonitrile containing 0.1% 
formic acid) over 5 min. Specific MS/MS experimental conditions are reported in chapter 2. 
Calibration curves were linear (r2 ≥ 0.994) over a range of 50-5000 ng/mL for warfarin, 10-750 
ng/mL for warfarin alcohol 1, and 1-150 ng/mL for warfarin alcohol 2. The intra- and inter-day 
accuracy and precision for all analytes in the analytical assay were within ±15%.  
A validated chiral assay was employed to measure total concentrations of R- and S-warfarin 
enantiomers. Analytes were resolved using Astec Chirobiotic V column (150 mm × 2.1 mm ID, 5 
µm) and an Astec Chirobiotic V guard column (10 mm × 2.1 mm ID; 5 µm), each supplied by 
Supelco (Bellefonte, PA, USA), with gradient elution of solvent A [10 mM ammonium acetate 
(pH 5.0) and acetonitrile (90:10, v/v)] and of solvent B (acetonitrile). The run time was 10 min per 
sample. All analytes were detected in negative ionization mode using selected reaction monitoring. 
The ion transitions in the chiral assay were m/z 307.106 161.144 for warfarin (collision energy 
= 21V) and m/z 312.162  255.298 for d5-warfarin (collision energy = 26V). Standard curves 
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were linear (r2 ≥ 0.997) over a range of 25-2500 ng/mL for both enantiomers. The intra- and inter-
day accuracy and precision for analytes were within ±10%.  
For the determination of the free fraction of warfarin, warfarin enantiomers and alcohol 
metabolites, 500 µL of serum was ultrafiltered at 4000 rpm for 30 min at 4oC using Centrifree 
ultrafiltration devices (Millipore, MA, USA). Serum ultrafiltrate (200 µL) was extracted as 
describe in chapter 2 using MTBE. Chromatographic separation and MS/MS detection were also 
as described earlier. Standard curves were linear (r2 ≥ 0.992) over the range of 1-50 ng/mL for 
warfarin and warfarin alcohol 1, and 0.5-25 ng/mL for warfarin enantiomers and alcohol 2 
metabolite. The intra- and inter-day accuracy and precision for all analytes were within ±15%. 
5.3.3 Pharmacokinetic Analyses 
Based on the assumptions of steady-state conditions, full compliance, and complete oral 
bioavailability, one point oral clearance was calculated for warfarin and its enantiomers as follows: 
CLtotal = D/(Css×τ), in which D is the daily warfarin dose (half the racemic dose for the 
enantiomers), Css is the steady-state concentration of analytes, and τ is the dosing interval=24 h. 
The validity of the steady-state and full compliance assumptions were verified by recording the 
INR values of the patients in the previous four clinic visits before blood collection. The INR should 
be stabilized and maintained within the therapeutic range over that period of time. Because 
warfarin has a long elimination half-life (~50h for R-warfarin and 30h for S-warfarin) (Maddison 
et al., 2013), obtaining a concentration in a single blood sample collected close to the mid-point of 
dosing interval will be approximate to the Css (Jensen et al., 2012). The free fraction (fu) of analytes 
was calculated by dividing the free unbound concentration (Cfree) by the total concentration (Ctotal). 
The unbound clearance (CLu) was calculated as follows: CLu = CLtotal/fu or D/(Cfree×τ).  
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5.3.4 Statistical Analyses 
Mean differences in demographic variables and PK parameters were compared between CKD 
groups using one-way ANOVA for continuous variables and chi square test for categorical 
variables. Significant ANOVA was followed by a post hoc Bonferroni analysis. Pearson’s 
correlation analysis was performed to express strength of relationships between variables. 
Multivariate linear regression analysis was used to determine the relative effect of age, gender, 
weight, BMI, race, eGFR, albumin concentration, and blood sampling time on outcome measures 
(i.e., warfarin clearance, S/R warfarin ratio, fraction unbound) as appropriate. Analysis was 
conducted using STATA software (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP) and GraphPad Prism (Version 5; GraphPad Software Inc., San 
Diego, CA). P<0.05 was considered significant for all comparisons. Results are expressed as mean 
± SD.   
5.3.5 Effect of Warfarin Alcohols on Clotting Factors Xa and XIa Activity In-vitro 
The activity of warfarin alcohols against purified human vitamin-K independent (XIa) and 
dependent (Xa) clotting factors was determined in vitro as previously described with minor 
modifications (Ma et al., 2013; Wong et al., 2011; Wong et al., 2008). Reagents used in these 
experiments included: human FXa and FXIa from Haematologic Technologies (Essex Junction, 
VT, USA); chromogenic substrates S-2765 (for FXa) and S-2366 (for FXIa) from Chromogenix 
AB (distributed by DiaPharma Group, West Chester, OH, USA); and apixaban from Cayman 
Chemical (Ann Arbor, MI, USA). Working solutions of clotting factors were prepared in the assay 
buffer (50 mM Tris, 100 mM NaCl, 0.01% BSA, pH 7.4). Clotting factor (0.5 nM) was pre-
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incubated with different concentrations of either warfarin alcohol 1 (5 nM – 32.2 µM), warfarin 
alcohol 2 (5 nM – 32.2 µM), warfarin (5 nM – 32.4 µM), or apixaban (0.25 nM – 2 µM) in 96-
well microtiter plates for 10 min at room temperature. Control incubations included clotting factor 
with the vehicle only (methanol for warfarin and alcohols, DMSO for apixaban). The reaction was 
initiated by the addition of the substrate dissolved in water (S-2765 or S-2366) to a final 
concentration of 200 µM. The mixture was incubated at room temperature for 30 min. Substrate 
hydrolysis (which reflects clotting factor activity) was monitored by measuring the absorbance at 
405 nm using a plate reader. Absorbance values were plotted against drug concentrations. 
Apixaban was used as a positive control for FXa and as a negative control for FXIa experiments. 
Similar experiments were also conducted at 0.5 nM FXIa by varying the concentrations of the S-
2366 substrate (0-800 µM) and warfarin alcohols (0-32 µM). Data analysis was performed using 
GraphPad Prism. 
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5.4 RESULTS 
5.4.1 Patient Characteristics  
A total of 25 patients with a mean age of 73.4 ± 11 were included in the study. Participants were 
separated according to their kidney function as follows: normal/mild CKD (eGFR (mean ±SD) = 
72 ± 6.8 mL/min/1.73m2; n=6), moderate CKD (eGFR= 42.8 ± 5.2; n=4), severe CKD (eGFR= 19 
± 3.4, n=5), ESRD with no renal replacement therapy (eGFR= 12.6 ± 2.8; n=5), and ESRD on HD 
(eGFR= 4.6 ± 2; n=5). The most common indications for warfarin therapy were atrial fibrillation 
(52%) and thromboembolic disease (32%). The mean warfarin weekly dose (mg) was 28.6 ± 14.3 
(range: 7-57.5 mg/week). The mean serum albumin level was 3.9 ± 0.35 g/dL (range: 3.1-4.6 g/dL). 
Patient characteristics in each CKD group were matched including age, gender, race, BMI, serum 
albumin, warfarin dose, and blood sampling time as listed in Table 5-1. 
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Table 5-1 Demographic and clinical characteristics of study patients  
  
All patients 
(n=25) 
Normal/Mild 
(n=6) 
Moderate 
(n=4) 
Severe 
(n=5) 
ESRD         
(n=5) 
ESRD/HD 
(n=5) 
P 
eGFR 
(mL/min/1.73m2) 
31.4 ± 26.6 72 ± 6.8 42.8 ± 5.2 19 ± 3.4 12.6 ± 2.8 4.6 ± 2.0 <0.001 
        
Age (year) 73.4 ± 11 65 ± 10.9 70.5 ± 12.6 79.4 ± 4.7 80.4 ± 9.9 72.6 ± 10.6 0.1051 
        
Weight (kg) 81.5 ± 15.7 81.5 ± 8.0 82.6 ± 9.9 83.4 ± 11.4 81.2 ± 15.6 78.7 ± 30.5 0.9942 
        
BMI (kg/m2) 29.8 ± 4.9 29 ± 2.4 30.0 ± 3.4 30.5 ± 4.3 29.5 ± 5.3 30.4 ± 8.8 0.9891 
        
Gender (% male) 52 50 50 60 80 20 0.4390 
        
Race (% white) 96 100 100 100 100 80 0.3840 
        
Serum albumin 
(g/dL) 
3.9 ± 0.35 4.2 ± 0.32 4.1 ± 0.25 3.9 ± 0.22 4.0 ± 0.29 3.7 ± 0.48 0.1713 
        
Warfarin dose 
(mg/week) 
28.6 ± 14.3 39.5 ± 15.4 25.6 ± 8.3 28.6 ± 13.6 20.3 ± 8.7 28.4 ± 19 0.2702 
        
Blood sampling 
time (h) 
15.9 ± 3.3 16.2 ± 3.1 16.1 ± 1.0 15.4 ± 3.1 16.4 ± 5.3 15.2 ± 3.6 0.9776 
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5.4.2 Warfarin Clearance and Kidney Disease  
No differences were found in mean values of the total and free steady-state clearance of warfarin, 
R-warfarin, and S-warfarin among well-matched patients with different degrees of kidney disease 
(Figure 5-1). 
 
Figure 5-1 Clearance of total warfarin, free warfarin, and warfarin enantiomers in patients with 
varying levels of kidney disease 
Clearance of total warfarin, free warfarin, and warfarin enantiomers was calculated from a single 
point plasma concentration close to the mid-point of warfarin administration. Data were compared 
using ANOVA test.  
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  Multiple regression analysis was performed to determine the contribution of different 
clinical parameters to the variability in warfarin clearance (Table 5-2). The results indicate a 
significant association between total warfarin and R-warfarin clearance with age and serum 
albumin (P<0.05), and a significant association between free warfarin and R-warfarin clearance 
with age only (P<0.05) after adjustment for sex, BMI, race, blood sampling time, and eGFR. Age 
was associated with a significant decline in total and free warfarin clearance by 0.049 and 5.5 
mL/min per year of age, respectively, and by 0.044 and 5.3 mL/min for total and free R-warfarin, 
respectively. In addition, each unit increase in serum albumin was associated with a significant 
decrease in total warfarin and R-warfarin clearance by 0.12 and 0.15 mL/min, respectively.   
On the other hand; eGFR was the only significant contributor to total S-warfarin clearance 
(P=0.045), with a 0.025 mL/min increase in clearance for every 1 mL/min/1.73m2 increase in 
eGFR. None of the covariates contributed to free S-warfarin clearance.  
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Table 5-2 Significant predictors of clearance of total and free warfarin and its 
enantiomers using multiple regression analysis 
Outcome Predictor Beta SE P 
Total Warfarin CL (mL/min)  Age -0.049 0.017 0.01 
 Serum albumin -0.124 0.051 0.025 
     
Total R-warfarin CL (mL/min)  Age -0.044 0.018 0.024 
 Serum albumin -0.154 0.054 0.009 
     
Total S-warfarin CL (mL/min)  eGFR 0.025 0.012 0.045 
     
Free Warfarin CL (mL/min)  Age -5.548 2.116 0.016 
     
Free R-warfarin CL (mL/min)  Age -5.257 1.999 0.015 
     
Free S-warfarin CL (mL/min)  None       
 SE: standard error 
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Age was the only significant modifier of average weekly warfarin dose for all patients. As 
age increases by one year, the average weekly warfarin dose decreases by 0.75 mg. In addition, 
significant negative relationships were observed between age and eGFR (r=-0.449, P=0.024) as 
well as age and weekly warfarin dose (r=-0.526, P=0.007) (Figure 5-2). 
 
 
Figure 5-2 Relationship between eGFR values and weekly warfarin dose with age in study 
patients 
 
5.4.3 Warfarin Alcohols Disposition and Kidney Disease  
Total and free dose-normalized alcohol 2 concentrations were significantly dependent on kidney 
function. Total warfarin alcohol 2 exposure was 6.5-fold higher in patients with ESRD compared 
to those with normal/mild CKD (64.3 ± 34.6 versus 9.9 ± 3.87 ng/mg*mL; P=0.015) (Figure 5-
3). Free warfarin alcohol 2 exposure was also about 6.5-fold higher in both patients with ESRD 
compared to those with normal/mild CKD (0.51 ± 0.29 versus 0.08 ± 0.08 ng/mg*mL; P=0.016), 
and in ESRD/HD group versus normal/mild CKD (0.49 ± 0.24 versus 0.08 ± 0.08 ng/mg*mL; 
P=0.025) (Figure 5-3). Similar significant trends were also observed with regard to total and free 
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alcohol 2 when normalized to the corresponding warfarin concentrations. Warfarin alcohol 1 
exposure was not different between kidney disease patients. 
 
 
Figure 5-3 Fold difference in dose normalized warfarin alcohol concentrations in patients with 
varying degrees of kidney disease 
P value obtained from ANOVA analysis.  
* indicates statistically different from the normal/mild group. 
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5.4.4 S/R Warfarin Ratio and Kidney Disease  
Mean total and free S/R warfarin ratio was significantly different between CKD patients (P=0.014 
and P=0.018, respectively). Post hoc analysis revealed that S/R ratio was 2.5-fold higher in 
ESRD/HD patients compared to severe CKD group for total (0.93 ± 0.32 versus 0.39 ± 0.07; 
P=0.016) and free S/R ratios (0.76 ± 0.23 versus 0.30 ± 0.06; P =0.018). Total S/R was also 2-fold 
significantly higher in ESRD/HD compared to normal/mild CKD group (0.93 ± 0.32 versus 0.47 
± 0.09; P=0.039) (Figure 5-4).  
eGFR was the only significant predictor for total (P=0.013) and free (P=0.043) S/R ratio 
in the regression model with a decrease in total and free S/R ratio by 0.006 and 0.004 receptively, 
with a unit increase in eGFR. Other variables included in the model (age, sex, BMI, race, serum 
albumin, sampling time and dose) did not have a significant contribution.    
 
 
Figure 5-4 Total and free S/R warfarin ratio by degree of kidney disease  
P value obtained from ANOVA analysis.  
* indicates statistically significant. 
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5.4.5 Protein Binding of Warfarin and Warfarin Alcohols  
The free unbound fractions of warfarin, R-warfarin, S-warfarin, alcohol 1, and alcohol 2 were not 
different between kidney disease patients. Considering the entire sample, the mean ± SD unbound 
percent was 0.92 ± 0.24 for warfarin, 0.84 ± 0.24 for R-warfarin, 0.70 ± 0.23 for S-warfarin, 0.97 
± 0.39 for alcohol 1, and 0.93 ± 0.29 for alcohol 2.  
5.4.6 In-vitro Effect of Warfarin Alcohols on Human FXa and FXIa Activity 
At concentrations up to 32 µM, warfarin alcohols and warfarin had negligible direct effect on 
clotting factors Xa and XIa activity in vitro. As expected, apixaban inhibited the activity of factor 
Xa in a concentration-dependent manner, but did not affect the activity of factor XIa. The IC50 
(defined as the concentration needed to inhibit the activity by 50%) for apixaban inhibition of 
factor Xa was around 4 nM (Figure 5-5 and Figure 5-6), which is comparable with a previous 
report (Jiang et al., 2009).  
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Figure 5-5 The effect of warfarin alcohol metabolites on the activity of human factor Xa 
Clotting factor FXa (0.5 nM) was pre-incubated with different concentrations of either warfarin 
alcohol 1, warfarin alcohol 2, warfarin, or apixaban (used as a positive control). The reaction was 
initiated by the addition of the substrate S-2765 to a final concentration of 200 µM. Substrate 
hydrolysis was monitored by measuring the absorbance at 405 nm. The estimated IC50 of apixaban 
inhibition of FXa was close to 4 nM. 
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Figure 5-6 The effect of warfarin alcohol metabolites on the activity of human factor XIa 
Clotting factor FXIa (0.5 nM) was pre-incubated with different concentrations of either warfarin 
alcohol 1, warfarin alcohol 2, warfarin, or apixaban (used as a negative control). The reaction was 
initiated by the addition of the substrate S-2366 to a final concentration of 200 µM. Substrate 
hydrolysis was monitored by measuring the absorbance at 405 nm.  
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Our results also indicate that warfarin alcohols did not influence FXIa activity when the 
clotting factor was incubated with different substrate and inhibitor (alcohols) concentrations. As 
depicted in Figure 5-7, the plots of absorbance versus S-2366 concentration were almost 
superimposable at different concentrations of warfarin alcohols (0, 0.5, 1, 5, 10, and 32 µM), 
suggesting the lack of effect.  
 
 
Figure 5-7 Plot of warfarin alcohols effect on human factor XIa activity at different substrate (S-
2366) concentrations 
Clotting factor FXIa (0.5 nM) was pre-incubated with different concentrations of either warfarin 
alcohol 1 or warfarin alcohol 2. The reaction was initiated by the addition of the substrate S-2366 
at different concentrations ranging from 0-800 µM. Substrate hydrolysis was monitored by 
measuring the absorbance at 405 nm.  
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5.5 DISCUSSION 
In this pilot study the steady-state kinetics of warfarin were evaluated in patients with varying 
degrees of kidney function. We have shown that kidney function is a significant predictor of total 
S-warfarin clearance. The results further reveal that the disposition of warfarin alcohol 2 and the 
enantiomeric warfarin (S/R) ratio are increased in patients with ESRD compared to those with 
normal/mild kidney function. Together, these data demonstrate that kidney disease may impact the 
nonrenal clearance of warfarin mediated by CYP2C9, and may alter the renal elimination and 
therefore the exposure of warfarin alcohol metabolites. 
 S-warfarin is primarily metabolized through CYP2C9 to produce warfarin hydroxy 
metabolites. Conversely, R-warfarin is metabolized through reduction and oxidation pathways 
with major contribution by hepatic reductases that generate alcohol metabolites (Kaminsky and 
Zhang, 1997). In this study, we found that kidney function is a significant predictor of total 
clearance of S-warfarin. This was supported by our findings of a 2.5-fold increase in total and free 
S/R warfarin in ESRD/HD patients compared to those with less severe kidney disease, which 
suggests reduced CYP2C9 activity in CKD. These results agree with a previous report showing 
that total S/R warfarin is increased by 50% in ESRD patients compared to controls (Dreisbach et 
al., 2003). However, we couldn’t find any differences in S/R in other groups of patients who have 
less compromised kidney function (i.e., moderate and severe CKD). Together, these data suggest 
that S-warfarin clearance may be impacted by severity of kidney disease; on the other hand, we 
found that age and serum albumin concentration are significant predictors of R-warfarin clearance. 
 Our finding of decreased warfarin dose requirements with age may be explained by the 
known physiological reduction of liver and kidney function with age (Kinirons and O'Mahony, 
2004; Meyer, 1989). These factors may contribute to the decreased total warfarin clearance in 
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older patients. Our data are in part consistent with the recent investigation of Jensen et al., who 
showed that R- and S-warfarin clearance is decreased by 0.3-0.5% per year of age (Jensen et al., 
2012). Our results also showed a minor correlation between warfarin dose and kidney disease 
(eGFR) (r=0.389, P=0.056). Because age was a significant predictor of warfarin clearance and 
dose, this may have confounded our findings of the minor correlation between eGFR and warfarin 
dose, as well as the observation of eGFR being a significant predictor of total S-warfarin clearance. 
Thus, future well-matched investigations for age, or others that could assess warfarin clearance in 
different age groups are warranted to further clarify these observations.   
Warfarin reduction contributes to about 20% of its total metabolism (Lewis et al., 1974). 
In addition, the alcohol metabolites produced by reduction exert anti-coagulant pharmacological 
activity mediated by decreased plasma levels of vitamin k-dependent clotting factors (Lewis et al., 
1973). One study documented that warfarin alcohols are 6-fold less potent than warfarin in their 
ability to inhibit the VKOR enzyme in vitro (IC50 12.5 vs. 2.2 µM) (Gebauer, 2007). Our study 
showed that the exposure of warfarin alcohol 2, but not alcohol 1, was increased with a decline in 
kidney function. Overall, increased exposure of warfarin alcohol 2 in CKD patients may partially 
contribute to the alterations in warfarin anticoagulant response and dosing requirements observed 
in kidney disease patients.   
Previous epidemiologic studies have reported poor outcomes such as stroke and mortality 
with warfarin therapy in CKD patients with INR in the therapeutic range (Chan et al., 2009a; Chan 
et al., 2009b). This has led us to hypothesize that warfarin alcohol metabolites may be altered in 
these patients and may contribute to the anticoagulant effect that is mediated through vitamin k-
independent clotting factors, which cannot be measured by the INR. Our in vitro studies, however, 
demonstrated negligible direct effect of warfarin alcohols on the activity of FXIa, an important 
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vitamin k-independent clotting factor in the coagulation cascade. Thus, further investigations are 
warranted to assess activity of clotting factors in CKD patients and their association with 
anticoagulant response.  
It has been suggested that protein binding of drugs is impaired in uremia (Reidenberg, 
1977). Consistent with the literature (Lomonaco et al., 2013), we found that warfarin enantiomers 
and warfarin alcohols are highly bound to plasma protein (99%), nevertheless, we couldn’t 
demonstrate any alterations of protein binding of these analytes in patients with decreased kidney 
function. This finding contrasts with a previous report which demonstrated impaired warfarin 
protein binding in uremia (Sjoholm et al., 1976). This discrepancy may be attributed to the small 
sample size and to the technical differences in measuring warfarin albumin binding. For instance, 
previous investigations utilized indirect techniques to measure warfarin protein binding without 
quantifying the free drug concentrations (Sjoholm et al., 1976). Thus, future investigations with 
larger number of patients are needed to further corroborate this conclusion. 
The major limitation of our study is the small sample size. Post-hoc power analysis 
revealed that this study is underpowered to detect a significant difference in warfarin clearance 
between kidney disease patients. Using F-test with alpha level of 0.05, our study had only 62% 
power to detect differences ranging from 27-35% in total warfarin clearance between patients with 
different degrees of kidney disease (the calculated effect size was 0.64). The study has other 
limitations such as incomplete recording of patient medical and medication history, as well as lack 
of CYP2C9 and VKOR1C genotyping.   
In summary, this study demonstrates that kidney disease selectively alters the exposure of 
warfarin alcohol metabolites and also decreases the nonrenal clearance of warfarin mediated by 
CYP2C9. These data suggest that kidney disease does not significantly impact warfarin protein 
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binding. Overall, the findings may partially explain altered warfarin dosing requirements in the 
setting of kidney disease. 
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6.0  CONCLUSIONS AND FUTURE DIRECTIONS 
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6.1 SUMMARY AND CONCLUSIONS 
The objective of this dissertation work was to characterize the effect of CKD on nonrenal drug 
clearance mediated by hepatic reduction. This was accomplished by 1) development and validation 
of a novel analytical method capable of measuring warfarin and its alcohol metabolites in various 
biological matrices, 2) investigating the effect of experimental kidney disease on rat hepatic 
reductase expression and activity utilizing warfarin as a substrate, 3) assessing human reductase 
expression and activity in livers of patients with or without ESRD, employing warfarin as a 
substrate, and 4) exploring steady-state warfarin pharmacokinetics in a pilot study of patients with 
different levels of kidney function. The important findings of each research chapter are 
summarized in the following sections. 
In the first part of this research, we report the development and validation of a sensitive, 
rapid, and robust UHPLC-MS/MS assay for quantitating warfarin and warfarin alcohol metabolites 
in microsomal and cytosolic incubates. This is the first LC/MS method validated for that purpose. 
The method was successfully applied to measure the analytes after in vitro incubations of 
subcellular fractions with warfarin as demonstrated in chapters 2-4. In addition, the method was 
utilized to quantify warfarin and its alcohol metabolites in the clinical PK study as shown in chapter 
5. The high sensitivity of the assay offers an advantage in identifying the unbound concentrations 
of warfarin and its alcohol metabolites.  
In the second part of this work, the assay developed was employed to evaluate hepatic 
reductase activity in rats subjected to nephrectomy. The effect of experimental kidney disease on 
gene and protein expression of the primary rat reductases found in liver cytosol and microsomes 
was also investigated. This study demonstrated that the activity of hepatic reductases is selectively 
impaired by kidney disease. Further, we demonstrated that mRNA and protein expression of 
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hepatic reductases are differentially impacted by kidney disease. However, significant down-
regulation was observed with many of the investigated reductases. The findings from chapter 3 
suggest that the nonrenal clearance of drugs mediated by reduction pathways is impaired in kidney 
disease, and also implicate transcriptionally or translationally mediated changes in enzyme 
function. 
 In the third part of this research, the in vitro function, mRNA and protein expression of 
human reductases were investigated in cadaveric livers collected from ESRD patients and control 
subjects. This work was conducted to evaluate whether the previous findings in rats with 
nephrectomy can be translated to humans. A trend toward selective decreases in the activity of 
human reductases in livers of ESRD patients was demonstrated. In addition, a trend towards 
decreased mRNA expression of several reductase isoforms was also documented. These findings 
were not statistically significant, partially due to the large variability (%CV) observed.. We have 
also documented the first evidence of a significant reduction in protein expression of CBR1 in 
livers from ESRD patients. These findings from chapter 4 suggest that human hepatic reductases 
may also be altered in the setting of kidney disease. The findings may also provide a mechanistic 
explanation for altered drug disposition in kidney disease; especially those metabolized by 
reduction. This novel discovery advances our understanding of the effect of CKD on this pathway 
of nonrenal drug clearance.   
In the final section of this dissertation, the steady-state pharmacokinetics of warfarin were 
assessed in patients with kidney disease. We have shown that eGFR is a significant predictor of  
total S-warfarin clearance. Also, increased S/R warfarin ratio was observed in ESRD patients 
compared to controls suggesting reduced CYP2C9 activity. We also demonstrated, for the first 
time, that the exposure of warfarin alcohol 2 metabolite is increased along with reduced kidney 
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function, suggesting reduction in its renal elimination. However, these alcohols were shown to 
have negligible effects on the activity of vitamin k-independent clotting factor (FXIa) as 
determined in vitro. These results presented in chapter 5 may highlight the importance of alcohol 
metabolites to the inter-individual variability of warfarin dosing. 
6.2 CLINICAL IMPLICATIONS 
The analytical assay that was developed and validated for measuring warfarin and its alcohol 
metabolites may be relevant for use in standard laboratories or other facilities that are equipped 
with modern instrumentation (i.e., mass spectrometry), and would benefit future investigations 
that require quantifying warfarin and metabolites in biological matrices. The method is highly 
sensitive and useful for measuring low concentrations as well as the unbound concentrations of 
warfarin and its metabolites. 
Several clinical studies have shown that the pharmacokinetics of drugs eliminated 
nonrenally can be altered in kidney disease, resulting in changes in drug bioavailability and 
disposition. Our studies also demonstrate that phase I metabolic reduction is modulated in kidney 
disease. This finding provides a mechanism for altering drug disposition of hepatic reductase drug 
substrates in the setting of kidney disease. Because several drugs are primarily metabolized by the 
reduction pathway (e.g., haloperidol, idarubicin, boceprevir, naltrexone, nabumetone), our data 
suggest that these drugs may need to be carefully dosed and regularly monitored in CKD patients. 
Thus, our results offer potential insight to improve pharmacotherapy in CKD patients by 
developing better approaches that incorporate kidney function as a covariate when calculating the 
dose in this patient population. 
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There are numerous endogenous substrates for hepatic reductase enzymes such as steroids, 
prostaglandins, fatty acids, etc. Diminished functional expression of reductases in kidney disease 
may change the degree to which these substrates are biotransformed, and that may be associated 
with biological consequences in CKD patients. For example, decreased activity of 11β-HSD1 in 
kidney disease may result in reduced production of the active form cortisol, and that may modulate 
the inflammation and immune system response processes in the body.   
Warfarin treatment in patients with kidney disease, especially those with ESRD, is 
challenging because of the increased risk of bleeding and stroke in this patient population. Our 
findings in the clinical PK study demonstrate alterations in the disposition of warfarin alcohol 2 in 
kidney disease patients. Increased exposure of warfarin alcohol 2, which exerts anticoagulant 
activity by inhibiting the VKOR enzyme, may enhance the overall pharmacological action of 
warfarin in patients with kidney disease. This corroborates the importance of considering kidney 
function in warfarin dosing and management. The current approaches for estimation of warfarin 
dose in CKD patients are reflections of those developed in the general medical population. In light 
of our findings, these approaches may be not suitable for CKD patients and have to be modified 
to account for changes in kidney function. Starting at lower warfarin doses may be warranted in 
CKD patients to avoid toxicity. However, the benefit of these new approaches should be tested in 
prospective randomized controlled trials. 
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6.3 LIMITATIONS AND FUTURE DIRECTIONS 
The results presented in this dissertation provide insights and open multiple avenues for future 
studies relating to the effect of kidney disease on non-renal clearance of drugs. The findings act as 
the basis and foundation for future preclinical and clinical investigations in the setting of kidney 
disease. These future studies would be necessary to further mechanistically explain, validate, 
support, and expand upon our data. It is important to note that our studies have also some 
limitations that must be considered and highlighted. A list of drawbacks and proposed future 
directions of this work is presented below.   
The inhibition studies demonstrated that isoforms of CBR and AKR as well as 11β-HSD 
reductases may contribute significantly to warfarin reduction. This was concluded by utilizing 
chemical inhibitors of reductase enzymes. However, the inhibitors used are selective for 
subgroups, but are not isoform specific. In addition, these inhibition studies were conducted 
without inclusion of positive controls (e.g., doxorubicin, naltrexone, bupropion), because the 
analytical assays that are required for measuring these analytes are not currently available in our 
laboratory. Hence, future investigations using recombinant enzyme systems of individual 
reductase isoforms with positive controls would be essential to confirm the specific reductases that 
are involved in warfarin reduction. This information is important and would be helpful in 
understanding the contribution of specific reductases to the overall variability in warfarin dose-
response.    
The number of human liver samples from patients with and without ESRD that were 
utilized in the study as described in chapter 4 is relatively small (n=10, n=11, respectively). The 
results of post-hoc power analysis revealed that our study was underpowered to detect a significant 
difference in reductase activity between ESRD and control livers. Further, the presence of co-
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morbid conditions and the cause of death might confound our observations of the trend toward 
selectively decreased reductase activity and expression in livers of patients with ESRD. For 
instance, diabetes mellitus has been shown to alter the expression and activity of several CYP450 
enzymes as well as the 11β-HSD isoform (Dostalek et al., 2011; Zhang et al., 2009). In our sample 
of ESRD livers, most patients had a history of diabetes and that may have confounded our findings. 
Variability in the region of the liver from which samples were collected may also have contributed 
to the variability observed between human liver samples. Therefore, future well-matched studies 
with larger sample size are warranted to further confirm these data.  
Our studies in chapters 3 and 4 demonstrated alterations in activity, mRNA or protein 
expression of reductase enzymes in the setting of kidney disease. However, further investigations 
are required to assess mechanistically the reasons behind these alterations. For example, changes 
in protein stability or activity over time in cells exposed to uremia can be explored by pulse-chase 
analysis (Yamaguchi et al., 2009). In addition, post-translational modifications of reductase 
enzymes can be assessed by Western blotting using specific antibodies, or by peptide analysis 
using mass spectrometry (Larsen et al., 2006). Lastly, alterations in reductase enzymes mediated 
through nuclear transcriptional factors and epigenetic modulation in promoter region of the genes 
can be explored by chromatin immunoprecipitation (ChIP) techniques (Velenosi et al., 2014). 
Although it is controversial, several studies have shown that genetic polymorphisms in 
reductase isoforms are associated with function and expression (Bains et al., 2010; Lal et al., 2010; 
Voon et al., 2013). In our studies of human liver tissue, genetic testing has not been performed on 
the liver samples. Polymorphic expression of reductases may contribute to the variability in the 
reductase activity observed in control and ESRD human liver samples. Thus, future investigations 
with larger sample size considering patients genotypes will be essential to validate our findings. 
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A recent study has shown that moderate CKD alters activity and expression of various 
CYP450 (Velenosi et al., 2012). The 5/6th nephrectomy rat model utilized in chapter 3 represents 
an advanced and progressive stage of uremia. In addition, the human liver tissue used in chapter 4 
was collected from patients with ESRD. Thus, our assessments were limited to the effect of 
advanced kidney disease on hepatic reduction. Continued investigations that incorporate earlier 
stages of kidney disease will be necessary to test whether hepatic reductases are also impacted 
with moderate changes in kidney function. Measuring creatinine levels over time after the first 
surgery would be necessary to determine how fast creatinine concentrations and kidney function 
are stabilized after the nephrectomy.   
Previous published reports have established that uremic toxins including cytokines and 
inflammatory mediators (e.g., p-cresol, hippuric acid, 3-indoxyl sulfate, PTH, benzyl alcohol, 
indole-3-acetic acid) play major roles in modulating the function and expression of drug 
metabolizing enzymes and transport proteins (Lalande et al., 2014; Yeung et al., 2014). Hence, 
future studies are required to investigate whether these toxins, which are present at high 
concentrations in uremic serum, can mechanistically explain our findings of decreased activity and 
expression of reductases in CKD. This can be tested by incubation of normal human/rat 
hepatocytes with different concentrations of uremic toxins or uremic serum followed by assessing 
the activity (using probe substrates) and expression (mRNA and protein) of reductase enzymes. 
Assessing the activity and expression will determine if uremia directly or indirectly affects 
reductase enzymes. In addition, exploring the effect of uremia on the expression of nuclear factors 
that mediate the transcriptional regulation of reductase genes such as Nrf2 and LXR (Chen and 
Zhang, 2012) will be helpful to determine whether the alterations in reductase expression in uremia 
is transcriptionally mediated. To simulate in vivo observations, hepatocyte systems are a better 
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approach to utilize compared to subcellular microsomal or cytosolic fractions. Applying different 
concentrations and individual cytokines may help identifying specific uremic toxins that have a 
major impact on reductive metabolism, and whether the clinically relevant concentrations have 
any impact on drug reduction.  
Our findings in chapter 5 revealed negligible effects of warfarin alcohols on the activity of 
clotting factor XIa in vitro. Thus, future studies are required to explore other possible mechanisms 
for increasing the bleeding risk of warfarin in CKD patients. This may be investigated clinically 
or by using rat or mouse models of kidney disease and coagulopathy (Hogan et al., 2002).  
The findings of decreased functional expression of hepatic reductases as well as altered 
warfarin alcohol exposure in CKD provide evidence that warfarin disposition may be altered in 
patients with CKD. This finding may support dosing optimization of warfarin in CKD patients, 
and consideration of kidney function as a covariate when developing new novel warfarin dosing 
algorithms. However, future randomized clinical trials of warfarin in patients with varying degrees 
of kidney disease would be necessary to definitively conclude the safety and efficacy of warfarin 
use in CKD patients. Our findings may also be applied to other drugs that are eliminated nonrenally 
primarily by reductases and are commonly used in CKD patients (e.g., bupropion, haloperidol, 
naltrexone). Dosing adjustments of these medications may also be necessary and would have to be 
validated in the setting of kidney disease.  
 Although it is an accepted approach (Chan et al., 1994; Jensen et al., 2012; Routledge et 
al., 1979), one point oral clearance as we performed in chapter 5 is not the optimal kinetic 
procedure for studying the effect of CKD on warfarin clearance. A study compared the clearance 
values based on a single plasma concentration measurement and total exposure using the area 
under the concentration-time curve (AUC), and demonstrated that a single point determinant of 
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warfarin clearance at steady-state was comparable with the AUC based clearance in only 6 of the 
10 subjects included in the study. This highlights the limitation of this approach in calculating the 
oral clearance (McAleer et al., 1997). Therefore, collecting multiple blood samples at steady state 
and assessing clearance based on the AUC measurements would be a better approach to assess 
steady state disposition of warfarin in CKD patients. Additionally, formation clearance of alcohol 
metabolites could be measured in order to assess the effect of kidney disease on reductase activity. 
This can be conducted by collecting urine samples to measure alcohol metabolites as well as blood 
samples to quantify warfarin concentrations in plasma. Our study did not measure the exposure of 
warfarin hydroxy metabolites generated by CYP450-mediated warfarin oxidation. Because these 
metabolites are excreted renally and along with the evidence of decreased CYP2C9 activity in 
ESRD (Dreisbach et al., 2003), assessing the effect of kidney disease on the disposition of hydroxy 
warfarin metabolites should be considered in future investigations. It is previously reported that 
the role of transporters (OATP) on warfarin disposition is minimal (Frymoyer et al., 2010), thus it 
is unlikely that altered drug transport confounded our results.   
The warfarin clinical study was conducted in a small number of patients (n=25). The post-
hoc power analysis indicated that our study was underpowered to detect a significant difference in 
total warfarin clearance between patients with varying degrees of kidney function. The small 
sample size along with the high interpatient variability may have impacted our final conclusions. 
In addition, complete patient information was not recorded. For example, genotyping of VKOR1 
and CYP2C9 was not conducted, and some of patients’ comorbid conditions and medical therapy 
were missing. These clinical parameters may have confounded our final observations. Therefore, 
to overcome these issues, future large multicenter studies considering all necessary patient 
demographic and clinical characteristics are warranted.  
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